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To investigate scaffold attachment factor B1 and 2 (SAFB1/2) function in acute 
lymphoblastic leukaemia (ALL), a transcriptomic differential array screen was 
interrogated and SAFB1 mRNA expression was found to be significantly lower in T 
cell ALL (T-ALL) cells compared to normal bone marrow (NBM) cells. Furthermore, 
the SAFB1/SAFB2 ratio was reduced significantly in both B cell precursor (BCP-) and 
T-ALL cells. I also found that SAFB2 protein expression was significantly elevated in 
both ALL subtypes and SAFB1 overexpression induced apoptosis within 48 hours in 
ALL cells. In contrast, apoptosis was not induced in NBM cells and fibroblasts following 
SAFB1 overexpression. These data suggest decreased SAFB1 protein expression 
may promote oncogenesis and overexpressing SAFB1 may form the basis for gene 
therapy strategies. 
 
The stress response (as characterised by the induction of heat shock factor 1 (HSF1), 
heat shock proteins (HSPs) and formation of nuclear stress bodies (nSBs) and action 
of anti-cancer HSP90 inhibitors (celastrol and 17-DMAG) has been characterised in 
ALL cells. Experiments to characterise the ALL stress response found that HSF1 was 
constitutively overexpressed and HSF1 nuclear border expression was present in 
primary BCP-ALL and T-ALL cells following heat shock and 17-DMAG treatment 
compared with NBM. SAFB1/2 co-localises with HSF1 following a HS in HeLa cells 
and primary fibroblasts. However, neither SAFB1 nor SAFB2 was found to co-localise 
with HSF1 following a HS in ALL cells. These findings suggest the stress response 
differs in ALL cells and may render them more permissive to treatment with HSP90 
inhibitors.  
  
RGG/RG and SUMOylation mutants of SAFB1/2 were made to investigate the 
importance of post translational modifications (PTMs) in regulating SAFB1/2 
interactions. Experiments revealed that SAFB1 SUMOylation mutants had a 
significantly increased interaction with the known oncogene, serine/arginine-rich 
splicing factor 1 (SRSF1), following heat shock. Results also showed that interactions 
between SAFB2 delta-RGG/RG methylation mutants and SRSF1 was reduced 
compared with wild-type SAFB2 under basal and heat shock conditions. Proteomic 
analyses of SAFB1/2 interactions were undertaken using Tandem Mass Tag Mass 
Spectrometry (TMT-MS) and bioinformatic analyses suggested they regulate RNA 
processing, splicing, transcription and translation. Interestingly SAFB2 bound more 
proteins than SAFB1 in T-ALL cells but bound significantly fewer proteins in HeLa cell.  
Together, these data highlight the pivotal role of SAFB1/2 play in regulating critical 
cellular processes and altered indicate SAFB1/2 expression ratios could be important 
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1.1 SAFB proteins 
1.1.1 Scaffold attachment factor B (SAFB) family  
The RNA binding protein Scaffold attachment factor B1 (SAFB1) was identified by 
three different research groups; it was found by Renz and Fackelmayer (1996) as a 
protein that interacts with scaffold/matrix attachment regions (S/MARs) (1). These 
regions attach chromatin to the nuclear matrix and the chromatin loop domains formed 
at these attachment regions are also thought to be sites controlling transcription and 
replication (2). A second research group identified a protein that interacted with the 
heat shock protein 27 (hsp27) ERE TATA-box (hsp27 ERE TATA-box-interacting 
protein (HET)) and found it repressed the transcriptional activity of hsp27 (3). A third 
group identified a hnRNP A1 associated protein (HAP) by two-hybrid  screening and 
subsequent sequencing determined that SAFB1, HET and HAP were identical (4). 
Subsequent to these findings, a paralogue of SAFB1 was found and termed SAFB2 
(5) and our group more recently found a homologue, SAF (scaffold attachment factor)-
like transcription modulator (SLTM) (6). SAFB1 and SAFB2 are located on human 
chromosome 19p13.3 in a bidirectional manner, separated by a 490 bp promoter (5) 










                                                                                              SAFB1 and SAFB2 are 




1.1.2 SAFB proteins have a modular structure 
SAFB1 and 2 proteins are highly similar at the amino acid level, sharing 74% 
homology. However, SLTM shares only 34% and 36% similarity with SAFB1 and 
SAFB2, respectively (Figure 1.2) (7). SAFB proteins are structurally similar and the 




various functional domains share a very high homology (ranging from 65-100%) 
(Figure 1.2). These functional domains include a SAF-A/B, Acinus and PIAS domain 
(SAP box) located at the N-terminus, an RNA-recognition motif (RRM) and nuclear 
localization signal (NLS) located in the central region and glutamic acid/arginine (E/R) 
and arginine/glycine-rich (R/G) regions at the C-terminus. The C-terminus region is 
crucial for protein-protein interactions. They also share a region with no known function 

























                                                                                                                         The diagram 
shows a region with no known function with high similarity (HS) the SAP-Box, RNA-recognition 
motif (RRM), nuclear localization signal (NLS), Glu/Arg rich (E/R) and Arg/Gly rich (R/G) 
domains. The amino acid homology of SAFB2 and SLTM compared to SAFB1 for each domain 
is given as a percentage. 
 
1.1.3 SAFB proteins’ expression profile and cellular localisation 
SAFB1 is primarily expressed in the nucleus, while its paralogue SAFB2 is expressed 
in both the nucleus and cytoplasm (5). This suggests that SAFB2 has additional 
functions distinct from those of SAFB1 in the nucleus. This is supported by the 




observation that SAFB2 is highly expressed in Sertoli cells compared to SAFB1 (9), 
suggesting SAFB1 and SAFB2 expression can be tissue specific and that they have 
distinct functions. SLTM is expressed in the nucleus and excluded from nucleolus, 
similar to SAFB1. SLTM partially co-localises with SAFB1 suggesting that proteins 
may share some functions (6).  
 
Proteomic analysis demonstrated that SAFB proteins are widely expressed across 
different tissues, including the bone marrow tissues where leukaemia cells reside. For 
example, SAFB1 and SLTM were expressed at high levels in bone marrow cells, 
whereas SAFB2 was expressed at moderate levels (Figure 1.3) (10). Furthermore, all 
SAFB proteins were expressed at high levels in a wide range of tissues, including the 
thyroid gland, heart, lung, kidney and placenta. The expression of SAFB proteins has 
also been investigated in neuronal tissues. It was found that SAFB1 was expressed at 
high levels throughout the hippocampus (11). In contrast, SAFB2 and SLTM were 
expressed at moderate levels (Figure 1.3) (10). These data again suggest that SAFB 
proteins might play different roles in various tissues. 
 
Endogenous genes targeted by SAFB were investigated in breast cancer cells using 
chromatin immunoprecipitation (Chip)-on-chip and gene expression analysis to extend 
our understanding about SAFB1/2 functions and to investigate which genes are 
controlled by SAFB1/2. Over 541 SAFB1/2 binding sites were identified and the 
majority of those binding SAFB1 coded for genes involved in regulating the immune 
system (interleukins, chemokines), followed by genes with roles in signalling and 
apoptosis, including Bcl-2-binding component 3 (BBC3), neural precursor cell 
expressed developmentally down-regulated protein 9 (NEDD9) and Osteoprotegerin 
(OPG) (12).  
 
SAFB1 was reported to be important in growth regulation, development and 
reproduction (13). SAFB1-knockout mice exhibited a number of abnormalities, 
including dwarfism, infertility, defects in testes and in the development of the 
haemopoietic system, suggesting SAFB1 plays a critical role in haemopoiesis (13). In 
contrast, mice lacking SAFB2 were viable and showed no major defects in growth or 











































                           Tissues were immunohistochemically stained and categorised into negative, 
low, medium and high based on staining intensities. Coloured bars represent tissues with 
similar features (10). 
 
1.2 Functions of SAFB proteins 
SAFB proteins have been implicated in a wide range of cellular processes, including 
transcriptional regulation, chromatin organisation, cellular stress response, DNA 









evidence suggesting SAFB1 and SAFB2 may have some distinct functions, the 
majority of studies to date have only investigated SAFB1 with very few investigating 
SAFB2.  
 
1.2.1 SAFB proteins in transcription 
SAFB1 was identified as a protein that bound and repressed hsp27 promoter activity 
(3) and hence SAFB1 was believed to be a negative regulator of transcription. Another 
study reported that SAFB1 repressed xanthine oxidoreductase (XOR) expression (15). 
A wider study demonstrated that knockdown of SAFB1 and SAFB2 resulted in the 
induction of 457 genes and repression of 259 genes (12). The mechanisms by which 
SAFB proteins might repress transcription involved interaction with chromatin-
modifying complexes, such as Polycomb repressive complexes (PRCs) and long non-
coding RNA (IncRNAs). For example, a study found that SAFB1 represses the 
androgen receptor and SAFB1 knockdown resulted in higher transcription of prostate-
specific antigen (PSA) in cultured prostate cells (16). Also, SAFB1 was shown to form 
a complex with Polycomb PRC2 components; Enhancer of zeste homolog 2 (EZH2), 
and Polycomb proteins  SUZ12 and EED (16), suggesting that SAFB1 mediates 
transcriptional repression by this pathway. However, SAFB1 transcription is not always 
repressive; for example, SAFB1 knockdown was shown to inhibit the expression of 
skeletal muscle genes, indicating a positive regulatory role of SAFB1 (17). SAFB1 
overexpression was shown to promote expression of muscle structural proteins. In 
contrast, SAFB1 knockdown was associated with inhibition of skeletal muscle gene 
expression. The interaction between SAFB1 and the polycomb PRC2 complex was 
suggested by the persistence of the Ezh2 component of PRC2 and the repressive 
histone marker H3K27me3 following SAFB1 knockdown (17). These data suggest that 
SAFB1 is necessary for chromatin transition from repression to the active state during 
myogenesis.  
 
1.2.2 SAFB proteins in cellular stress response 
SAFB1 was reported to be involved in regulating the response to a stress such as heat 
shock (HS). SAFB1 co-localised with HSF1 in nuclear stress bodies (nSBs) and was 




following stress (4),(18). nSB formation requires ongoing transcription and was shown 
to be sensitive to RNase indicating that RNA is a main component (4),(19). Further 
studies found that a region close to the C-terminal [580–788aa] region of SAFB1 is 
needed upon HS to be recruited to the nSBs	(20). Deletion of both the E/R and R/G at 
the C-terminal caused SAFB1 to translocate to the cytoplasm suggesting multiple C-
terminal interactions govern SAFB1 function. 
 
1.2.3 SAFB proteins in the DNA damage response 
RNA binding proteins (RBPs) are known to play an important role in DNA repair (21). 
SAFB1 was shown to be rapidly recruited to DNA double-strand breaks and this was 
required for histone γH2AX to be efficiently phosphorylated (22) which governs DNA 
damage response (DDR) signalling. SAFB1 recruitment was dependent on poly(ADP 
ribosyl)ation (PARylation) pathway, which was rapidly activated in response to DNA 
breakage. PARylation also facilitates the recruitment of several chromatin modifiers, 
including	aprataxin-PNK-like factor (APLF) and amplified in liver cancer 1 (ALC1) and 
repair factors, including breast cancer type 1 susceptibility protein (BRCA1) and P53 
Binding Protein 1 (53BP1) to damaged sites  (22). It was shown that  a deletion mutant 
of SAFB1, lacking the R/G domain (aa 785–917) at the C-terminal, was sufficient for 
SAFB1 recruitment to damaged chromatin and was needed for PARP recruitment (22). 
These data suggest that SAFB1 is an essential component of the general response to 
DDR by rendering the chromatin permissive to DNA damage signalling. 
 
1.2.4 SAFB proteins in apoptosis 
High levels of SAFB1 were reported to arrest T24 (human bladder carcinoma) cells in 
the G2-M phase suggesting a role in the control of cell division (23). The 
overexpression of SAFB1 also leads to multinuclearity and considerable changes in 
the cell cycle (23). Our group has also found that SLTM overexpression induces 
apoptosis (6). After activating apoptosis, SAFB1 expression (24) was seen in the 
nucleolus within 30 minutes. By 2 hours, most cells display peri-nucleolar staining of 
SAFB1. After 3-4 hours, the peri-nucleolar feature was absent (24) and this was found 
to be dependent on RNA binding. It was concluded that SAFB1 is required to direct 




apoptosis, these data suggest that SAFB1 is likely to be involved in the programmed 
cell death pathway. 
1.3 Post-translational modification of SAFB proteins 
SAFB proteins have been found to undergo phosphorylation, ubiquitylation, 
SUMOylation, arginine methylation, PARylation and acetylation. However, this section 
focuses on phosphorylation, small ubiquitin-like modifier (SUMO)ylation and arginine 
methylation. SAFB1 was reported to be phosphorylated (2) and another study reported 
that all SAFB proteins became phosphorylated in response to DNA damage (25) and 
is required for the amplification of DDR signalling (22).  
 
SUMOylation is dynamic process that conjugates the SUMO moiety on target proteins. 
It is involved in a diverse range of functions, such as DNA replication, genome stability, 
nuclear transport, and gene transcription (26). All SAFB proteins were proposed to be 
substrates for SUMOylation. SUMOylation was demonstrated on Lys 231 and Lys 294 
of both SAFB1 and SAFB2 (27) and SUMOylation of SAFB1 has been shown to be 
mediated by SUMO-1 and SUMO 2/3 (28).	 SAFB1 SUMOylation status was linked to 
the stress response, with SAFB proteins becoming de-SUMOylated upon heat stress 
(27). Subsequently, it was found that SUMOylation was required for transcriptional 
repression to be mediated by SAFB1	(29). More recently, it was found that transcription 
of ribosomal proteins (RPs) was enhanced by SUMOylated SAFB1 (28).  
 
Protein methylation can occur on arginine or lysine residues and is essential in the 
regulation of histone and non-histone proteins in many signal transduction pathways 
(30). The UniProt database showed that SAFB proteins were methylated on the 
RGG/RG arginine motif sites (aa 868–875 in SAFB1), located on the R/G rich domain 
within the C-terminal domain. However, how the methylation of SAFB proteins 
regulates cellular functions is not known. Arginine methylation regulates many 
processes, including gene expression, DNA damage repair and protein translocation 
(30). Also, evidence suggests that RGG/RG motifs are the substrates for protein 
arginine-N-methyltransferases (PRMT), i.e. PRMT1, PRMT3, PRMT5, PRMT6 and 
PRMT8 (31) which were shown to modify many protein functions and are implicated 




1.4 SAFB proteins in cancer 
There have been a number of studies suggesting that altered SAFB protein expression 
is linked to oncogenesis. Disruption of SAFB1 expression is associated with 
immortalisation in mouse embryonic fibroblasts (MEFs) (32). SAFB1 down regulation 
was associated with an increase in growth rate (23). SAFB1 mutations were identified 
in breast tumours but not in the normal adjacent tissue. The implications of SAFB1 
mutations were not studied and further experiments are needed. A high loss of 
heterozygosity (LOH) of 78% was detected at the SAFB chromosomal locus in 
invasive breast cancer. A high rate of LOH is a feature of genes with roles in cancer 
suppression (33). Further analysis of 19p13 locus showed that adenomatous 
polyposis coli-like (APCL), a tumour suppressor candidate, is involved (33). SAFB2 
was shown to be a substrate for breast cancer type 1 (BRCA1) and the latter was 
proven to enhance SAFB2 protein expression (33). 
Lower levels of SAFB expression are associated with worse overall survival in breast 
cancer patients (34). SAFB1 expression was also lower in prostate cancer (16) and 
more recently, a group found low levels of SAFB1 promoted the activation of NF-κB 
signalling in colorectal cancer patients. Also, SAFB1 down regulation was correlated 
with poor survival and aggressive phenotype in colorectal cancer patients (35). 
Together these findings suggest that SAFB1 overexpression is associated with 
inhibition of cancer cells and SAFB1 was hypothesised to be a tumour suppressor 
gene. However, further experiments need to be performed to prove this hypothesis.  
 
1.5 SAFB protein interactions with RNA and proteins 
Spectrometric analyses found that SAFB1, SAFB2 and SLTM bind mRNA (36), (37), 
suggesting that SAFB proteins could be involved in mRNA processing. Therefore, 
individual nucleotide resolution cross-linking and immunoprecipitation (iCLIP) 
technology was used with deep sequencing to identify SAFB1 binding sites in the SH-
SY5Y neuroblastoma cell line. SAFB1 binding with RNA was enriched in exons and 
associated with the purine rich pentamers GAAGA and AAGAA, occurring with the 
highest frequency in proximity to intron-exon and exon-intron boundaries, suggesting 
a role in mRNA splicing (38). In addition, SAFB1 binding was also enriched in ncRNAs, 




expression. Another group used the iCLIP technique to investigate the interaction of 
SAFB1 with RNA in MCF-7 breast cancer cells (39). Similar results were produced 
with enrichment in introns, open reading frames (ORFs), in 3’ and 5’ UTRs with higher 
enrichment in ncRNA. Using iCLIP technology, several ncRNA transcripts were bound 
to SAFB1, including metastasis associated lung adenocarcinoma transcript 1 
(MALAT1), nuclear enriched abundant transcript 1 (NEAT1), taurine upregulated gene 
1 (TUG1) and X-inactive specific transcript (XIST) which are involved in the regulation 
of gene regulation (38). Moreover, it was shown that SAFB1 is bound with many 
microRNA transcripts, including the miR-17-92 cluster (38). Knockdown of SAFB1 was 
associated with decrease in mature miR-19A expression and increase in the primary 
miR-17-92 transcript expression, indicating that SAFB1 is required for processing miR-
19A (38). SAFB1 and the microRNA 17-92 were shown to regulate RNA processing 
(38).  
 
In addition to RNA interactions, SAFB1 was shown to interact with several regulatory 
proteins (11), discussed below. It is important to consider the methodology used to 
identify protein-protein interactions. Two-hybrid assays have been used for protein-
protein identification but are subject to false positive results. In contrast, co-
immunoprecipitation technology provides a better picture for protein-protein 
interactions. However, the choice of the extraction conditions may influence the 
results. For example, high salt concentrations will help in identifying stable interactions 
but could miss important weaker interactions. Also, co-immunoprecipitation does not 
distinguish between direct and indirect interactions. SAFB1 was reported to interact 
with several heterogeneous nuclear ribonucleoproteins (hnRNP) proteins, including 
hnRNPC (4), hnRNPD (40), hnRNPG (9) and hnRNPPI (4). hnRNP proteins regulate 
many processes, including transcription, processing and transport of mRNA. The SR 
(serine–arginine-rich) proteins, such as serine and arginine rich splicing factor 1 
(SRSF1), SRSF3, SRSF7 and SRSF9 interact with SAFB1. They play important roles 
in splicing and are concentrated in nSBs together with SAFB1. It was shown that 
SAFB1 interact with several RNA splicing proteins, including transformer-2 sex-
determining protein (Tra2), SRSF9, SRp30c, SFRS12, cytoskeletal signalling 
protein  (SLM1) and SLM2) (9). Splicing of Tra2 was found to be inhibited by SAFB1 
(41) and SAFB2 (9). SAFB1 was identified to be a component of spliceosomes (42), 




nuclear ribonucleoproteins assisting in the removal of introns (43). However, SAFB1 
was not found in an analysis of spliceosomes, suggesting a transient association 
between SAFB1 and spliceosomes (44).  Furthermore, SAFB1 was shown to interact 
with proteins involved in transcription, such as RNA polymerase III (2) and p53 (45). 
SAFB1 was shown to bind with p53 and supress its activity (45). In addition, SAFB1 
interacted with several proteins with roles in determining chromatin structure and 
function, including nuclear receptor co-repressor 1 (NCOR) (29), histone deacetylase 
3 (HDAC3) (29), chromodomain-helicase-DNA-binding protein 1 (CHD1) (46), 
Brahma-related gene-1 (BRG1) (15) and matrin3 (47). CHD1 was shown to interact 




Haemopoiesis is the term used to describe the process of blood cell production; which 
emerges from haemopoietic stem cells (HSCs). HSCs are rare cells sitting at the top 
of haemopoietic hierarchy that have the ability to produce all blood cell types 
throughout a lifetime and they have the characteristics of self-renewal and 
differentiation (48).  
Blood cell differentiation starts with HSCs, followed by multipotent progenitor cells, 
which are unique in their developmental capacity and then they become progressively 
lineage-restricted. One class of multipotent progenitor cells are multi lymphoid 
progenitors (MLP), which give rise to mature B, T and natural killer (NK) cells. Another 
subset of multipotent progenitor cells are common myeloid progenitors (CMP), which 
eventually give rise to mature erythrocytes, megakaryocytes, monocytes, 
granulocytes and dendritic cells (49). A schematic for blood lineages during 



























                                                                                                                     HSCs give 
rise to multipotent progenitors (MPP) which maintain the ability to differentiate into both 
myeloid and lymphoid lineages. Myeloid and lymphoid pathways diverge after from MPP into 
either common myeloid progenitors (CMP) or multi lymphoid progenitors (MLP). Progenitors 
then differentiate, with CMP giving rise to megakaryocyte erythroid progenitors (MEP) or 
granulocyte-monocyte progenitor (GMP) and MLP becoming early T cell progenitors (ETP) or 
B/ natural killer cell progenitors (B/NK). These progenitors then	 give rise to mature and 
specialised haemopoietic cells. 
 
 
During embryonic and fetal development, haemopoiesis takes place in different 
anatomical sites, including the yolk sac, then the aorta-gonad- mesonephros (AGM) 
region, followed by the liver and eventually the bone marrow (50). The initial stage of 
haemopoiesis in the yolk sac called primitive which helps in the production of 
erythrocytes, facilitating oxygenation of rapidly growing embryo (50). Primitive 
haemopoiesis is transient and replaced by definitive haemopoiesis in the AGM region 
which gives rise to primitive HSCs. At the later stages of fetal development, the 




functional HSCs migrate to the liver where they expand (51). The shift in locations 
during the fetal haemopoiesis is important as the embryo is developing. The bone 
marrow is the main site for haemopoiesis during adulthood as the bone marrow can 
provide the microenvironment needed to conserve the multipotency of HSCs  (51). 
The bone marrow niche has the potential to maintain the HSC self-renewal and 
differentiation balance (52). Haemopoiesis also happens in the spleen and also in the 
thymus where T lymphocytes mature. 
 
The HSC fate is associated with changes in gene expression. Regulation of HSC self-
renewal and differentiation is controlled by various transcriptional factors, molecular 
signaling pathways and epigenetic modifiers. Several transcriptional factors were 
shown to regulate HSCs during embryogenesis, including purine box binding protein 
1 (Pu.1), runt-related transcription factor1/acute myeloid leukemia1 (Runx1/AML1), 
globin transcription factor-1 (GATA1), GATA2, stem cell leukemia/T cell acute 
lymphocytic leukemia-1 (SCL/tal1), LIM domain only 2 (Lmo2), friend leukemia 
integration1 transcription factor (FLI1) and ETS related gene (ERG) (53). Pu.1, one of 
the most important factors that regulate haemopoiesis, is essential for B lymphocyte 
and monocyte differentiation (54). Pu.1 overexpression forced HSCs to differentiate 
into macrophages instead of B lymphocytes (53). Also, Pu.1 disruption resulted in a 
failure commitment of HSCs to differentiate into both myeloid and lymphoid lineages  
(53).  
During adulthood the regulation of HSCs takes place in the bone marrow niche. The 
bone marrow niche contains cells and extracellular matrix (ECM). ECM provides the 
physical support and interacts with HSCs through adhesion molecules. Niche cells are 
responsible for HSC quiescence, proliferation and differentiation. Osteoblasts, one of 
the most important niche cells, secrete various cytokines such as granulocyte-colony 
stimulating factor (G-CSF), macrophage colony stimulating factor (MCSF), 
granulocyte macrophage colony stimulating factor (GM-CSF), interleukin (IL)-1, IL-6, 
IL-7, osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (NF-κB), 
tumour necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), all of 





The balance between HSC self-renewal and differentiation is essential for the 
maintenance of hemopoieses and requires tight regulation. For example, the 
overexpression of the proto-oncogene c-Myc was shown to increase HSC 
differentiation. In contrast, c-Myc deficient HSCs lack the ability to generate lineage 
committed haemopoietic precursors (52), leading to the formation of immature 
granulocytes, erythrocytes and platelets. In addition to the role of the transcriptional 
factors in regulating HSCs, numerous signaling pathways are also implicated in 
regulating this process, including Notch and Wnt signaling pathways (55). Mis-
regulation of the pathways involved in regulating HSC self-renewal and differentiation 
leads to cancer. 
 
1.7 Acute lymphoblastic leukaemia 
1.7.1 Background  
Acute lymphoblastic leukaemia (ALL) is initiated in the bone marrow following the 
expansion of uncontrolled regulation in the early progenitor lineages during 
haemopoiesis. ALL is associated with several symptoms, including bruising and 
bleeding resulting from thrombocytopenia. ALL patients also exhibit other symptoms, 
such as pallor and fatigue resulting from anaemia (56). The involvement of 
extramedullary sites (thymus, liver, spleen, kidney and the testes in males) is common, 
occurring in 20% of patients. The central nervous system (CNS) involvement of those 
patients present in 5-8% of ALL cases and associated with poor prognosis  (57).  
ALL is the most common cancer in children, accounting for approximately 25% of all 
childhood malignancies occurring before age 15 years (58). Eighty percent of ALL 
cases occur in children (57), with the peak incidence at 3-5 years of age (56). An 
annual incidence of 3,000 in million children (59) diagnosed with ALL reported annually 
in the US. A total of 400 new cases of ALL are diagnosed annually in the UK in children 
younger than 15 years every year. The remission rate has increased dramatically from 
10% to 90% (60). ALL is divided into B cell precursor ALL (BCP-ALL) and T cell ALL 
(T-ALL). BCP-ALL accounts for the majority (85%) of ALL cases (61). T-ALL patients 
have poorer prognosis compared to those with BCP-ALL (62). ALL is more common 




1.7.2 Genetic landscape in ALL 
There are several chromosomal structural and genetic abnormalities associated with 
ALL patients (63). About 75% of ALL cases are associated with genetic alterations 
(61). Common genetic alterations in BCP-ALL and T-ALL are highlighted in Figure 1.5 
(64). Significant improvements in cytogenetic and genomic technologies contributed 
to better understanding of the disease and provide prognostic and predictive markers 
for therapy (65),(66). Such advances will also provide novel markers which might help 























                                                           The figure highlights several genetic alterations in 
BCP-ALL (blue bars), including ETV6-RUNX1, resulting from t(12;21) (p13;q22); BCR-ABL1, 
resulting from t(9;22)(q34;q11) and TCF3-PBX1, resulting from t(1;19) (q23;p13). It also 
shows different alterations such as hyperdiploidy, hypodiploidy, MLL rearrangements, 
iAMP21, ERG and dicentric. In T-ALL, TAL1, TLX1, ETP, TLX3 and LYL1 were commonly 
found to be disregulated (red bars). The yellow bars represent different genetic alterations in 
ALL but mostly common in BCP-ALL, including BCR-ABL1-like and CRLF2 (64). 
 
 
Genetic abnormalities in ALL can be structural aberrations, such as chromosomal 
translocations, and numerical aberrations such as hypodiploidy (<44 chromosomes) 




and high hyperdiploidy (˃50 chromosomes) (61). The translocation t(12;21) (p13;q22) 
resulting in the ETV6-RUNX1 fusion gene is the most common translocation (22%) in 
BCP-ALL patients and children with this mutation have good prognoses (63). The 
ETV6-RUNX1 fusion gene disrupts haemopoiesis as ETV6 and RUNX1 are important 
transcriptional factors mediating this process (61). The ETV6-RUNX1 translocation 
thought to cause alterations in B-cell progenitor self-renewal and differentiation but 
this is not sufficient to cause the disease as ETV6-RUNX1 did not induce leukaemia 
in transplanted mice, indicating that other factors are cooperating for BCP-ALL 
progression (61). Hyperdiploidy is another frequent abnormality (20%) in BCP-ALL 
patients and associated with good prognosis and 5-year overall survival (OS) rates 
˃90% (63). However, some hyperdiploid patients relapse and this is due to the fact 
that many mutations were found to be frequently associated with hyperdiploidy, 
including fms-like tyrosine kinase-3 (FLT3), neuroblastoma ras viral oncogene 
homolog (NRAS) and paired box 5 (PAX5) (61). Hypodiploidy is less common (1%) 
compared with hyperdiploidy and associated with poor prognosis (64). Patients with 
hypodiploidy can be near haploid (24–31 chromosomes), low hypodiploid (32–39 
chromosomes), hypodiploid (40–43 chromosomes) and near diploid (44 or 45 
chromosomes) with lower chromosome numbers associated with poorer outcome 
(61).  
 
The genetic landscape in T-ALL is different compared with the BCP-ALL genetic 
signature and generally associated with poor outcome. The most common regulator 
of T cells is NOTCH1, which regulates the commitment of haemopoietic progenitors 
to the Tcell lineage during development, was found to be mutated in T-ALL (67). 
NOTCH1 mutations were found in 60% of T-ALL patients and associated with good 
prognosis (68). Genomic analyses found that the oncogenic transcriptional factors are 
associated with T-ALL subgroups. Such oncogenic transcription factors, include basic 
helix-loop-helix (bHLH) family members, such as TAL1 t(1;14)(p32;q11); LIM-only 
domain (LMO) genes, such as LYL1 t(7;19)(q34;p13) and	HOXA homeobox (HOX) 
genes, such as TLX1 t(11;14)(p15;q11) and TLX3 t(11;14)(p15;q11) (68). The TAL1 
is largest subgroup (7%) with other subgroups having lower frequency (69). TAL1 is 
an important regulator of HSC development (67). Another oncogenic transcription 




in paediatric and 5% of adult T-ALLs (70),(71). TLX3 overexpression was associated 
with poor prognosis and high risk of relapse, while TLX1 overexpression was 
associated with good prognosis and low relapse risk (70),(71). 
 
1.8 Treatment in ALL 
Effective treatment strategies for ALL have been developed and the remission rate for 
paediatric ALL has reached 90% compared with 1960s when survival was just 10% 
(72). Despite the remarkable treatment success, prognosis remains poor for a subset 
of ALL patients (73). For example, patients with hypodiploidy and MLL rearrangements 
are associated with increased rates of treatment failure and relapse (73). However, 
evidence shows that around 50% of ALL patients with intermediate and low risk 
disease relapse (section 1.6.1) (74). These data demonstrate an unmet need to 
develop more effective therapies that reduce the risk of relapse. The chemotherapy 
doses can not be increased as it is associated with toxicity of normal cells. Therefore, 
developing more targeted therapies would be useful. 
 
1.8.1 Treatment stages 
The front line of chemotherapy for newly diagnosed patients with ALL consists of 5 
phases, including induction, consolidation, interim maintenance, delayed 
intensification and maintenance (72). The induction therapy is the first phase of 
treatment and lasts for up 6 weeks to induce a complete remission (75). The second 
phase is consolidation which involves 2 blocks of chemotherapy at intervals with the 
aim to eliminate residual leukaemia cells and lasts for up to 9 months (75). The third 
phase is interim maintenance and aims to further destroy any residual leukaemia cells 
and lasts for 8 weeks (75). The fourth phase is delayed intensification which is 
important to improve a child’s event-free survival and lasts for 8 weeks (72). The final 
phase is maintenance which aims to destroy any cancerous cells and prevent relapse 
and lasts for 84 days (72). Details of the current treatment in the UK and the drugs 
used are shown in Table 1.1, which is based on the UK-ALL 2011 trial protocol (76). 
In this trial, BCP-ALL patients are treated on either regimen A or B for 4 weeks, 




start on regimen B. During induction, patients are randomised and receive high dose 
(HD) dexamethasone for 14 days or a lower dose (LD) for 28 days (76) During interim 
maintenance and maintenance, patients are randomised again with vincristine and 
dexamethasone are given (76). Patient found to have near and low haploidy, iAMP21 




Table 1.1 Chemotherapeutic drugs used to treat ALL patients in the UK. 
Regimen A  
Induction Vinc, Asp, Dex (HD 14d or 28d)  
Consolidation Merc 
Interim maintenance Merc, Meth (OR, IT), Vinc and Dex pulses 	
Delayed intensification  Vinc, Dox, Dex, Asp, Phos, Cyta, Merc 	
Maintenance  Merc, Meth (IT), Vinc and Dex pulses 	
Regimen B  
Induction Vinc, Asp, Dex (HD 14d or 28d), Daun 
Consolidation Phos, Cyta, Merc 	
Interim maintenance Merc, Meth (OR, IT), Vinc and Dex pulses 	
Delayed intensification Vinc, Dox, Dex, Asp, Phos, Cyta, Merc 	
Maintenance  Merc, Meth (IT), Vinc and Dex pulses 	
Regimen C  
Augmented consolidation 	 Vinc, Phosph, Cyta, Merc, Asp 	
Augmented intensification 	 Vinc, Dox, Dex, Asp, Phos, Cyta, Merc	
Maintenance Merc, Meth (IT), Vinc and Dex pulses 	
Vinc = Vincristine; Asp = Pegasparginase; Cyta = Cytarabine; Daun = Daunorubicin; 
Dex = Dexamethasone; Merc = mercaptopurine; Meth = Methotrexate; Dox = 
doxorubicin; OR = Oral; IV = Intravenous; IT = Intrathecal; HD = High dose. 
 
 
There is no consensus on the optimal drug doses/types but many factors are attributed 
to provide better treatment management (66). Chemotherapy intensity/type depends 
on the severity of the disease, age, leukocyte count and genetic abnormalities (77). 
For example, paediatric ALL patients over 10 years old, ALL with Philadelphia 




amplification of chromosome 21 (iAMP21) are high risk groups and require more 
intensive therapy (75). The Philadelphia chromosome t(9;22) is first found in CML and 
is characterised by the translocation of the q34 portion of chromosome 9 and the q11 
locus of chromosome 22. The fusion gene produced (ABL1/BCR) links the tyrosine 
kinase ABL1 on chromosome 9 with the BCR gene on chromosome 22, resulting in a 
constitutively active kinase protein (75). Much attention must be paid to determine the 
best drugs to improve life quality of ALL patients.  
 
It is widely believed that the initial response to therapy predicts outcome. Historically, 
initial assessment of treatment was evaluated morphologically. Currently, evaluating 
patients for measurable residual disease (MRD) is the standard method (57) and 
considered to be the best prognostic indicator of patient outcome. MRD analysis is 
used to determine the levels of residual leukaemia remaining after the induction 
therapy. Patients are stratified based on MRD status into low, intermediate and risk 
groups. At day 29, if ALL cell burden is below <0.005% the patient is classified as MRD 
low risk, while if there is evidence of MRD of ≥0.005%, patients are classified as MRD 
risk. At week 14, MRD risk patients are further classified into either MRD high risk 
(MRD ≥0.5%) or MRD intermediate risk (MRD <0.5%). MRD is determined using flow 
cytometry to detect abnormal WBS’s known as leukaemia blasts based on surface 
markers and/or real time quantitative polymerase chain reaction  (RT-qPCR) to detect 
immunoglobulin (Ig)/T-cell receptor (TCR) rearrangements (78). RT-qPCR can detect 
1 ALL cell in 105 normal cells, while flow cytometry is less sensitive (1 ALL cell in 104) 
(79). Flow cytometry is a faster method for MRD analysis compared with RT-qPCR 
(80). The next generation sequencing (NGS)-based method is a newer addition to 
MRD analysis techniques with higher sensitivity capable of detecting 1 ALL cell in 106 
normal cells (81),(82). However, its use is still limited due to cost. 
 
1.9 Leukaemia initiating cells 
The current chemotherapy used to treat ALL reduces the bulk of the leukaemia cells 
but these treatments may fail to eliminate leukaemia cells that can self-renew and 
differentiate, eventually leading to relapse (83). These cells are known as leukaemia 




as well as other solid cancers. LICs were initially proposed to be the population of cells 
expressing CD34 but lacking CD7 or CD4 in paediatric T-ALL (84). However, it was 
found that CD34+/CD4- or CD34+/CD7- cells from mature T-ALL cases did not possess 
LIC activity but have normal haemopoietic differentiation potential in non-obese 
diabetic–severe combined immune deficient (NOD/SCID) mice (85). Currently, 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ NOD/LtSz-scid IL-2Rϒc null (NSG) mice are 
considered to be more permissive hosts than NOD/SCID mice for engrafting human 
BCP-ALL and T-ALL (86) and human haemopoietic cells (87), so they are used as  a 
model to study the ability of human LICs to differentiate. Several T-ALL subpopulations, 
including CD34+/CD7+, CD34-/CD7+ and CD34-/CD7- were able to engraft more successfully 
in NSG than NOD/SCID mice. However, CD34+/CD7- engraftment in both mice was 
faster and required 2-100 fold fewer cells compared with other subpopulations such 
as CD34+/CD7+, CD34-/CD7+ and CD34-/CD7- cells, suggesting that the CD34+/CD7- 
cells were the most primitive subpopulation (86). In addition, the self-renewal ability of 
some T-ALL populations such as CD34+/CD7+, CD34-/CD7+ and CD34-/CD7- 
subpopulations was more limited. In contrast, CD34+/CD7- cells had stable levels of 
engraftment and were able to differentiate in vivo (86). CD99 was shown to be 
overexpressed and used as a diagnostic marker for MRD in T-ALL (88). Cells 
expressing CD34+/CD99+, CD34+/CD99-, CD34-/CD99+ and CD34-/CD99- could 
propagate in NGS mice, suggesting that targeting CD99 alone is not an effective 
approach to eradicate the disease. However, CD34+/CD99- cells were shown to have 
higher frequencies of LICs (89). These data suggest that using CD99 for MRD analyse 
may lead to false negative results, as not all LIC express it. 
 
BCP-ALL LICs were described as the cells expressing CD34+/CD38- in NOD/SCID 
mice in Philadelphia positive ALL (Ph-ALL) cases (90). Later, it was found that all 
different subpopulations of BCP-ALL cells, including CD34+/CD19+, CD34+/CD19-, 
CD34- /CD19+ and CD34- /CD19- have LICs with different content (Discussed below). It 
was found that the majority of cells at sorting were CD34+/CD19+. It was also reported 
that most of the cells proliferating at week 6 were derived from the CD34+/CD19- cells, 
suggesting that they are the most primitive subpopulation. In contrast, CD34- /CD19+ 
and CD34- /CD19- cells had the lowest proliferative capabilities in vitro (91). LIC 
engraftment was compared in NOD/SCID and NSG mice. It was found that 




The CD34+/CD19- subpopulation showed the highest engraftment in both NOD/SCID 
and NSG with lower engraftment in NOD/SCID (86). CD34+/CD19- cells have the ability 
to differentiate in vivo and induce the disease resembling that of the patient from which 
the sample was taken (86). Another study showed that CD34+/CD38+/CD19+ and 
CD34+/CD38-/CD19+ populations can initiate BCP-ALL in NOD/SCID mice (92). LICs 
have been shown to express CD133 and CD133+/CD19- cells were capable of long-
term culture in vitro and in vivo and can engraft serial NOD/SCID recipients (93).  
 
Several papers have investigated the response of LICs to ALL treatment. It was 
reported that CD133+/CD19- ALL cells were resistant to standard chemotherapeutic 
agents such as dexamethasone and vincristine (93). Parthenolide (PTL) is known to 
induce apoptosis and was analysed in our laboratory to evaluate its effect on ALL cells 
(94). It was found that PTL was effective against bulk ALL cells but was less effective 
towards CD34+/CD19-, CD34+/CD7- and CD34- subpopulations, suggesting they are 
more drug resistant cells (94). HSP90 inhibitors (Celastrol and 17-DMAG) have been 
reported to be effective anti-cancer drugs used to treat ALL. Celastrol and 17-DMAG 
induce apoptosis in the bulk leukaemia in T-ALL and BCP-ALL cells. Using both drugs 
in combination were associated with significant reduction in viability in BCP-ALL and 
in LIC (CD34+/CD19+, CD34+/CD19-, CD34-/ CD19+ and CD34-/CD19-) subpopulations 
(96).  
 
1.10 Targeted therapy 
Although chemotherapy has improved the patient response compared to 50 years ago, 
many complications remain, such as cardiac dysfunction, organ toxicity and the risk of 
secondary malignancies (73). In addition, relapse is another challenge which occurs 
in 20% of ALL patients and is associated with poor prognosis (69). Infection is the 
main cause for treatment related mortality, is reported to be between 2 and 4% (96). 
Thus, attention should be paid on identifying treatments with specific targets on ALL 
cells and thus causing less toxicities on normal cells. This led researchers to focus on 
specific targets that were dis-regulated and/or mutated in ALL rather than the non-
specific targeting achieved by conventional chemotherapy (75). Many therapies were 




altered signalling pathways (73). Advances in understanding the genetic and biology 
of ALL has guided the research for drug development towards more specific molecular 
targets (97). Examples of targeted therapies are detailed below. 
 
1.10.1 Tyrosine kinase inhibitors 
ALL patients with Philadelphia chromosome (Ph+ ALL) are associated with poor 
prognosis and higher rates of relapse (73). Allogeneic haemopoietic stem cell 
transplantation (HSCT) following chemotherapy was the gold standard therapy for the 
maintenance of the complete remission to treat those patients. However, HSCT is 
associated with higher toxicities and graft-versus-host disease (GVHD) (98). Receptor 
tyrosine kinases (RTKs) are involved in a wide range of processes, including growth, 
differentiation and metabolism and dysregulation of RTKs is a common target, which 
is reported in human cancer. The fusion gene, BCR-ABL1 resulting from 
t(9;22)(q34;q11), in Ph+ leukaemia is a fusion of the tyrosine kinase ABL1 with the 
gene BCR (73). BCR-ABL1 is found in 3-5% in paediatric ALL (101). This translocation 
results in less control of cellular proliferation and it also has the potential to escape 
from apoptosis (73). Therefore, molecules that target RTKs have been considered as 
anti-cancer drugs used to treat Ph+ ALL patients (99). Imatinib was developed to target 
BCR-ABL1 and was the first-generation of tyrosine kinase inhibitors to treat Ph+ CML 
(100). Imatinib was reported to have excellent effect when combined with 
chemotherapy (100). In clinical trials, imatinib increased 3-year event-free survival 
rates to 80% compared with 30% with chemotherapy and this improvement was 
achieved with less toxicities (100). Although imatinib was promising, mutations in the 
kinase domain were developed and associated with resistance. Therefore, the 
second-generation tyrosine kinase inhibitors were developed (dasatinib) to overcome 
the kinase domain mutations, which was shown to have more potency than imatinib 
(73). Dasatinib was shown to eliminate BCR-ABL1 cells and induce apoptosis (102). 
However, the T315I mutation was shown to be resistant to dasatinib (73). Next, 
ponatinib was developed as the third-generation tyrosine kinase inhibitor and used for 





1.10.2 Monoclonal antibody therapy  
Another newer strategy in the treatment of ALL is the monoclonal antibody therapy 
and one approach of using this technology is targeting CD19. Targeting CD19 is an 
attractive approach as it is expressed at all stages in B lymphocytes. Blinatumomab is 
a promising monoclonal drug which has been used in the treatment of ALL. 
Blinatumomab is a bispecific T-cell engager (BiTE) antibody, which has the ability to 
bring the CD3+ T cells in contact with the CD19+ cells, resulting in the release of 
perforin and granzymes form cytotoxic T-cells and leading to target cell destruction 
(105),(73). Treatment with Blinatumomab resulted in the induction of remission and 
long-term survival rate for patients with relapsed BCP-ALL (106). However, not all 
BCP-ALL cells express CD19+, so CD19- cells would not be targeted by this drug and 
have the potential to cause relapse. 
 
Limited monoclonal options are avaliable for treatment of T-ALL comapred with BCP-
ALL. The monclonal antibody alemtuzumab (anti-CD52) was studied in clinical trials, 
however, it ended due to toxicities (107). A New monoclonal antibody drug that needs 
further investiagtion is daratumumab (anti-CD38) as the majority of T-ALL cells 
express CD38 with low levels on normal lymphoid and meyloid cells (108). 
Daratumumab was shown to be effective against patient-derived xenografts (PDX) for 
T-ALL (109). However, not all T-ALL expresses CD38+ cells. Evidence showed that 
CD34+/CD38+/CD19+ and CD34+/CD38-/CD19+ populations can initiate BCP-ALL in 
NOD/SCID mice (92). 
 
1.10.3 Chimeric antigen receptor T cells  
A novel method which uses engineered T lymphocytes to target leukaemia cells called 
chimeric antigen receptor (CAR) therapy is now an emerging and promising approach 
for ALL treatment. The CAR is introduced by viral transfection and composed of an 
extracellular target binding domain for a specific marker of the cancer cells (96). CAR-
T technology has shown promise in various blood cancers (110),(111). One example 
of CAR-T technology is targeting the antigen CD19 for the treatment of BCP-ALL. 
CD19 CAR-T was successful in relapsed BCP-ALL in 70% of patients with MRD 




cells will not be eliminated by CD19 CAR-T.  It was also shown that BCP-ALL patients 
relapse after treatment with CD19 CAR-T with CD19- disease (105). CD19- cells were 
shown to have LIC activity which could account for the relapse.  
 
There are fewer CAR-T therapies for T-ALL compared to BCP-ALL (107). It was shown 
that CAR-T cells can be used to target CD7 expressing cells (112). CD7 CAR-T cells 
were cytotoxic against T-cell lines and primary T-ALL cells (112). As normal T 
lymphocytes and NK cells express CD7 they are likely to be targeted by anti-CD7 CAR 
cells. However, not all T-ALL cells express CD7 antigen. CD7- cells were shown to 
have leukaemia initiating capacity. Recently, another group showed that CD1a-
specific CAR was cytotoxic against refractory cortical T-ALL (co T-ALL) in vitro and in 
vivo with limited target to host cells (113). A general concern for CAR-T therapy is that 
engineered T cells induce high levels of cytokines (interleukin-6 and tumour necrosis 
factor), causing cytokine release syndrome, which can be fatal (96).  
 
1.10.4 Heat shock protein 90 inhibitors 
HSP90 is an ATP-dependent chaperone that comprises 1 to 2 % of the total protein in 
non-stressed conditions and exhibits twofold higher expression following stress (114). 
HSP90 is a homodimer and each monomer has an N-terminal domain, a flexible linker 
region, a middle domain and a C-terminal domain (114) (Figure 1.7). The N-terminal 
domain contains the adenosine triphosphate (ATP) binding site and is essential for co-
chaperone and nucleotide binding. The middle domain is involved in binding both the 
client and co-chaperone proteins, while the C-terminal domain is essential to connect 
two monomers to form a dimer (114), which is important for protein client maturation. 
  
HSP90 was proposed to be a promising target for cancer treatment for several 
reasons. Firstly, HSP90 has the ability to stabilise and activate a wide range of client 
proteins, including oncogenic tyrosine kinase (v-Src kinase), mutated oncogene 
(BCR/ABL, FLT3), tumour suppressor (p53 protein) and steroid receptors (115). These 
client proteins were shown to be important for the development, proliferation and 
survival of several cancers, such as breast cancer and leukaemias (116). Secondly, 
HSP90 is found at high levels in acute myeloid leukaemia (AML) and is correlated with 




(including ovarian, breast, cervical, renal and oral cancers) and haematological 
cancers (such as myeloma and various leukaemias) suggesting a role in cancer 
growth and survival (114), due to disruption of the client proteins that associated with 






















                                                      Structural regions of HSP90 consist of N-terminal 
domain, a flexible linker region, a middle domain and a C-terminal domain. HSP90 inhibition 
sites by 17-DMAG and celastrol are shown.  
 
 
As HSP90 is associated with and stabilises many client proteins (97), HSP90 inhibition 
leads to degradation of these proteins, therefore targeting HSP90 is a promising 
approach for anticancer therapy. There are many drugs that target specific pathways, 
including regulators of cell survival (BCL-2, ABT-263), oncogenic proteins such as 
BCR/ABL (Tyrosine kinase inhibitors) and cell-cycle regulating proteins such as the 
cyclins (Flavopiridol) (97). However, disruption of one target may not abrogate the 
cancer phenotype in most cancers. Thus, HSP90 with its many functions is proposed 
to be a good target for ALL treatment.  




There are different mechanisms for HSP90 inhibition, including blocking the N-terminal 
domain ATP binding site, disturbing co-chaperone/HSP90 interaction and antagonism 
of client/HSP90 association (118). HSP90 inhibitors were first introduced in 1990s as 
a strategy for treating cancers and include geldanamycin and radiciol, both of which 
bind the ATP binding site leading to client protein degradation. However, their use in 
the clinic was limited due to poor solubility and significant toxicity (119). Two 
geldanamycin analogues, 17 allylamino-17 demethoxygeldanamycin (17-AAG; 
tanespimycin) and 17 dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG; alvespimycin) were developed (119). 17-AAG was tested in more than 30 
clinical trials but its effectiveness was limited with cytotoxicity and poor solubility. In 
contrast, 17-DMAG was shown to be less toxic and a water-soluble drug (120). 17-
DMAG is in development in treatment for carcinomas and leukaemias (121),(122) and 
was proven to be cytotoxic to chronic myeloid leukaemia (CML) cells but not normal 
lymphocytes (123).  
 
Inhibition of HSP90 has further expanded to various modulators of HSP90 machinery, 
such as the co-chaperones (124). HSP90 was reported to form complexes with co-
chaperones, including cell division cycle 37 (Cdc37), HSP70 and activator of Hsp90 
ATPase protein 1 (Aha1) (116). Cdc37 binds to the C-terminal ATP binding domain of 
HSP90 and is overexpressed in AML (125). These co-chaperones are involved in 
maintaining the client protein interactions and regulating HSP90 (125). Co-chaperones 
can also modulate the HSP90 ATPase rate and client protein recruitment (120). 
Therefore, inhibiting co-chaperones may be therapeutically beneficial, especially if 
combined with HSP90 inhibition.  
 
The ability of celastrol to inhibit HSP90 was discovered more than 10 years ago when 
its mode of action is uncertain. Celastrol was initially shown to inhibit HSP90 by binding 
to the ATP binding site (126). Celastrol was also shown to reduce HSP90 ATPase 
activity in the human monocytic leukaemia cell line U937 (127). Conversely celastrol 
was reported to bind directly to the C-terminal region of HSP90, disrupting the 
interaction between HSP90 and the co-chaperone Cdc37 in 293T cells (124) and in 
pancreatic cancer cells (125) (Figure 1.6). The HSP90-cdc37 complex is important in 
regulating different kinases that are implicated in cancer progression, including 




Since HSP90 inhibition leads to the release and subsequent misfolding of client 
proteins, HSP90 inhibitors were assessed for their ability to induce the cellular stress 
response. Celastrol was shown to induce HSF1 activation and hyperphosphorylation 
and subsequently HSP gene expression (128),(129). Furthermore celastrol was 
shown to upregulate HSP70 expression in Jurkat human leukaemia cell lines (130). 
Similarly, 17-DMAG treatment induces the activation of HSF1 and HSP70 induction in 
vivo (131).  
 
1.10.4.1 The role of HSF1 in the stress response 
Exposure of cells to high temperatures triggers a well-characterised protective 
response known as the heat shock response (HSR) or stress response (132). Heat 
shock proteins (HSPs) are produced following stress and are regulated by several 
heat-shock factors (HSF1– HSF4) with HSF1 being the master regulator of the stress 
response in humans (132). A variety of other stresses including osmotic shock, 
oxidative stress and heavy metals also trigger the stress response (4). 
 
HSF1 is a monomer and bound to hsp90 in the cytoplasm under normal conditions 
Upon stress, it is released from hsp90 (usually due to competition with misfolded 
proteins), undergoes trimerisation (132) and is translocated to the nucleus where it 
binds to heat shock elements (HSEs) in HSP promoters (133) leading to HSP mRNA 
synthesis. HSF1 activation is regulated by many post-translational modifications, 
including phosphorylation, SUMOylation and acetylation (134). HSPs are highly 
expressed following stress and act as molecular chaperones to prevent protein 
misfolding and aggregation (132). There are several families of HSP proteins including 
HSP40, HSP60, HSP70 and HSP90 that have different cellular localisation and 
functions (97). Competition for Hsp90 binding in the cell is also known to result in the 
activation of HSF1 and the induction of a stress response. However, the stress 
response following HSP90 inhibitors (inducer of the stress response) has never been 






Upon stress, in addition to HSP production, HSF1 also transcribes G-rich long non-
coding satellite-III (SatIII) RNAs  (135) mediating nSBs formation (136).  nSBs were 
first identified in HeLa cells exposed to heat shock (137) and later HSF1 was found to 
be concentrated at these sites (138),(139). SatIII RNA is located on the 
pericentromeric heterochromatic q12 band of chromosomes 9, 12 and 15	(140). The 
binding of HSF1 to the SatIII locus mediates the recruitment of the histone 
acetyltransferase (HAT) CREB-binding protein (CBP) (139) and SatIII is transcribed 
by RNA polymerase II (141). SatIII RNAs act as scaffolds to recruit other proteins such 
as SAFB1, SRSF1 and 9G8 thus forming  nSBs (4),(135),(139). nSBs are known to 
be transient storage sites for splicing factors and RNA binding proteins (142). Splicing 
factors and RNA binding protein sequestration is thought to be a significant strategy 
to restrain splicing machinery components from the damage induced from the stress 





















                                                                         HSF1 trimerises following heat shock and binds to satellite III sequences recruiting histone 
acetyltransferase (HAT) CREB-binding protein. RNA polymerase is also recruited to initiate transcription. Different splicing factors, including 
SAFB1 are recruited to satellite III transcripts leading to nSBs formation. 
 




1.10.4.2 HSF1 in cancer 
HSF1 activities extend far beyond the classical stress response and accumulating 
evidence has linked HSF1 with oncogenesis (144). HSF1 activation in cancer is 
caused by many factors, such as tumour microenvironment, aneuploidy and reactive 
oxygen species (134). HSF1 activation occurs to allow cancer cells to cope with the 
proteomic instability (147) and is associated with poor prognosis in prostate, lung, 
colon (145),(148) and melanoma cancers (149). HSF1 was found to be overexpressed 
in prostate cancer cell lines (150), human breast cancer cells (148), chronic 
lymphocytic leukaemia (CLL) (151) and found in the nucleus of CLL B cells but not in 
normal B cells (152). HSF1-knockout mice are less susceptible to tumorigenesis 
induced by oncogenic Ras or mutant p53 (153). HSF1-knockout mice showed 
impaired growth, invasion and metastasis of xenograft hepatocellular carcinoma 
(HCC) (154) and melanoma cells (155). HSF1 knockdown is associated with less 
proliferation and survival rates of cancer cells (156). These studies clearly emphasise 
the significant role of HSF1 in cancer progression and survival (156). CHIP seq 
analyses found that HSF1 binds more genes in highly malignant cells in comparison 
to less aggressive breast cancer cells, many of which (e.g. cyclin-dependent kinase 
interacting protein (CKS2), glycophosphatidyl-inositol-anchored membrane protein 
(LY6K) and probable RNA-binding protein 23 (RBM23)) were not classical heat shock 
genes (145), suggesting that HSF1 supports highly malignant cancers. HSF1 was 
shown to be regulated by polyploidy generation in prostate cancer cells, suggesting a 









1.11 Project aims 
Although SAFB1 has been implicated in carcinogenesis in several cancers, the 
biological functions and underlying mechanisms of SAFB1 and SAFB2 in the 
progression of paediatric ALL patients are largely unknown. Treatment with HSP90 
inhibitors induces apoptosis in ALL cells (95) and several publications report that 
HSP90 inhibition induces a heat shock response (157,122,158). SAFB1 is reported to 
be sequestered into nSBs in HeLa cells following heat shock and co-localises with the 
transcription factor HSF1. However, SAFB1, SAFB2 and HSF1 localisation/expression 
was not explored in primary ALL cells following heat shock and treatment with HSP90i. 
SAFB1 and SAFB2 were shown to be methylated and SUMOylated and SAFB1 was 
reported to interact with several proteins. However, whether the methylation and 
SUMOylation status of SAFB1/2 influences their binding partners in primary ALL have 
never been investigated.  
 
The overall aims of this thesis were therefore to:  
(i) Characterise SAFB1 and SAFB2 expression in ALL 
(ii) Compare the stress response in HeLa and ALL cells following heat shock 
and treatment with HSP90 inhibitors 
(iii) Investigate SAFB1 and SAFB2 interactions in HeLa and ALL cells and 
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2.1 Primary ALL and NBM samples 
Bone marrow (BM) cells from children (median age, 11 years; range, 2 - 18) diagnosed 
with T-ALL (n=14) and BCP-ALL (n=18) at diagnosis or relapse were collected with 
approval of University Hospitals Bristol NHS Trust. Patient characteristics are shown 
in Table 2.1. Normal BM (NBM) cells from healthy donors were used as controls. 
Samples’ selection was based on the availability of materials. Most patients were 
males and taken at diagnosis, however, some patients were taken at the time of 
relapse. MRD status of patients were classified as low, intermediate and risk groups. 
Patients karyotype were variable and associated with good or poor prognosis.  
 
2.1.1 Mononuclear cell isolation 
Mononuclear cells were isolated from ALL and normal bone marrow (NBM) by density 
centrifugation. Bone marrow samples were mixed with an equal volume with Iscove's 
Modified Dulbecco's Medium (IMDM, Invitrogen, Paisley, UK) and layered carefully on 
one volume of Histopaque®-1077 (Sigma-Aldrich, Poole, UK) and centrifuged at 1500g 
for 20 minutes. For example, 4ml of bone marrow sample is mixed with 4ml of IMDM 
and layered with 4ml of Histopaque®-1077. Blood components were separated with 
mononuclear cells and platelets being retained in a single layer above the ficoll layer. 
The mononuclear cells were collected, washed with 10ml of IMDM and centrifuged at 
350g for 5 minutes to remove platelets. The supernatant was removed, the cell pellet 
was resuspended in 10ml of IMDM and centrifuged at 1000g for 5 minutes. The 
supernatant was removed and the cell pellet was resuspended in red cell lysis buffer 
(Miltenyi Biotec, Bisley, UK) for 10 minutes at room temperature. Cells were 
centrifuged at 500g for 5 minutes and the cell pellet was resuspended in 10ml of IMDM. 
The supernatant was removed and the isolated mononuclear cells were resuspended 
in 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO). Samples were 
cryopreserved in liquid nitrogen (LN2) until use. Upon use cells were thawed in a water 
bath at 37oC then 10ml of FBS was added drop-wise to the cells. The cells were then 
washed with 10ml of FBS and IMDM at 1:1 ratio and viability checked by a 
MACSQuant 10 flow cytometer (Miltenyi Biotec) using Propidium Iodide (PI, Miltenyi 
Biotec). Cells were resuspended in RPMI 1650, penicillin (50U/ml), L-glutamine 




Table 2.1 Patient sample characteristics 
	
ID Classification Karyotype Age (y) Sex Disease status 
MRD risk 
Status* 
1 T-ALL t(11;14) 2 M Relapse Low 
2 T-ALL 46XY 14 M Diagnosis Risk 
3 T-ALL del 6q 3 F Diagnosis Risk 
4 T-ALL del 6q 2 M Diagnosis Risk 
5 T-ALL N/A 6 M Diagnosis Low 
6 T-ALL t(9;22) 10 M Diagnosis Risk 
7 T-ALL N/A 8 M Diagnosis Risk 
8 T-ALL +4, +9 15 M Relapse Risk 
9 T-ALL N/A 15 M Diagnosis Low 
10 T-ALL del 6q 14 M Diagnosis Risk 
11 T-ALL N/A 5 M Diagnosis N/A 
12 T-ALL N/A 12 M Diagnosis N/A 
13 T-ALL del 4q 15 M Diagnosis Low 
14 T-ALL 46XY 8 M Diagnosis Low 
       
15 Pre-pre B High 
hyperdiploidy 
8 M Diagnosis Risk 
16 Pre B -1 + Mar 2 F Diagnosis Low 
17 Pre B +4, +9 2 M N/A Low 
18 Pre B 46XY 8 M Diagnosis Risk 
19 Pre B t(12;21) 2 M Diagnosis Low 
20 BCP N/A 10 F Diagnosis Low 
21 Pre-pre B del 6q 4 M Diagnosis Risk 
22 Pre B dic(9;20) 4 F Diagnosis Low 
23 Pre B t(12;21) 3 M Diagnosis Low 
24 Pre B iAMP21 11 M Diagnosis Intermediate 
25 Pre B 46XY 16 M Diagnosis Risk 
26 Pre B -1 + Mar 10 F Diagnosis Low 
27 Pre B t(12;21) 17 M Relapse Low 
28 Pre B t(12;21) 5 M Diagnosis Low 
29 Pre B t(12;21) 18 M Diagnosis Low 
30 BCP      
31 Pre B 46XY 3 F Diagnosis Low 
32 Pre B 46XY 12 F Diagnosis Intermediate 
           
 
 
2.2 Cell culture 
2.2.1 Human cervical cancer cell line (HeLa cells)  
HeLa cells were used in this thesis for practice and optimisation purposes. HeLa cells 
were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 
penicillin (50U/ml), L-glutamine (2mM) and streptomycin (50μg/ml) and 10% FBS (all 
Sigma-Aldrich). Cells were grown in T75 flasks and maintained at 370C in 5% CO2. 
Cells were passaged twice a week with complete media changes. 




2.2.2 Mouse embryonic fibroblasts (MEFs) 
MEFs were used as a highly proliferating cell model to assess the effect of SAFB1 
overexpression. MEFs were maintained in DMEM supplemented with penicillin 
(50U/ml), L-glutamine (2mM) and streptomycin (50μg/ml), 10% FBS, 0.01% β -
mercaptoethanol and 1% non-essential amino acids (NEAAs) (all Sigma-Aldrich). 
Cells were grown in T75 flasks and maintained at 37oC in 5% CO2. Cells were 
passaged once a week with a complete media change. 
 
2.2.3  Primary T-ALL 
Prior to Co-IP, primary T-ALL cells were plated at 5x105 cells/ml in 30 well plates in 
serum free media, supplemented with IL-3 (50µg/ml), IL-7 (25µg/ml), stem cell factor 
(50µg/ml)	(all Miltenyi Biotec) and bovine serum albumin (BSA), insulin, and transferrin 
(BIT) 9500 serum substitute (stemcell technologies, Cambridge, UK). Viability and cell 
count were checked regularly using the annexin V-PI flow cytometric assay. Cells were 
harvested after 10 days with half media change after 5 days in co-IP lysis buffer. Cell 
lysis and protein assays were performed as described previously (section 2.12) in co-
IP lysis buffer (Table 2.10). 
	
	
2.3 Plasmid preparation 
2.3.1 Transformation 
pEGFP.SAFB1, pEGFP.SAFB2 and pRRL.sin.cppt.CMV.EGFP.WPRE were 
transformed into 50μl of chemically competent E.coli cells such as Stbl3 or DH5α 
(Invitrogen, UK), incubated on ice for 30 minutes, heat shocked at 420C for 45 seconds 
and then placed immediately on ice for 2 minutes. A volume of 250μl of super optimal 
broth with catabolite repression (SOC, Invitrogen) media was added, incubated at 
37oC for one hour and plated overnight on luria broth (LB, Invitrogen) agars with 
appropriate antibiotic (50μg/ml kanamycin, Sigma-Aldrich) or (100μg/ml ampicillin, 
Sigma-Aldrich). Several colonies were picked and grown in 3ml LB with ampicillin 





2.3.2 Plasmid purification 
One to three millilitres of bacterial culture was purified on a miniprep scale to isolate 
plasmid DNA using QIAprep Spin Miniprep Kit (Qiagen, Manchester, UK) according to 
the manufacturer’s instructions. Five hundred millilitres of bacterial culture were 
purified on a maxiprep scale using the density gradient centrifugation method. Five 
hundred millilitres of LB were incubated with 1ml of bacterial culture and incubated 
overnight in a shaking incubator at 37oC. The bacterial culture was centrifuged at 
1800g for 30 minutes at room temperature. The supernatant was removed and the cell 
pellet was resuspended in 18ml of solution 1. Two millilitres of lysozyme solution and 
40ml of solution 2 was added, then the pot was inverted 6 times and left for 10 minutes 
at room temperature to lyse bacteria. Twenty millilitres of solution 3 were added, the 
pot was inverted 6 times and left for 10 minutes on ice to neutralise the lysate. All 
solutions used are detailed in Table 2.2. The lysate was centrifuged at 1800g for 20 
minutes at 4oC. The supernatant was filtered and 0.6 volume isopropanol was added, 
mixed once and left for 10 minutes at room temperature to precipitate plasmid DNA. 
The tubes were centrifuged at 4000g for 20 minutes at room temperature. The 
supernatant was removed and the pellets were left to dry. The pellets were dissolved 
in TE buffer (1M Tris pH8 and 500mM EDTA). An equal mass of caesium chloride 
(CsCl, Sigma-Aldrich) was dissolved in the DNA solution. Ethidium bromide was 
added and centrifuged at 4000g for 12 minutes at room temperature. The supernatant 
was transferred into a Beckman optiseal ultracentrifuge tube and topped up with 
TE/CsCl (1:1). The tube was placed in an NVTi65 rotor (Beckman Coulter) and 
centrifuged overnight at 475000g. The pink band (plasmid DNA) was collected 
carefully, mixed with butanol (Sigma-Aldrich) several times to remove ethidium 
bromide from the DNA. The DNA was transferred into a 50ml falcon tube, 10ml dH2O 
and 45ml of ethanol was added. The tube was mixed, left in the fridge for 20 minutes 
to precipitate plasmid DNA and centrifuged at 4000g for 20 minutes at 4oC. The 
supernatant was removed and the DNA pellet was washed with 70% ethanol. The tube 
was centrifuged at 4000g for 5 minutes at 4oC. Ethanol was removed, the pellet was 
left to dry and resuspended in dH2O. Plasmid DNA concentrations were measured 






Table 2.2 Maxi-prep solutions 
	
Solution 1 Final Concentration 
Glucose 5mM 
Tris pH8 25mM 
EDTA 10mM 
Lysozyme solution Final Concentration 
Lysozyme 5mM 
Tris pH8 10mM 
Solution 2 Final Concentration 
NaOH 200mM 
SDS 1 % 
Solution 3 Final Concentration 
Potassium Acetate 3M 
Glacial acetic acid 11.5 % 
	
2.3.3 Restriction Endonuclease reactions 
Appropriate restriction enzymes were chosen using Serial Cloner software to check 
the size of the plasmids. All restriction enzymes and buffers were purchased from 
(NEB, Hitchin, UK) or (Roche, Welwyn Garden, UK). All restriction enzyme reactions 
were carried out in a total volume of 20μl for 1-2 hours according to the manufacturer’s 
instructions. 
 
2.3.4 Agarose gel electrophoresis and sequencing 
One percent agarose gels were prepared using agarose (Melford, Suffolk, UK) and 
100ml of TAE (Tris / acetic acid / EDTA) buffer with 0.5μg of ethidium bromide (Sigma-
Aldrich). Digested plasmid DNA samples were mixed with 0.17 volumes of 6 X loading 
buffer and run on the gel in TAE buffer at 100-110 V until sufficient separation of DNA 
fragments was achieved. One kilobase (1kb) DNA ladder (NEB) was used to estimate 
the DNA length. Gels were visualised and photographed using a UV transilluminator 
(Bioimaging systems). Plasmid DNA was sequenced by Source Bioscience 






2.3.5 Plasmid transfection 
For plasmid transfection experiments, HeLa cells were plated in 24 well-plates, at 
1x104 cells/ml. Primary ALL and NBM cells were plated at 1x106 cells/ml in 96 well 
plates prior to transduction. Cells were then transfected with appropriate plasmids 
using Lipofectamine 2000 (Invitrogen) and Optimem (Gibco) according to the 
manufacturer’s instructions. A concentration of 500ng of plasmid DNA/ml was used 
throughout.  
 
2.4 Adenoviral transduction 
Primary ALL and NBM cells were plated at 1x106 cells/ml in 96 well plates prior to 
transduction. Ad.CMV.EGFP.SAFB1 and Ad.CMV.EGFP.SAFB2 were used at a 
multiplicity of infection (MOI) of 50. As a control, Ad.CMV.EGFP was used. Cells were 
then left at 37oC in 5% CO2 and 5% O2 for 24 and 48 hours prior to assessing viability. 
 
2.5 Mutagenesis 
SAFB1 mutagenesis was performed using QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent technologies, UK) according to the manufacturer’s 
instructions. pEGFP.SAFB1 plasmid was used as a template to mutate the arginine 
methylation sites (aa557, aa754, aa811, aa868, aa874, aa884 and aa902).  All primers 
were ordered from (Sigma-Aldrich, UK) according to protocol guidelines, as shown in 


















aa557 (RG)  
 
F: 5’ CACAAAGTCAGGAAGTAAGGGGACCGAACGGAC 




aa754 (RG)  
 
F: 5’ GACCACAGGGACAAGGGCCGCTACCCCG 
R: 5’ CGGGGTAGCGGCCCTTGTCCCTGTGGTC 
 
Mutation 3: 
aa811 (RG)  
 
F: 5’ GGATGAGCGAGGGCAAGGGGCTGCCTCCTCC 






aa874 (RG)  
 
F: 5’ CCACATGATGAACAAGGGAGGAATGTCAGGGAAGGGCAGCTTTGC 
R 5’ GCAAAGCTGCCCTTCCCTGACATTCCTCCCTTGTTCATCATGTGG 
 
Mutation 6: 
aa884 (RG)  
 
F: 5’ GGCGGGGCCTCCAAGGGCCACCCCATCC 
R: 5’ GGATGGGGTGGCCCTTGGAGGCCCCGCC 
 
Mutation 7: 
aa902 (RG)  
 
F: 5’ GGAGGCCAGAGCAAGGGGAGCAGGCCC 
R: 5’ GGGCCTGCTCCCCTTGCTCTGGCCTCC 
 
 
The reaction mix for the first mutation (aa557) was prepared, containing 1x reaction 
buffer, 10ng plasmid template (pEGFP.SAFB1), 125ng forward and reverse primers, 
dNTPs mix, quick solution and Pfu HF polymerase (50μl total volume). The cycling 
parameters are shown in Table 2.4. 
 
 
Table 2.4 Cycling parameters 
	
Segment Cycles Temperature Time 
1 1 95oC 1 





1 minute/kb of plasmid length 
3 1 68oC 7 minutes 
 
 
Following cycling, the reaction tubes were immediately placed on ice for 2 minutes. 
One microlitre of the Dpn I restriction enzyme was added. After mixing, the reactions 
were incubated at 37oC for 1 hour to digest non-mutated plasmid. Two microlitre of β-




incubated on ice for 10 minutes with gentle swirling every 2 minutes. Two microlitre of 
the Dpn I-treated plasmid was added to ultracompetent cells and incubated on ice for 
30 minutes. The tubes were heat shocked at 42oC for 30 seconds and then incubated 
on ice for 2 minutes. A volume of 0.5ml of preheated (42°C) NZ amine (casein 
hydrolysate) and yeast (NZY+) broth was added to each tube and incubated at 37oC 
for an hour. A total of 250μl of the transformation reaction was plated on LB agar plates 
containing 80μg/ml X-gal and 20 mM Isopropyl-1-thio-β-D-galactopyranoside (IPTG) 
and kanamycin antibiotic. The plates were incubated at 37oC for >16 hours. Plasmid 
purification, agarose gel electrophoresis and sequencing were performed as 
described previously (section 2.3). The mutated plasmid was used as a template to 
perform the next mutation. The final plasmid with all sites (aa557, aa754, aa811, 
aa868, aa874, aa884 and aa902) mutated was used for the subsequent experiments. 
 
2.6 Heat shock (HS)  
HeLa cells were seeded at 1x103 cells/ml in 200μl DMEM in 96 well plates and 
maintained for 48h prior to heat shock. In some instances, HeLa cells were transfected 
with 500ng plasmid DNA/ml. Primary ALL and NBM cells were grown at 1x106 
cells/well in 200μl DMEM in 96 well plates. Cells were then transferred to a heat block 
at 42oC within the incubator for 80 minutes with either no recovery period or a 1 hour 
recovery at 37oC with 5% CO2. In addition, some cells were not heat shocked as 
controls.  
 
2.7 Heat shock protein 90 inhibitors  
Celastrol and 17-DMAG (Stratech Scientific Ltd,Cambridge, UK) were dissolved in 
DMSO at a 1mM stock concentration. The required concentrations were achieved by 
diluting in DMEM supplemented with 10% FBS and L-glutamine (2mM) to obtain final 
concentrations of 10μM, 5μM, 1μM, 0.1μM, 0.01μM, 0.001μM, 0.0001μM and 
0.00001μM. Cells treated with DMSO were used as controls and DMSO concentration 
was kept constant. To measure cell death following HSP90i treatment, HeLa cells 
were seeded at 4x104 cells/ml in 500μl DMEM in 24 well plates, while primary ALL and 




treated with different concentrations of both 17-DMAG and/or celastrol and left for 24 
and 48 hours. Cells were then fixed and immunostained for SAFB1, SAFB2, HSF1, 
SRSF1 and HSP70 (Section 2.8). Also, Hela cell lysates were subjected to Western 
blotting analyses to measure HSP70 expression. At 48 hours post treatment, HeLa 
cells were also incubated with MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich) product (section 2.11). However, 
primary ALL and NBM cells were evaluated for viability using Annexin-V/PI flow 
cytometric assay (section 2.9).  
 
2.8 Immunofluorescence 
Wells were coated with an appropriate volume of 0.1% poly-l-lysine (Sigma-Aldrich-
P8920) for 5 minutes and subsequently washed carefully with phosphate buffer saline 
(PBS). Wells were left to dry for 5 minutes and then primary ALL and NBM cells were 
seeded and incubated for 1 hour at 370C in the incubator prior to treatment. Media 
was removed and cells were washed once with PBS before fixation with 4% 
paraformaldehyde (PFA) for 10-15 minutes. Cells were blocked and permeabilised 
with 0.3% Triton X-100 with 0.05% donkey serum in PBS for 1 hour with gentle rocking. 
Cells were incubated overnight at 40C with primary antibodies (Table 2.5). After 3x10 
minute washes with PBS with gentle rocking, cells were incubated with the appropriate 
secondary antibodies for 1 hour at room temperature (Table 2.6).  After 3 x 10 minute 
washes with PBS, cells were stained with Hoechst (1μg/mL) for 15 minutes with gentle 
rocking and cells were washed twice with PBS. Images were taken using a confocal 
laser microscope (Perkin Elmer Opera LX system) at 63x magnification. Fluorescence 
intensities and the number of nuclear stress bodies were detected using ImageJ 
software. For HSF1 nuclear border expression, nuclear outlines were first determined 
using blue and red fluorescence channels using ImageJ. Each nucleus object was 
then split into two objects: an edge object, comprising a 5-pixel wide region at the edge 
of the nucleus, and the remaining central region. Red channel intensity was measured 







Table 2.5 Primary antibodies 
	
Antibody Dilution Company Catalogue 
SAFB1 (rabbit) 1 in 200 Bethyl A300-811A 
SAFB2 (rabbit) 1 in 200 Bethyl A301-112A 
HSF1 (rat) 1 in 200 ENZO Life sciences ADI-SPA-950 
SRSF1 (mouse) 1 in 200 Thermo Fisher Scientific 32-6400 
HSP70 (mouse) 1 in 200 ENZO Life sciences ADI-SPA-810-D 
 
 
Table 2.6 Secondary antibodies 
	
Antibody Dilution Company Catalogue 
donkey anti rabbit 
IgG Cyanine 3 
1 in 200 Jackson Laboratories 711-165-152 
donkey anti rat IgG 
Cyanine 3 
1 in 200 Jackson Laboratories 712-165-150 
donkey anti rabbit 
IgG Cyanine 2 
1 in 200 Jackson Laboratories 711-225-152 
donkey anti mouse 
IgG Alexa Fluor 488 
1 in 200 Thermo Fisher Scientific R37114 
	
	
2.9 Annexin V/PI apoptosis assay 
After plasmid transfection and adenoviral transduction, primary ALL and NBM cells 
were washed and stained with Annexin V-FITC at 1:20 (Miltenyi Biotec) for 10 minutes 
in the dark. Cells were resuspended in Annexin V buffer (100μl) and PI (1μl) was 
added. Viability and apoptosis were measured using a MACSQuant 10 flow cytometer 
(Miltenyi Biotec).  As an example, lymphocytes were gated according to side scatter 
(SSC) and forward scatter (FSC) based on the size and granularity of cells, 
respectively (Figure 2.1A). The gating strategy was set up based on unstained cells 
(Figure 2.1B). Cells are considered to be viable when PI and Annexin-V are negative. 
Cells in late apoptosis are positive for PI and Annexin-V. Early apoptotic cells are PI 
negative and Annexin-V positive. Dead cells are positive for both PI only (Figure 2.1C). 





































                                                                                                                                    (A) 
Lymphocytes were gated according to SSC and FSC based on the size and granularity of cells (B) 
Gating was set up based on un-stained cells. (C) Dead, apoptotic and live cells can be discriminated 
based on PI and annexin-V and cells are alive when PI and Annexin-V (FITC) are negative. Numbers 










2.10 Drug effect calculations 
The Annexin-V/PI flow cytometry method or MTT assay were used to measure the 
effect of drugs on viability. As an example, 17-DMAG was used at increasing 
concentrations to generate a dose response curve and find a dose that kill half of cells 
treated, known as the half maximal inhibitory concentration (IC50). Following that, a 
second best fit curve was generated and the IC50 value was measured based on the 






Figure 2.2 17-DMAG dose response curve. 
Viability of BCP-ALL at 24 hours post 17-DMAG treatment (0.01-1000nM) was calculated 
using annexinV/PI assay. A second order best fit curve (red) shows the IC50 based on 
the viability.  
 
2.11 MTT Assays 
Viability of HeLa and MEF cells was assessed using the MTT assay, which estimates 
metabolic activity of cells by measuring the mitochondrial-dependent conversion of 
MTT to a coloured formazan product. MTT (0.5mg/ml) was added directly to each well 
and incubated in 5% CO2 at 37°C for 3h. The medium was then aspirated and 200µl 
acidified isopropanol was added to solubilise the coloured formazan product that is 




spectrophotometer (Bio-Rad, London, UK), after agitating the plates on a shaker for 5 
minutes.  
 
2.12 Quantitative Polymerase Chain Reaction (qPCR)  
2.12.1 RNA extraction 
RNA was isolated from primary BCP-ALL, T-ALL and NBM cells using ReliaPrep RNA 
cell miniprep system (Promega, Southampton, UK) according to the manufacturer’s 
instructions. Briefly, cells were washed with cold PBS and lysed in BL buffer 
supplemented with 1-thioglycerol. A 20-gauge needle was used to further lyse the cells 
and shear genomic DNA. Isopropanol was added to precipitate the RNA before 
transferring the lysate to the ReliaPrep mini column. After centrifugation, DNase was 
added and incubated for 15 minutes at room temperature to digest DNA. After several 
washes, RNA was eluted in 30µl of dH2O. RNA concentration and purity was assessed 
using Nano drop (Thermo Fisher) and stored at -800C. 
 
2.12.2 cDNA synthesis 
RNA was reverse transcribed using GoScript Reverse Transcription system 
(Promega) according to the manufacturer’s instructions. Briefly, Random primers (0.5 
µg) were mixed with 80ng/µl of RNA and incubated at 700C for 5 minutes (denaturation 
step), then placed on ice. The reverse transcription reaction mix was prepared, 
containing RT buffer (1x), MgCl2 (2mM), PCR nucleotides mix (0.5mM), recombinant 
RNasin ribonuclease inhibitor (20 unit) and GoScript reverse transcriptase. The 
RNA/primer sample and reverse transcription reaction mix were combined and 
incubated at 250C for 5 minutes (annealing step). Next, the tubes were incubated at 
420C for 60 minutes (cDNA synthesis step), followed by incubation at 700C for 15 
minutes to inactivate reverse transcriptase. The cDNA was diluted in nuclease free 







2.12.3 Real-time qPCR for SAFB1 and SAFB2 expression 
cDNA samples were mixed with SYBR green master mix (Applied Biosystems, 
Warrington, UK) and 300nM of forward and reverse primers (Table 2.7) from (Sigma-
Aldrich) in 96 well plates. The SYBR green dye binds to double strand DNA and this 
results in fluorescence, indicating cDNA amplification is taking place. Each 
amplification is measured as a cycle threshold (CT). GAPDH and Beta actin were used 
as endogenous controls to normalise CT values. Samples were run by Step-One Plus 
Real-Time PCR Systems (Applied Biosystems).  
 
 
Table 2.7 Primer sequences 
	
Gene Sequence 







R’- CAGAGGCGTACAGGGATAGCAC  
	
2.12.4 Analysis 
SAFB1 and SAFB2 relative expression was calculated using the ΔΔCT method. 
Briefly, CT values were normalised against the mean of the endogenous controls, 
GAPDH and Beta actin and then to the calibrator sample (NBM). Then the normalised 
values (ΔΔCT) were converted to the linear scale (2- ΔCΔCT) to give fold change 
comparison between samples. 
 
2.13 Western blotting  
2.13.1 Cell lysis and protein assays 
Cells were washed twice with cold PBS and were then scraped in 
radioimmunoprecipitation assay (RIPA) buffer (50mM Tris-HCL pH8, 150mM NaCl, 




with phosphatase inhibitor phosSTOP and protease inhibitor complete mini (Roche). 
Lysates were transferred to a pre-cooled Eppendorf tube and centrifuged at 20000g 
for 30 min at 40C to remove cell debris. The supernatant was frozen at - 800C until 
use. The protein concentration was measured using the bicinchoninic acid assay (BCA 
assay, Thermo Fisher, USA). The BCA working solution was made according to the 
suggested ratio by the supplier. A volume of 2µl of protein samples and known protein 
standards were loaded into 96 well plates. After that, 98µl of BCA working solution 
was added and incubated at 370C for 60 minutes. The colorimetric change was 
measured at 567nm absorbance using a plate reader (Glomax, Promega). 
 
2.13.2 Sodium dodecyl sulfate poly acrylamide (SDS) gel electrophoresis 
Eight percent acrylamide gels (0.1% SDS, 8% acrylamide gel, 150mM Tris pH8.8, 
0.1% APS, TEMED) were cast in Mini Protean II apparatus (Bio-Rad). Once 
polymerised a stacking gel (0.025% SDS, 8% acrylamide gel, 250mM Tris pH6.8, 
0.025% APS, TEMED) was added on and a comb used to form sample wells. A volume 
of 2 X sample loading buffer (100mM Tris base, 25% glycerol, 2% SDS, 0.01% 
bromophenol and 10% mecaptoethanol, Dithiothreitol, 0.5M) (all Sigma-Aldrich) was 
added to protein samples (usually 20µg). Samples were heated at 1000C for 5 minutes 
to denature proteins prior to loading. Samples along with a broad range protein 
standard (NEB) were loaded to the gel and electrophoresed at 100V. 
 
2.13.3 Transfer, staining and detection of proteins 
The gel transfer was performed using Trans-Blot Turbo system (Bio-Rad) according 
to the manufacturer’s instructions. Briefly, the gel was placed on top of the membrane 
and stacks in the cassette. Additional stacks were arranged on the top. The cassette 
was closed and transfer performed for 10 minutes using the high molecular weight 
protocol suggested by the manufacturer. The membrane was blocked in 5 % milk 
(dried skimmed milk, Marvel) and PBS 0.1 % tween for an hour with rocking. The film 
was incubated overnight at 40C with the primary antibodies and diluted in PBS 0.1 % 
tween and 1 % milk (Table 2.8). SAFB1 and SAFB2 antibodies were previously 
validated (Rivers et al., 2015). After 3 x 10 minute washes with PBS 0.1 % tween, the 




secondary antibodies and diluted in PBS 0.1 % tween and 1 % milk (Table 2.9). After 
3 x 10 minute washes with PBS 0.1 % tween, the membrane was then incubated for 
5 minutes with enhanced chemiluminescence (ECL) reagent (Pierce) and the 
membrane was exposed to an autoradiographic film (Amersham, GE Healthcare, 
Freiburg, Germany). The relative protein expression was calculated by densitometry 
using ImageJ and normalised to Alpha tubulin to control for loading. 
 
 
Table 2.8 Primary antibodies 
	
Antibody Dilution Company Catalogue 
SAFB1 (rabbit) 1 in 1000 Bethyl A300-811A 
SAFB2 (rabbit) 1 in 1000 Bethyl A301-112A 
SRSF1 (mouse) 1 in 1000 Thermo Fisher Scientific 32-6400 
SRSF1 (rabbit) 1 in 1000 Abcam Ab38017 
HSP70 (mouse) 1 in 1000 ENZO Life sciences ADI-SPA-810-D 
Alpha tubulin (mouse) 1 in 2000 Sigma T5168 
 
 
Table 2.9 Secondary antibodies 
	
Antibody Dilution Company Catalogue 
anti mouse IgG HRB-
linked whole Ab 
1 in 10000 GE healthcare NA391 
anti rabbit IgG HRB-
linked whole Ab 
1 in 10000 GE healthcare NA394 
 
2.14 Co-Immunoprecipitation (co-IP) 
For co-IP of endogenous proteins HeLa cells were seeded in 10cm dishes at 1x105 
cells/ml and incubated for 48h. For co-IP of EGFP tagged proteins HeLa cells were 
seeded in 10cm dishes at 5x104 cells/ml, the next day cells were transfected with 
SAFB1-EGFP or SAFB2-EGFP plasmid (15µg/dish). Cells were incubated for 48h 






2.14.1 Cross-linking of antibodies for co-IP 
Three micrograms of antibody (rabbit SAFB1 (A300-811A, Bethyl), rabbit SAFB2 
(A301-112A, Bethyl), rabbit IgG (2729, cell signalling, USA) mouse EGFP (Memorial 
Sloan-Kettering, USA) and mouse IgG (14-4714-82, Invitrogen) were incubated with 
20µL Pierce Protein G magnetic beads (Thermo Fisher) and PBS 0.02% tween 
(PBST), taking the final volume to 1ml and rotated at 4˚C overnight. Following 
incubation, beads were applied to a magnet and supernatant was removed. Beads 
were washed with PBST 3 x 10 seconds with tubes inverted a few times. Beads were 
washed again 3 x for 10 seconds in coupling buffer (0.2M triethanolamine (Sigma-
Aldrich) in PBS with 0.01% Tween-20) at pH9. Next, beads were crosslinked in 20mM 
Dimethyl pimelimidate dihydrochloride (DMP, Sigma-Aldrich) in coupling buffer for 1 
hour at room temperature. The crosslinked antibodies were quenched in 50mM 
ethanolamine (Sigma-Aldrich) in PBST for 30min at room temperature. After 
quenching, beads were washed in elution buffer (0.2M glycine (Sigma-Aldrich) pH2.5 
with PBST with vortexing to remove uncrosslinked antibody. The crosslinked beads 
were resuspended in PBST and stored at 40C until use. 
 
2.14.2 SAFB1 and SAFB2 co-IP 
Three micrograms of crosslinked IgG were washed 3 x in PBST. Beads were rotated 
with the protein lysates of interest for 6 hours in the cold room at 40C to remove 
background interacting events. After incubation, beads were applied to a magnet and 
the supernatant collected (pre-cleared lysate). A total of 500µg pre-cleared lysate was 
incubated with 3µg of cross-linked antibody overnight at 40C. The next day, beads 
were applied to a magnet and the supernatant was removed and kept 
(immunodepleted lysate). The beads were washed 6 x with 500µL co-IP lysis buffer 
with gentle mixing. Beads were always kept on ice between washes. After the final 
wash, 2/3 of the volume of beads was stored at -800C for proteomic analyses. The 
remainder was resuspended in 2 X SDS gel buffer and Dithiothreitol (DTT, 0.5M), 






Table 2.10 Co-IP lysis buffer 
	
 Final Concentration 
Tris (pH 7.5) 20 mM 
NaCl 150 mM 
EDTA (disodium salt dehydrate, Sigma E5134) 1 mM 
EGTA (Sigma E3889) 1 mM 
IGEPAL CA-630 1 % 
Sodium pyrophosphate (tetrabasic decahydrate, 
Sigma S6422) 2.5 mM 
Sodium orthovanadate (Sigma S6508) 1 mM 
Β-glycerophosphate (disodium salt hydrate, Sigma 
G9422) 1 mM 




2.15 Mass spectrometry (MS) 
2.15.1 Tandem Mass Tag (TMT) labelling  
SAFB1, SAFB2 and IgG co-IP samples were prepared and analysed by MS by the 
Proteomics Facility, University of Bristol. Immunoprecipitated samples were digested 
on the beads with trypsin and labelled with TMT ten-plex reagents according to the 
manufacturer’s instructions (Thermo Fisher Scientific), then pooled. Samples were 
then fractionated by high pH reversed-phase chromatography using an Ultimate 3000 
liquid chromatography system (Thermo Fisher Scientific). Samples were analysed by 
Nano-LC Mass Spectrometry. 
 
2.15.2 Data analyses 
The raw data files were quantified using Proteome Discoverer software v1.4 (Thermo 
Fisher Scientific) and searched against the UniProt Human database. The abundance 




transformed so they are normally distributed. The fold change for SAFB1 and SAFB2 
against the corresponding IgG for each biological replicate was calculated and the fold 
change average was also calculated. Paired T test were performed. Proteins with <2 
unique peptides were removed. Only proteins with statistical significance (P<0.05) 
compared to the corresponding IgG were considered for further analyses. 
 
2.16 SAFB genes expression by Microarray analysis   
Microarray analyses were previously performed on different primary human cell 
samples, using Agilent Whole Human Genome Oligo Microarrays (Miltenyi Biotec, 
Germany). RNA samples were taken from HSCs and peripheral blood cells from 
healthy individual, patients with BCP-ALL and T-ALL. For BCP-ALL, the bulk 
leukaemia population was obtained as well as lymphocytes that were sorted for the 
presence or absence of surface cell markers CD34 and CD19. Similarly for T-ALL, the 
bulk leukaemia population was obtained as well as lymphocytes that were sorted for 
the presence or absence of surface cell markers CD34 and CD7. For our purposes, 
SAFB genes expression were plotted as mean with standard deviation (SD) and as 
SAFB1/2 ratio.  
 
2.17 Statistical analysis   
The data were analysed using GraphPad Prism software version 6.04 (La Jolla, CA, 
USA). Differences in SAFB gene expression, viability following treatment with HSP90i 
(17-DMAG and celastrol), plasmid transfection, adenoviral transduction and changes 
in protein expression following heat shock and HSP90i in HeLa cells were analysed 
using one-way analysis of variance (one-way ANOVA), with Tukey post hoc analysis 
of means. Dose response curves following HSP90i and changes in protein expression 
following heat shock and HSP90i in primary ALL and NBM cells were analysed using 
two-way analysis of variance (two-way ANOVA) with Bonferroni post hoc analysis of 
means. GraphPad Prism 6.04 was used to determine the IC50 following HSP90i 






CHAPTER 3 :                                                          
Characterising SAFB1 and SAFB2 expression and 













































There remains a need to identify novel molecular pathways, markers and genetic 
alterations in ALL to assist in the development of new more effective treatments (56). 
SAFB1 interacts with S/MARs, which serve as anchors to attach chromatin to the nuclear 
matrix (1), and the chromatin loop domains formed at these attachment regions are 
thought to be sites controlling transcription and replication (2). The SAFB1 interaction 
with S/MARs is mediated via its SAP domain, and thereby mediates association with the 
nuclear matrix and promotes or represses transcription. Evidence also suggests that 
SAFB1 may direct the reorganization and segregation of nuclear RNA and DNA prior to 
endonuclease-mediated DNA cleavage during apoptosis (24). SAFB1 has been shown 
to interact with a number of alternative RNA splicing regulators (159) and to have a high 
affinity for RNA polymerase II suggesting it may be a component of the spliceosome 
(2),(160),(161). A variety of cellular stresses leads to the formation of nSBs which are 
accumulation sites for RNA-binding proteins involved in pre-mRNA splicing. SAFB1 co-
localises with nSBs, which was suggested to play a role in transcriptional control and 
alternative splicing in cells following stress (4). There have also been a number of papers 
suggesting that altered SAFB protein expression is linked to oncogenesis (7,11, 8,39). 
High levels of SAFB1 were reported to arrest cells in the G2-M phase suggesting a role 
in the control of cell division (23). An observation supported by studies that show the 
disruption of SAFB1 expression led to cell immortalisation (32). SAFB1 mutations were 
identified in breast tumours but not in the normal adjacent tissue. The consequences of 
SAFB1 mutations were not well established and further experiments are needed. A high 
loss of heterozygosity (78%) was also detected at the SAFB chromosomal locus in 
invasive breast cancer (33). Decreased SAFB expression is associated with colorectal 
cancer (35), prostate cancer (16) and a worse overall survival of breast cancer patients 
(34). Together these findings suggest that low levels of SAFB1 may alter gene 
expression (particularly those associated with the control of the cell cycle and apoptosis) 








The aims of this chapter were to investigate:  
(i) The hypothesis that SAFB1 expression is decreased in BCP-ALL and T-ALL  
(ii) Whether increasing SAFB1 expression in ALL cells has a compensatory pro-
apoptotic effect?  




















3.2.1 Investigating the expression of SAFB1 and SAFB2 in primary T-ALL and 
BCP-ALL 
Prior to investigating the effect of overexpressing SAFB1 in primary T-ALL and BCP-
ALL cells, endogenous mRNA levels of SAFB1 and SAFB2 in leukaemia cells were 
measured. We initially interrogated microarray data (www.ebi.ac.uk/arrayexpress, 
accession number E-MTAB-4006) obtained from the BM from 5 BCP-ALL, 5 T-ALL 
patients and 5 healthy individuals to investigate SAFB1 expression levels in primary 
cancer cells (89). We found that SAFB1 expression levels were significantly lower in 
T-ALL patients (3.70±1.77, P<0.05) but not BCP-ALL patients (6.28±1.24) when 
compared to NBM controls (5.47±0.70, Figure 3.1A). SAFB1 and SAFB2 expression 
is controlled by a bidirectional promoter and knocking down SAFB1 expression results 
in the up-regulation of SAFB2 levels (39) (results not shown) and we would therefore 
predict an inverse relationship between SAFB1 and SAFB2 expression. Interestingly, 
when our array data was interrogated it was found SAFB2 mRNA levels were 
significantly increased in BCP-ALL (8.10±1.744, P<0.05) and T-ALL cells (7.63±2.15, 
P<0.01) when compared to NBM (4.88±2.26, Figure 3.1B) and the SAFB1/SAFB2 
ratio was significantly reduced in both BCP-ALL (0.77±0.10, P<0.05) and T-ALL cells 
(0.50±0.27, P<0.01, Figure 3.1C). Together, these results suggest that SAFB2 levels 


















































                                                                                                                                  
(A) SAFB1 and (B) SAFB2 gene expression in samples from BCP-ALL (n=5), T-ALL cases 
(n=5) and from NBM (n=5) analysed using Agilent Whole Genome Oligo microarrays. Data 
shows side by side comparisons of log2 signal intensities from individual samples. (C) 
SAFB1/SAFB2 expression ratios in cells derived from BCP-ALL and T-ALL patients and NBM. 
Circles, squares and triangles represent NBM, BCP-ALL and T-ALL samples, respectively and 
each colour represents a single sample. Results were analysed by one-way ANOVA. Values 


















































































Previous work from our group found that several subpopulations contain LICs in BCP-
ALL and can maintain the disease, including (CD34+/CD19+, CD34+/CD19-, CD34-
/CD19+, CD34-/CD19-) in BCP-ALL and CD34+/CD7+, CD34+/CD7-, CD34-/CD7+, 
CD34-/CD7- in T-ALL. Therefore, we aimed to investigate whether the altered 
expression of SAFB1 and SAFB2 is also seen in these populations.  
 
Results showed that SAFB1 and SAFB2 mRNA expression was not significantly 
different between CD34+/CD19+, CD34+/CD19-, CD34-/CD19+, CD34-/CD19- BCP-
ALL subpopulations compared with CD34+/CD38- HSC (Figure 3.2A and B). The 
SAFB1/SAFB2 ratio was similar in CD34+/CD19+ (0.78±0.12), CD34+/CD19- 
(0.90±0.51) and CD34-/CD19- (0.71±0.11) BCP-ALL subpopulations compared with 
HSCs (0.62±0.37) and no significant difference was seen. However, CD34-/CD19+ 
cells had higher mean ratio than HSCs but was not statistically significant (1.48±0.85, 
Figure 3.2C). 
 
Similarly, SAFB1 and SAFB2 mRNA expression was not altered in CD34+/CD7+, 
CD34+/CD7-, CD34-/CD7+, CD34-/CD7- T-ALL subpopulations compared with HSCs 
(Figure 3.2D and E). There was no significant difference in SAFB1/SAFB2 ratios 
between CD34+/CD7+ (0.61±0.13), CD34+/CD7- (1.03±0.70), CD34-/CD7+ 
(0.64±0.04), CD34-/CD7- (0.47±0.09) T-ALL subpopulations compared with HSCs. In 
contrast, CD34+/CD7- cells had higher mean ratio (0.78±0.12) than HSCs (0.62±0.37) 































































                                                                                      
 
                                                                                      
SAFB1 and SAFB2 gene expression in LICs in (A-C) BCP-ALL (n=5) and (D-E) T-ALL cases 
(n=5) compared with HSCs. (A, B, D, E) Data shows side by side comparisons of log2 signal 
intensities from individual samples. (C, F) SAFB1/SAFB2 expression ratios in cells derived 
from BCP-ALL and T-ALL patients and HSCs. Circles, squares and triangles represent normal 
HSCs, BCP-ALL and T-ALL samples, respectively and each colour represents a single 



























































































































































































































To validate SAFB1 and SAFB2 mRNA expression, RNA was extracted from BCP-ALL, 
T-ALL and NBM cells. cDNA was generated and SAFB1 and SAFB2 mRNA levels 
were measured via qPCR. Results showed that SAFB1 expression was significantly 
lower in T-ALL (0.67±0.14, P<0.05) but not BCP-ALL patients (1.22±0.10) compared 
with NBM (Figure 3.3A). Moreover, SAFB2 expression was significantly increased in 
T-ALL (1.73±0.11) and BCP-ALL (1.56±0.21, P<0.01) when compared with NBM 
(Figure 3.3B). These results confirm the altered SAFB1/SAFB2 expression rations 













































































                                                                                                                               
RNA was harvested from samples from BCP-ALL (n=3), T-ALL cases (n=3) and from 3 NBM 
donors. cDNA was generated to measure (A) SAFB1 and (B) SAFB2 relative mRNA 
expression using qPCR. GAPDH and beta-actin were used as endogenous genes. Data 
represent fold change from control cells (NBM). Results were analysed by one-way ANOVA. 







































































To see if the changes in SAFB1 mRNA levels and SAFB1/SAFB2 expression ratios 
reflected altered SAFB1/SAFB2 protein levels, BCP-ALL and T-ALL cells were 
immunocytochemically stained using previously validated specific anti-SAFB1 and 
anti-SAFB2 antibodies (Rivers et al., 2015). The results showed SAFB1 and SAFB2 
were expressed at comparable levels in NBM cells (6.12±1.18 and 4.98±1.10) 
respectively. SAFB2 levels were significantly increased in both BCP-ALL (15.43±1.90, 
P<0.05) and T-ALL cells (24.69±2.48, P£0.001) compared with SAFB1 (6.44±3.20, 






































                                                                                                     
Photomicrographs of DAPI nuclear staining (upper panels) and SAFB1 and SAFB2 immunocytochemical staining (lower panels) in 
NBM, BCP-ALL and T-ALL cells. Bar graphs show SAFB1 and SAFB2 expression and correspond to the conditions detailed in the 
panels above. Values are means+SD of 3 independent experiments.  *=P<0.05, ***= P£0.001. 

























































































Figure 3.4 SAFB1 and SAFB2 expression in NBM and ALL cells. 
SAFB1	 SAFB2	 SAFB1	 SAFB2	 SAFB1	 SAFB2	




3.2.2 Studying whether rebalancing SAFB expression can induce apoptosis in 
cancer cells 
T-ALL, BCP-ALL and NBM cells were transfected with pEGFP.SAFB1 plasmid or 
adenoviral vector expressing EGFP-SAFB1. Cells were left for 24 and 48 hours before 
being fixed with 4% PFA and images were taken to assess EGFP positive cells. 
Results showed that both plasmid transfection and adenoviral transduction resulted in 
high efficiency of EGFP-SAFB1 expression in primary ALL and NBM cells at 24 hours 
(Figure 3.5). There is no difference in the pictures in terms of cell number of ALL cells, 











































                                                                                                                                          EGFP-SAFB1 was overexpressed in BCP-and T-
ALL and NBM cells via plasmid transfection and adenoviral transduction and transfection efficiency was assessed after 24 (upper panels) and 48 
(lower panels) hours by fluorescence microscopy. Hoechst was used for nuclear visualisation.




We next explored the effects of overexpressing SAFB1 on T-ALL and BCP-ALL cells 
and used annexin/PI assays to measure apoptosis. T-ALL, BCP-ALL and NBM cells 
were transfected with pEGFP.SAFB1 plasmid and adenoviral vector expressing 
SAFB1. Cells were left for 24 and 48 hours and viability was assessed. Results 
showed that overexpressing SAFB1 via adenoviral transduction induced apoptosis in 
BCP-ALL and T-ALL cells but not in NBM cells 24 and 48 hours after transfection 
(Figure 3.6A). Adenoviral transduction resulted in higher apoptosis than NBM with 
(52.02±5.65%) and (55.21±5.92%, P£0.001) viability in BCP-ALL and T-ALL cells at 
24 hours, respectively, while viability of ALL subtypes was 34.94±5.32% and 
35.21±5.92% at 48 hours (Figure 3.6A) respectively. NBM cells were relatively 
resistant to adenoviral transduction with less apoptosis was induced following SAFB1 
overexpression. Using plasmid transfection, both ALL subtypes viability was 
significantly reduced (P£0.01, P<0.05) at 24 and 48 hours, respectively (Figure 3.6B). 
Viability of both BCP-ALL and T-ALL cells were 71.40±5.58% and 73.09±3.59% at 24 
hours, respectively. However, BCP-ALL and T-ALL viabilities were further reduced to 
55.57±4.06% and 42.60±22.47% at 48 hours, respectively (Figure 3.6B). Viability of 




























































                                                                                                       
SAFB1 was overexpressed in BCP-ALL, T-ALL and NBM cells via adenoviral transduction and 
plasmid transfection and viability was measured after 24 and 48 hours by flow cytometry using 
Annexin V and PI. Viability was determined as a percentage of the EGFP positive cells. Data 














Next, the effect of SAFB2 overexpression on T-ALL and BCP-ALL cells was studied and the 
annexin/PI assays were used to measure apoptosis. T-ALL, BCP-ALL and NBM cells were 
transfected with pEGFP.SAFB2 plasmid and adenoviral vector expressing SAFB2. Cells were 
left for 24 and 48 hours and viability was assessed. Results showed that adenoviral 
transduction resulted in higher apoptosis in BCP-ALL (64.95±8.12%) and T-ALL cells 
(62.95±10.67%, P£0.01) viability compared with NBM at 24 hours, while viability of ALL 
subtypes was 55.94±4.42% and 48.25±10.91% at 48 hours (Figure 3.7A) respectively. NBM 
cells were relatively resistant to adenoviral transduction with less apoptosis was induced 
following SAFB2 overexpression. Using plasmid transfection, both ALL subtypes viability was 
significantly reduced (P<0.05) at 24 and 48 hours, respectively (Figure 3.7B). Viability of both 
BCP-ALL and T-ALL cells were significantly reduced (79.29±9.41%, P<0.05) and 
(83.27±8.77%) compared with NBM at 24 hours, respectively. In addition, BCP-ALL and T-
ALL viabilities were further reduced to 63.40±6.58% and 58.52±4.78% at 48 hours, 
respectively (Figure 3.7B). Viability of NBM cells was not significantly altered following plasmid 















































































SAFB2 was overexpressed in BCP-ALL, T-ALL and NBM cells via adenoviral transduction and 
plasmid transfection and viability was measured after 24 and 48 hours by flow cytometry using 
Annexin V and PI. Viability was determined as a percentage of the EGFP positive cells. Data 
represent mean±SD of 3 independent samples for each cell type.  *=P<0.05, **=P£0.01. 




3.2.3 SAFB1 overexpression in non-cancerous dividing and non-dividing cells 
Data showed that SAFB1 overexpression induced apoptosis in primary ALL cells 
(Figure 3.6). Therefore, it was interesting to investigate the effect of expressing SAFB1 
in normal dividing MEFs and non-dividing primary neurons. MEFs were transfected 
with pEGFP.SAFB1 and left for 24 and 48 hours. The transfection efficiency was 
assessed and viability was measured by MTT activity. MTT was used as a 
measurement and correlate with viability. Results showed that transfection efficiency 
was high (Figure 3.8A) and transfection of mitotic MEF cells with SAFB1 did not 
































                                                                                                                             
Primary MEFs were transfected with pEGFP.SAFB1 and left for 24 and 48 hours. (A) 
Transfection efficiency was assessed and (B) viability was measured by MTT activity at 24 
and 48 hours. Viability was determined as a percentage of the EGFP positive cells. Values 
represent mean±SD. 




Previous work in the lab showed that SAFB1 overexpression was closely associated 
with chromatin. Therefore, experiments performed by Youn-Bok Lee in the lab 
assessed the effect of expressing SAFB1 in non-dividing primary neurons. Primary 
cortical and hippocampal neurons were transduced with Ad.HA.SAFB1 at MOIs of 50, 
100 and 200 (titres that killed SH-SY5Y cells after two days) and found there was no 
change in viability as assessed by MTT activity (Figure 3.9A) and 





























               (A) Primary cortical and hippocampal neurons were transduced with Ad.HA.SAFB1 
at various MOIs and MTT activity measured 6 days later. (B) Photomicrographs of primary 
hippocampal and cortical neurons transduced with Ad.HA.SAFB1 and detected using an anti-
HA tag Ab. The confocal images also show DAPI stained neurons.  
	
 






SAFB1 and SAFB2 are known to interact with important regulators of tumorigenesis 
and the deletion of SAFB1 is associated with cellular immortalisation (32). In addition, 
decreased expression of SAFB1 has been found in prostate (16), breast (34) and 
colorectal cancers (35). However, it is not known if such alterations in SAFB1 are 
restricted to solid tumours. Consequently, we examined the expression profile of 
SAFB1 and its paralogue SAFB2 in primary BCP- and T-ALL cells. Initial analysis of 
microarray data showed that SAFB1 mRNA expression was significantly lower in T-
ALL cells compared to BCP-ALL and NBM cells. We also report for the first time that 
SAFB2 protein expression was significantly elevated in both ALL subtypes. 
Interestingly, we also found that the SAFB1/SAFB2 ratio was reduced significantly in 
both BCP- and T-ALL cells compared with NBM. SAFB1 and SAFB2 are under the 
control of a bidirectional promoter and knocking down SAFB1 or SAFB2 results in a 
compensatory increase in SAFB2 and SAFB1, respectively (39). The mechanism has 
not been studied but presumably is a feedback mechanism for SAFB1/2 regulation. 
Thus, these results suggest that the altered transcriptional activity associated with ALL 
and other cancers promotes a decrease in the SAFB1/SAFB2 protein expression ratio. 
SAFB proteins regulate, chromatin structure, polymerase II activity (2), DNA repair 
(22), the cell cycle (23), apoptosis (24) and splicing (159). Considering these important 
roles in regulating gene expression and the cell cycle, these results suggest that 
aberrant SAFB1/2 protein expression may be associated with the development of 
tumorgenicity.  
 
Next, it was interesting to evaluate the pattern of SAFB1 and SAFB2 expression within 
LICs in BCP-ALL. Data showed that there was no significant difference in SAFB1 and 
SAFB2 expression between BCP-ALL subpopulations. However, it was found that the 
ratio of SAFB1/SAFB2 in CD34-/CD19+ cells were higher compared with HSCs. The 
CD34-/CD19+ cells are known to have less proliferative capacity subpopulations to 
maintain the disease compared to other LIC subpopulations (91),(86),(94), indicating 
that this population may have a less aggressive function. Also, the expression of 
SAFB1 and SAFB2 within T-ALL subpopulations was investigated. Results showed 
that SAFB1/SAFB2 ratio seems to be higher in CD34+/CD7- cells compared with 




that CD34+/CD7- cells might not be associated with reduced functional capacity. 
Further experiments are needed to understand these observations. CD34+/CD7- cells 
are known to be the most primitive subpopulation in T-ALL and have more LICs, 
compared to other LIC subpopulations which enable them to differentiate in vivo and 
maintain the disease (84), (86). 
 
Previously it was found that overexpression of SAFB1 was highly effective at activating 
protein kinase R (PKR) and inhibiting protein translation. Further to these findings, 
ectopically expressed SAFB1 was closely associated with chromatin and mediated the 
formation of multinucleated cells indicating powerful effects on pathways governing 
the cell cycle. In this study it was found that SAFB1 overexpression was associated 
with initiating apoptosis in both primary T-ALL and BCP-ALL cells. However, SAFB1 
did not mediate these actions in a range of normal cells including NBM, fibroblasts or 
primary neuronal cells. We have previously shown that SAFB1 plays a role in the 
apoptotic process, helping to reorganize and segregate nuclear RNA and DNA prior 
to endonuclease-mediated DNA cleavage (162). In addition, the SAF protein SLTM, 
(which shares 30% homology with SAFB1) when overexpressed has also been shown 
to induce apoptosis in cancer lines (6). These results suggest that compared to normal 
dividing cells, cancer cells are uniquely sensitive to SAFB1 protein overexpression. 
There are a number of possible explanations for the potential pro-apoptotic actions of 
ectopically expressed SAFB1: (i) SAFB1 binds active chromatin (euchromatin) unique 
to cancer cells prior to and during replication and hence disrupts cell division. This 
possibility is supported by the observation that SAFB1 has been shown to interact with 
a number of important modifiers of chromatin structure e.g. CHD1, NCOR, HDAC3, 
BRG1, Matrin 3 (reviewed in (39),(11)). SAFB1 was also shown to form a complex 
with the growth inhibitory kinase MST1 and the histone methyltransferase EZH2 at 
chromatin sites in association with PRC2 (16). (ii) SAFB1 alters the unique 
transcriptional activity of cancer cells by interacting with promoter regions (e.g. with 
TA rich regions and E-box regions via its SAF box) and/or by interacting with 
transcription factors (via its C-terminal domain) such as p53, c-Jun, oestrogen receptor 
and PPAR gamma. (iii) SAFB1 alters the splicing of cancer promoting genes. For 
instance, we have shown that SAFB1 regulates the splicing of Oncomir-1 (miR-17-92 
cluster), MALAT1, ELK3 and MAP3K7 (38). SAFB proteins are subject to a number of 




methylation, phosphorylation and/or SUMOylation may promote oncogenesis. For 
example, cellular stress is known prevent the SUMOylation of SAFB1 and inhibit its 
ability to mediate transcriptional repression (29). 
 
The effect of SAFB2 overexpression on ALL cells was also examined. In the current 
study, it was shown that SAFB2 overexpression induced apoptosis in both primary T-
ALL and BCP-ALL cells to less extent compared with SAFB1. However, SAFB2 
overexpression did not induce apoptosis in NBM cells. The potential pro-apoptotic 
effect of SAFB2 is not well established compared with SAFB1 role and further 
experiments are warranted to define these observations. However, there are a number 
of possible reasons for the potential pro-apoptotic actions of SAFB2 overexpression: 
(i) SAFB2 could be competing with SAFB1, as SAFB2 was shown to co-localise with 
SAFB1 (9) (ii) SAFB1 and SAFB2 are under the control of a bidirectional promoter and 
it could be that a feedback mechanism for SAFB1/2 regulation can be involved.  
 
We report for the first time that the expression ratio of SAFB1 and SAFB2 is reduced 
in both paediatric BCP-ALL and T-ALL cases. SAFB1 levels have previously been 
reported to be lowered in prostate, breast and colorectal cancers and also be 
associated with poor prognosis. The lower expression of SAFB1 in T-ALL correlates 
with these patients generally having a worse outcome than BCP-ALL cases. These 
results therefore suggest that altering the expression levels/function of these important 
regulators of gene expression and the cell cycle may promote oncogenesis. We also 
investigated the pro-apoptotic properties of SAFB1/2 and the results showed that 
SAFB1 inhibited translation (Youn-Bok Lee, personal communication) and induced 
apoptosis within 48 hours of expression. In contrast the overexpression of SAFB1 in 
NBM cells, fibroblasts and non-dividing primary hippocampal and cortical neurons did 
not result in a reduction in viability or mediate apoptosis. Considering the selectivity of 
cellular disruption mediated by SAFB1, its overexpression may form the basis for gene 
therapy strategies aimed at mediating cell death in cancer cells. Such strategies could 
be significantly less toxic to non-cancerous cells and thereby decrease treatment 
related mortality. 
 





CHAPTER 4 : Investigating the effect of anti-cancer 
drugs (HSP90 inhibitors) on the stress response in 












































4.1 Introduction  
Hsp90 has important roles in cell survival and it is an important regulator of the stress 
response (163). Hsp90 functions to promote protein folding, prevents misfolding (163) 
and HSP90 is often associated with HSP70 and co-chaperones such as Cdc37  (117). 
HSP90 is found to be highly expressed in many solid (prostate, lung) and 
haematological (leukaemia) cancers (116) and is associated with poor prognosis  
(163),(117). HSP90 inhibition leads to degradation of client proteins, such as 
oncogenic tyrosine kinase v-Src, mutated oncogene Bcr/Abl, tumour suppressor p53 
protein and steroid receptors. Therefore, targeting HSP90 is a promising approach for 
anticancer therapy (163),(115). Several HSP90 inhibitors have been identified, 
including 17-DMAG and celastrol. Both drugs induce apoptosis in T-ALL and BCP-
ALL cells. Both drugs in combination also reduce viability in BCP-ALL LIC 
(CD34+/CD19+, CD34+/CD19-, CD34-/CD19+ and CD34-/CD19-) subpopulations. 
However, neither of the HSP90 inhibitors had a cytotoxic effect on normal cord blood 
(CB) and HSCs (95). Furthermore, when T-ALL cells were treated with both drugs in 
combination and inoculated into NSG mice, engraftment of all LIC (CD34+/CD7+, 
CD34+/CD7-, CD34-/CD7+ and CD34-/CD7-subpopulations) was prevented 2/3 of 
cases (95). In the third case, a patient in relapse, engraftment was only prevented in 
CD34-/CD7- cells. However, engraftment was reduced in unsorted, CD34+/CD7+ and 
CD34-/CD7+ cells.  
 
Competition for Hsp90 binding in the cell is also known to result in the activation of 
HSF1 and the induction of a stress response. HSF1 is the master regulator of the 
stress response and in its active state HSF1 also transcribes lncSatIII RNAs and 
recruits other proteins such as SRSF1 and 9G8 into nSBs to regulate splicing (20). 
HSF1 activities extend far beyond the stress response and accumulating evidence has 
linked HSF1 with oncogenesis (144). HSF1 activation is associated with poor 
prognosis in prostate, lung, colon (148),(164),(145) and melanoma cancers (149). 
HSF1 was found to be overexpressed in prostate cancer cell lines (150), CLL (151) 
and found in the nucleus of leukaemia B cells but not in normal B cells (152). SAFB1 
also co-localises with HSF1 in nSBs and it was suggested to play a role in 




Whether cancer cells respond to Hsp90i inhibitors by inducing a stress response is not 
known. In addition, the contribution of stress response induction to cancer cell viability 
has not been investigated. 
 
Therefore, the aims of this chapter were to: 
(i) Characterise the stress response by observing nSBs formation by assessing the 
expression/localisation of SAFB1, SAFB2 and HSF1 following heat shock and 
measuring HSP70 induction in HeLa cells. 
 
(ii) Investigate whether HSP90 inhibitors also induce a stress response in HeLa cells  
 
(iii) Assess the ability of ALL cancer cells to generate nSBs by monitoring the 
distribution of HSF1, SAFB1 and SAFB2 following heat shock. 
 
(iv) Validate the effect of HSP90 inhibitors on the viability of ALL cancer cells and 
assess their efficacy when used in combination. 
 
(v) Validate the effectiveness of pharmacological inducers (HSP90i) of a stress 
response by measuring HSP70 induction and expression/localisation of SAFB1, 

























4.2.1 Establishing the base line stress response following heat shock and 
HSP90 inhibitors in HeLa cells 
HSF1 is the master transcription factor in humans and is known to mediate the 
transcription of SATIII and also to be recruited into nSBs (20). SAFB1 is known to be 
recruited to nSBs and it is frequently used as a marker of nSB formation. SAFB2, a 
paralogue of SAFB1 with high similarity at the amino acid level and until recently it has 
been difficult to generate SAFB2 specific antibodies. However, antibodies specific to 
SAFB1 and SAFB2 are now available and therefore their localisation was compared 
following a stress response in cancer cells.  
 
Prior to investigating the effect of HSP90 inhibitors on HSP70 induction and nSB 
formation cells were heat shocked and HSP70 expression and nSB formation were 
measured to allow comparison. To achieve this, HeLa cells were heat shocked at 420 
C for 1 hour followed by 0 hours recovery (HS+NR) and left for a 1 hour recovery 
period (HS+R) and the expression of HSP70, HSF1, SAFB1 and SAFB2 measured 
immunocytochemically. Prior work in the laboratory (39) and live imaging analysis of 
stress body formation using Incucyte analyses (performed by Renate Raele) showed 
that a one hour heat shock consistently produced stress body formation. This work 
also showed that following a heat shock plus 1 hour recovery the majority of stress 
bodies had lost HSF1 staining and therefore represented an intermediate recovery 
period.  
 
Under basal conditions, HSP70 was found to be expressed in the nucleus and 
cytoplasm but excluded from the nucleolus. Following HS (HS+NR), HSP70 was 
overexpressed and found to be more concentrated in the nucleolus (Figure 4.1A). The 
translocation of HSP70 into the nucleolus was more pronounced following the 
recovery period (HS+R). To quantify HSP70 expression the intensity of HSP70 
immunofluorescence was calculated using ImageJ. HSP70 was overexpressed 
significantly following HS+NR (81.75±3.59, P£0.01) and HS+R (66.75±4.78, P<0.05) 



















                                                               (A) HeLa cells were heat shocked at 420C and 
immunostained with an anti-HSP70 primary antibody and visualised with Alexa 488 secondary 
antibody (green). Cells were also stained with Hoechst for nuclear visualisation (blue). Images 
were captured using a 63x lens confocal laser microscope. (B) Bar graph represents HSP70 
intensities using ImageJ. Data was analysed by one-way ANOVA. Values represent mean±SD 




































HeLa cells were immunostained with anti-SAFB1 and anti-HSF1 primary antibodies 
and visualised with Cy3 and Cy2 secondary antibodies respectively. Cells were 
stained with Hoechst for nuclear visualisation. Under basal conditions, SAFB1 and 
HSF1 were diffusely expressed in the nucleus with HSF1 also being expressed in the 
cytoplasm. Immediately after HS (HS+NR), SAFB1 distribution was unchanged, while 
HSF1 (the main marker for nSBs) started to form large nuclear puncta characteristic 
of nSBs. SAFB1 was not recruited into HSF1 puncta following heat shock (HS+NR). 
After the recovery period (HS+R), SAFB1 also started to form nuclear puncta with 
some colocalising with HSF1 in nSBs (Figure 4.2A). Analyses showed the number of 
cells with colocalised SAFB1 and HSF1 puncta (used as a measure of SAFB1 positive 
nSBs) was significantly greater in the HS+R (45.50±6.19, P£0.001) compared with 












































                                                                                     (A) HeLa cells were heat shocked at 420 
C and immunostained with anti-SAFB1 and anti-HSF1 primary antibodies and visualised with 
Cy2 (green) and Cy3 (red) secondary antibodies respectively. Hoechst was used to stain the 
nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (B) The 
percentage of cells with nSBs were counted in 200 cells indicated by arrows. Data was 











































HeLa cells were also immunostained with anti-SAFB2 and anti-HSF1 primary 
antibodies and visualised with Cy3 and Cy2 secondary antibodies respectively. Cells 
were stained with Hoechst for nuclear visualisation. Under basal conditions, SAFB2 
and HSF1 were diffusely expressed in the nucleus with HSF1 also being expressed in 
the cytoplasm. Immediately after HS (HS+NR), SAFB2 was found in puncta, some of 
which overlapped with HSF1 (Figure 4.3A). After the recovery period (HS+R), a 
greater number of SAFB2 puncta were found colocalised with HSF1 (Figure 4.3A). 
SAFB2 puncta appeared larger than those seen with SAFB1 and were more frequently 
colocalised with HSF1 than SAFB1 following HS+R (76.76±4.09, P£0.001) compared 












































                                                                                      
                                                                                     (A) HeLa cells were heat shocked at 420 
C and immunostained with anti-SAFB2 and anti-HSF1 primary antibodies and visualised with 
Cy2 (green) and Cy3 (red) secondary antibodies respectively. Hoechst was used to stain the 
nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (B) The 
percentage of cells with nSBs were counted in 200 cells indicated by arrows. Data was 













HeLa cells were treated with increasing concentrations of 17-DMAG or celastrol 
ranging from 0.01nM to 10µM for 24 and 48 hours then viability was monitored using 
the MTT assay. Two time points were used to obtain the best time point with effective 
cytotoxicity as previous work in our laboratory found that 17-DMAG was effective on 
primary ALL at 24h and celastrol was more effective at 48h (95). Viability experiments 
were conducted to obtain the IC50 (section 2.10) to investigate the contribution of stress 
response induction to cancer cell viability at doses that kill 50%. Also, the aim was to 
see whether cancer cells are more sensitive to HSP90 inhibitors than normal cells via 
the stress response pathway. The results showed that viability was not altered in 
response to celastrol at doses below 1µM, with a decrease in viability from 
90.40±13.80% to 37.00±8.18 85% at 24 hours and 92.28±13.85% to 22.45±5.29% at 
48 hours between 1 and 2µM. Therefore, further concentrations of celastrol were used 
to generate a dose response curve. Doses below 2µM showed a gradual reduction in 
viability, with a significant difference at 2µM (22.45±5.29%, p<0.05) compared to un-
treated cells (Figure 4.4A). In contrast, cells started to respond to 17-DMAG, with a 
significant difference observed at 0.1 (70.91±4.22%), 1 (53.5±2.90%) and 10µM 
(16.31±4.19%, p£0.01) compared to un-treated cells (Figure 4.4B).  
Moreover, it was essential to investigate viability following the application of the 
various doses of both drugs by determining the half-maximal inhibitory concentration 
(IC50) values. Results revealed a higher IC50 for 17-DMAG compared to celastrol at 24 
hours with 4.04μM versus 1.72μM, while the IC50 was similar at 48h with 1.78μM and 
1.68μM for 17-DMAG and celastrol, respectively. Subsequently, the IC50 doses of both 
drugs were used in combination to treat HeLa cells and viability was evaluated using 
the MTT assay. The combined treatment with both 17-DMAG/Celastrol (DM-Ce) 
resulted in higher toxicity (35.75±7.38% viable) at 24 hours and (28.17±2.03% viable, 
p£0.001) at 48 hours compared to treatment with celastrol alone (52.17±7.60% viable) 
and (43.16±19.00% viable), respectively. However, there was no significant difference 
between DM-Ce and 17-DMAG at either timepoint (p£0.26, Figure 4.4C and D). 17-
DMAG resulted in higher toxicity compared with celastrol (43.80±7.38% to 
52.17±7.60% viable, p<0.05) and (36.83±2.32% to 65.16±19.00% viable, p£0.001) at 




























                                                                              HeLa cells were treated with increasing 
concentrations of (A) celastrol (1-5 µM) and (B) 17-DMAG (1-10 µM) alone to calculate the 
IC50 doses. Cells were treated with the IC50 doses alone and in combination for (C) 24h and 
(D) 48h. Viability was assessed using MTT assay. Viability was determined as a percentage 
of the untreated control cells. Data was analysed by one-way ANOVA (C and D) and two-way 
ANOVA (A and B). Values represent mean±SD of 4 independent replicates. * = P<0.05; ** = 
P£0.01; *** = P£0.001. 




Heat shock induced the stress response as characterised by HSP70 induction and 
nSB formation (Figure 4.1, 4.2, 4.3). However, the stress response assessed by 
HSP70 induction was not characterised following other stresses such as HSP90 
inhibitors (17-DMAG and celastrol), using IC50 doses. It is not known whether HeLa 
cells contribute to cell death by dysregulation of the stress response. HSP70 
expression is reported to be a reliable measurement of the efficiency of HSP90 
inhibition (164). For example, 17AAG (a hydrophobic inhibitor of the HSP90 activity) 
was reported to cause a 4-6 fold increase in HSP70 expression in several cell lines, 
including MCF-7, PC-3, Myc-CaP, A549 and HT 1080 (158). To investigate this, HeLa 
cells were treated using IC50 doses with 17-DMAG (1.78μM) and celastrol (1.68μM) 
as single agents and in combination for 48 hours and the stress response 
characterised by HSP70, HSF1, SAFB1 and SAFB2 immunocytochemistry. HeLa cells 
were immunostained with an anti-HSP70 as described in section 4.2.1. Under basal 
conditions, HSP70 was expressed mainly in the cytoplasm with low expression in the 
nucleus and a similar pattern was observed following celastrol treatment (Figure 4.5A), 
suggesting it had no effect on HSP70 induction. However, increased HSP70 
expression was seen in the nucleus and cytoplasm following 17-DMAG alone and DM-
Ce and the cell morphology was also altered (Figure 4.5A) with the cells appearing 
larger. To quantify HSP70 expression, the intensity of HSP70 immunofluorescence 
was calculated using ImageJ. Treatment with celastrol resulted in a slight increase in 
HSP70 (208.80±49.03) but was not significantly different to control cells or 17-DMAG. 
In contrast, treatment with 17-DMAG alone and DM-Ce resulted in higher expression 
of HSP70 (360.90±60.30 and 424.60±180.00, P<0.05), respectively compared to 
controls (95.23±19 Figure 4.5B). Moreover, analysis of HSP70 by western blotting also 
showed an increase in HSP70 expression following 17-DMAG and DM-Ce (Figure 





















                                                                                                              (A) HeLa cells were treated with celastrol, 17-DMAG and DM-Ce 
using the IC50 doses for 48h. Cells were then immunostained with an anti-HSP70 primary antibody and visualised with Alexa 488 secondary 
antibody (green). Cells were also stained with Hoechst for nuclear visualisation (blue). Images were captured using a 63x lens confocal laser 
microscope. (B) Bar graph represents HSP70 intensities calculated in 200 cells using ImageJ. Data was analysed by one-way ANOVA. Values 
represent mean±SD of 3 independent experiments. * = P<0.05. (C) A representative WB showing HSP70 induction following HSP90 inhibitors 
















Next, the aim was to investigate whether 17-DMAG and celastrol trigger nSB formation 
in a similar way to heat shock and whether SAFB1 is recruited into nSBs. HeLa cells 
were immunostained with anti-SAFB1 and anti-HSF1 primary antibodies as described 
in section 4.2.1. Under basal conditions, SAFB1 and HSF1 are expressed in the 
nucleus with HSF1 also expressed weakly in the cytoplasm (Figure 4.6A). Following 
celastrol treatment, SAFB1 formed several small puncta within the nucleus whilst 
HSF1 remained diffuse in the nucleus and cytoplasm, suggesting celastrol did not 
induce the nSB stress response. Following treatment with 17-DMAG alone and DM-
Ce, HSF1 was observed in a few punctate structures similar to nSBs. However, 
although SAFB1 puncta were observed following treatment with 17-DMAG alone and 
DM-Ce, these did not colocalise with HSF1 puncta (Figure 4.6A). HS+NR treatment 
induced HSF1 puncta co-localised with SAFB1, as seen previously (Figure 4.2) and 
also caused SAFB1 to have a more punctate distribution in the nucleus. Subsequently, 
the percentage of cells with HSF1 puncta was counted following HSP90 inhibitors and 
HS+NR. Results showed that HS+NR treated cells had a higher number of HSF1 
puncta (59.52±10.32%, P£0.001) compared with 17-DMAG alone (18.16±4.07%) and 
DM-Ce (17.36±3.67%, Figure 4.6B). Cells with HSF1 puncta following treatment with 
17-DMAG alone were similar compared with DM-Ce. There were no HSF1 puncta 






































                                                                                                                                  (A) 
HeLa cells were treated with celastrol, 17-DMAG and DM-Ce using the IC50 doses for 48h. 
Cells were immunostained with anti-SAFB1 and anti-HSF1 primary antibodies and visualised 
with Cy2 (green) and Cy3 (red) secondary antibodies respectively. Hoechst was used to stain 
the nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (B) The 
percentage of cells with HSF1 puncta were counted in 200 cells indicated by arrows using 
ImageJ. Data was analysed by one-way ANOVA. Values represent mean±SD of 4 
independent replicates. *** = P£0.001.
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Also, we investigated whether 17-DMAG and celastrol alters SAFB2 expression and 
lead to its recruitment into nSBs as seen following heat shock. Cells were 
immunostained with anti-SAFB2 and anti-HSF1 as described in section 4.2.1. Under 
basal conditions, SAFB2 and HSF1 are expressed in the nucleus with HSF1 being 
also expressed weakly in the cytoplasm. Results also showed that following celastrol 
treatment, SAFB2 expression was not altered and HSF1 staining remained diffuse in 
the nucleus and cytoplasm, suggesting celastrol is not inducing a stress response. In 
contrast, HSF1 was found in nuclear puncta following treatment with 17-DMAG alone 
and with DM-Ce. However, unlike after heat shock, SAFB2 was not recruited into 
HSF1 puncta following 17-DMAG treatment (Figure 4.7A). HS+NR treatment induced 
HSF1 puncta, as seen previously, and also caused SAFB2 to be recruited into nSBs 
overlapping with HSF1. Subsequently, the percentage of cells with HSF1 puncta was 
counted following treatment with inhibitors and HS+NR. In agreement with the data in 
Figure 4.6B results showed that HS+NR had higher percentage (64.25±6.48%) of 
HSF1 puncta compared with 17-DMAG alone (14.37±1.37%) and DM-Ce 
(12.39±1.10%, P£0.001, Figure 4.7B). In contrast, treatment with celastrol did not 


































                                                                                                                                  (A) 
HeLa cells were treated with celastrol, 17-DMAG and DM-Ce using the IC50 doses for 48h. 
Cells were immunostained with anti-SAFB2 and anti-HSF1 primary antibodies and visualised 
with Cy2 (green) and Cy3 (red) secondary antibodies respectively. Hoechst was used to stain 
the nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (B) The 
percentage of cells with HSF1 puncta were counted in 200 cells indicated by arrows using 
ImageJ. Data was analysed by one-way ANOVA. Values represent mean±SD of 4 
independent replicates. *** = P£0.001.
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4.2.2 Investigating the stress response following heat shock in primary ALL 
cells 
The ability of primary ALL cells to generate nSBs following heat shock and induce 
HSP70 has never been explored. Further, the altered SAFB1 and SAFB2 expression 
ratio found in BCP-ALL and T-ALL cancers, suggest the nuclear stress response may 
be altered in ALL cells. To characterise the stress response in ALL, compared to 
normal haemopoietic cells, BCP-ALL (n=3), T-ALL (n=3), and NBM (n=3) cells were 
heat shocked at 420 C for 1 hour and followed by 0 hours recovery (HS+NR) or 1 hour 
recovery (HS+R). Cells were immunostained with an anti-HSP70 primary antibody as 
described in section 4.2.1. to examine the stress response.  
 
Under basal conditions, HSP70 was expressed mainly in the cytoplasm. After HS+NR 
and HS+R, HSP70 was expressed in the nucleus and cytoplasm of NBM (Figure 4.8A), 
BCP-ALL (Figure 4.8B) and T-ALL cells (Figure 4.8C), indicating that cells are under 
stress. To quantify the nuclear HSP70 expression, the fluorescence intensity was 
measured. HSP70 expression was significantly increased following heat shock 
(HS+NR) in BCP-ALL (from 5.66±1.54 to 9.50±1.32) and T-ALL (from 5.89±1.09 to 
9.33±1.52, P<0.05) compared with controls (NHS, Figure 4.8D). However, no 
significant difference in HSP70 expression was observed following heat shock 
(HS+NR) and the recovery period (HS+R) in BCP-ALL and T-ALL compared with 
NBM. HSP70 expression was found to be lower following the recovery period (HS+R) 
compared with HS+NR in NBM (7.36±1.50), BCP-ALL (7.27±1.47) and T-ALL 





























                                                                            (A) NBM, (B) BCP-ALL and (C) T-ALL cells were heat shocked at 420 C and immunostained with 
an anti-HSP70 primary antibody and visualised with Alexa 488 secondary antibody (green). Cells were also stained with Hoechst for nuclear 
visualisation (blue). Images were captured using a 63x lens confocal laser microscope. (D) Bar graph represents HSP70 intensities calculated in 
200 cells (2 replicates) using ImageJ in 3 independent experiments. Data was analysed by two-way ANOVA. Values represent mean±SD of 3 

















































SAFB1 and HSF1 were found to be recruited into nSBs following heat shock (HS+R) 
in HeLa cells (Figure 4.2). To monitor the distribution of HSF1 and SAFB1 expression 
in primary ALL, cells were immunostained with anti-SAFB1 and anti-HSF1 primary 
antibodies as described in section 4.2.1. Under basal conditions, SAFB1 was 
expressed in the nucleus, whereas HSF1 was found in the nucleus and cytoplasm in 
all cell types. After HS+NR and HS+R, HSF1 expression was altered, with a weaker 
diffuse nuclear and pronounced nuclear border expression observed in NBM (Figure 
4.9A), BCP-ALL (Figure 4.9B) and T-ALL (Figure 4.9C). SAFB1 expression remained 
the same and was not recruited into HSF1 sites. To quantify SAFB1 and HSF1 
expression, the fluorescence intensity was measured. There was no significant 
difference in SAFB1 expression in BCP-ALL (13.95±1.94 and 15.33±2.08) and T-ALL 
cells (15.46±2.25 and 12.36±3.51) compared with NBM (12.89±2.64 and 12.66±1.54) 
following heat shock (HS+NR) and the recovery period (NH+R, Figure 4.9D) 
respectively. There was a significant increase in HSF1 expression under basal 
conditions in BCP-ALL (18.33±2.09) and T-ALL (19.66±2.15, P<0.05) cells compared 
with NBM (13.29±1.58, Figure 4.9E). Also, there was a slight increase in HSF1 
expression in BCP-ALL (13.38±3.05) and T-ALL cells (15.42±1.96) following heat 
shock (HS+NR) compared with NBM (9.98±1.88) but no significant difference was 
observed. Next, the percentage of cells with the HSF1 nuclear border staining was 
counted. Results showed that HSF1 nuclear border staining increased significantly 
following HS+NR in BCP-ALL (68.40±16.28) and T-ALL (58.08±13.00, P£0.01) 
compared with NBM (12.00±2.23, Figure 4.9F). There was also a significant increase 
in HSF1 nuclear border staining following HS+R in BCP-ALL (61.26±12.17) and T-ALL 

























                                                                                         (A) NBM, (B) BCP-ALL and (C) T-ALL cells were heat shocked at 420 C and 
immunostained with anti-SAFB1 and anti-HSF1 primary antibodies and visualised with Cy2 (green) and Cy3 (red) secondary antibodies 
respectively. Hoechst was used to stain the nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (D-F) Bar graph 
represents SAFB1, HSF1 intensities and the percentage of cells with HSF1 nuclear border staining respectively quantified in 200 cells (2 
replicates) indicated by white arrows using ImageJ. Data was analysed by two-way ANOVA. Values represent mean±SD of 3 independent patient 
samples. * = P<0.05, ** = P£0.01. 




Anti-SAFB2 and anti-HSF1 primary antibodies were used to immunostain ALL cells as 
described in section 4.2.1. Under basal conditions, SAFB2 was expressed in the 
nucleus, whereas HSF1 was found in the nucleus in all cell types (Figure 4.10A-C). 
Following heat shock, SAFB2 expression remained unchanged. To quantify SAFB2 
expression the fluorescence intensity was measured. Like SAFB1, there was no 
significant difference in SAFB2 expression in BCP-ALL (16.33±3.21, 15.39±2.11, 
12.66±1.52) and T-ALL cells (15.67±2.51, 12.88±2.64, 12.29±3.54) compared with 
NBM (12.61±1.45, 13.87±1.92, 15.34±2.10) under basal conditions and following heat 
shock (HS+NR) and the recovery period (NH+R, Figure 4.10D) respectively. As in 
Figure 4.9F the percentage of cells with the HSF1 nuclear border staining was counted 
as previously described. Consistent with data in Figure 4.9D, results showed that 
HSF1 nuclear border staining increased following HS+NR in BCP-ALL (74.20±6.83) 
and T-ALL (61.40±11.12, P£0.01) compared with NBM (15.40±3.84, Figure 4.10F). 
There was a significant increase in HSF1 nuclear border staining following HS+R in 
BCP-ALL (61.40±11.12) and T-ALL (47.36±6.21, P£0.01) compared with NBM 
(17.40±2.70). There was no significant difference following heat shock (HS+NR) 
compared with the recovery period (NH+R) in BCP-ALL (74.20±6.83, 61.40±11.12), 
T-ALL (61.40±11.12, 47.36±6.21) compared with NBM (15.40±3.84, 17.40±2.70, 



























                                                                                          (A) NBM, (B) BCP-ALL and (C) T-ALL cells were heat shocked at 420 C and 
immunostained with anti-SAFB2 and anti-HSF1 primary antibodies and visualised with Cy2 (green) and Cy3 (red) secondary antibodies 
respectively. Hoechst was used to stain the nucleus (blue). Images were captured using a 63x lens confocal laser microscope. (D-F) Bar graph 
represents SAFB2, HSF1 intensities and the percentage of cells with HSF1 nuclear border staining respectively quantified in 200 cells (2 
replicates) indicated by white arrows using ImageJ. Data was analysed by two-way ANOVA. Values represent mean±SD of 4 independent patient 
samples. * = P<0.05, ** = P£0.01.




4.2.3 Effect of HSP90 inhibitors on the viability of primary ALL cells  
As inhibitors of HSP90 are used to preferentially kill cancers cells in vitro we 
investigated the effect of HSP90 inhibitors on the viability of ALL cells. BCP-ALL, T-
ALL and NBM cells (all, n=4) were treated with increasing concentrations of 17-DMAG 
and celastrol as single agents for 24 and 48 hours and viability was monitored using 
Annexin-V and PI (Figure 4.11). Initial results showed that cells from 4 T-ALL cases 
treated with a concentration range from 0.01 to 1000nM celastrol were unaffected at 
concentrations up to 100nM with a drop in viability from 73.66±13.10% to 
29.98±12.63% at 24h and from 67.61±11.19% to 23.22±9.98% at 48h between 100 
and 1000nM doses, suggesting that the drug’s effectiveness was within this range. 
Therefore, additional concentrations of celastrol within this range were used to treat 
cells from 4 additional T-ALL cases to give a dose response curve and determine the 
IC50. Similarly, T-ALL cells responded to 17-DMAG at concentrations just under 
1000nM, so further concentrations up to 2000nM were used to generate a dose 
response curve and calculate the IC50. The IC50 for celastrol in T-ALL was 467.03nM 
at 24h and 431.37nM at 48h. In contrast, the IC50 for 17-DMAG in T-ALL was 
861.20nM at 24h and 574.64nM at 48h. BCP-ALL cells responded to lower doses of 
celastrol (IC50 of 50.55nM at 24h and 47.69nM at 48h) and 17-DMAG (IC50 of 6.63nM 
at 24h and 0.83nM at 48h) than T-ALL. In contrast, NBM cells were relatively resistant 
with viabilities of 63.36±4.52% and 56.82±7.39% at the highest doses of celastrol 




























                                                                                     BCP-ALL, T-ALL and NBM cells 
were treated with increasing concentrations of celastrol (0.01-1000nM) and 17-DMAG (0.01-
2000nM) for 24 and 48 hours. Viability was assessed using annexin-V/PI assay. Viability was 
determined as a percentage of the untreated control cells. Data was analysed by two-way 












17-DMAG and celastrol induced apoptosis in BCP-ALL cells when used as single 
agents. Subsequently, the effects of using both drugs in combination were examined 
and the Chou Talalay test was used to determine whether effects were additive, 
synergistic or antagonistic. The Chou Talalay method is calculated on the basis of 
median-effect equation and the mass-action law theory (153). The IC50 doses were 
used in this method with 2 and 4-fold higher (IC50*2, IC50*4) and lower (IC50/2, IC50/4) 
doses. The doses selected were based on IC50 values of 17-DMAG (6.63nM at 24h 
and 0.83nM at 48h) and celastrol (50.55nM at 24h and 47.69nM). The dose range for 
17-DMAG was 1.6-26.5nM for 24h and 0.20-3.3nM for 48h, whilst the dose range for 
celastrol was 12.63-202.nM for 24h and 11.92-190.76nM for 48h. Combining 17-
DMAG with celastrol showed no effect on cytotoxicity for 24 and 48 hours at any dose 
compared to either drug alone (Figure 4.12). Results also showed that the combined 
drugs at the IC50 dose reduced viability slightly to 46.75±8.22% compared with 
individual drugs at 24h where celastrol and 17-DMAG reduced viability to 
51.26±11.16% and 55.08±12.45%, respectively (Figure 4.12A). Data in Figure 4.12B 
showed that combining both drugs resulted in slight reduction in viability to 
52.28±7.42% compared with 56.48±4.73% and 60.08±9.82% with celastrol and 17-
DMAG alone, respectively at 48h. However, this was not significantly different 
compared with individual drugs. 
The effects of each drug as a single agent or in combination were used to derive the 
combination index (CI). The CI gives a quantitative measurement and reveals whether 
the drug has an additive effect (CI = 1), synergistic effect (CI < 1), or antagonistic effect 
(CI > 1). Results showed that combining both drugs resulted in drug antagonism for 
24 and 48 hours indicated by high CI values in all doses tested. Using both drugs at 
the lowest combination dose (IC50/4) resulted in CI value of 1.1 at 24h. The CI was 
slightly higher (1.3) following treatment with IC50 and IC50*4. Furthermore, there was 
an increase in the CI following the treatment with IC50*2 with CI value of 2. However, 
the highest CI was seen with IC50/2 dose at 24h, reaching 2.2 (Figure 4.12). Results 
showed that IC50/4, IC50/2, IC50 and IC50*4 resulted in a CI values of 1.4, 1.6, 1.6 and 


























                                                                                                      (A) BCP-ALL cells 
were treated with celastrol (12.63-202.nM, green), 17-DMAG (1.6-26.5nM, blue) and in 
combination (red) for 24 hours. (B) Cells were also treated with 17-DMAG (0.20-3.3nM, green), 
celastrol (11.92-190.76nM, blue) and in combination (red) for 48 hours. Viability was assessed 
using annexin-V/PI assay. Values represent mean±SD of 3 independent patient samples. 
Data was analysed by two-way ANOVA. The combination index represents the drug 
antagonism between 17-DMAG and celastrol at 24 and 48 hours. 
 




Similar to BCP-ALL, 17-DMAG and celastrol induced apoptosis in T-ALL cells when 
used as single agents. Next, it was investigated whether using both drugs in 
combination enhanced cytotoxicity. As in Figure 4.12, 17-DMAG and celastrol were 
combined to assess cytotoxicity using the Chou Talalay test. The doses selected were 
based on IC50 values of 17-DMAG (6.63nM at 24h and 0.83nM at 48h) and celastrol 
(50.55nM at 24h and 47.69nM). The dose range for 17-DMAG was 1.6-26.5nM for 24h 
and 0.20-3.3nM for 48h, while the dose range for celastrol was 12.63-202.nM for 24h 
and 11.92-190.76nM for 48h. Results showed that combining 17-DMAG with celastrol 
showed no effect on viability for 24 and 48 hours in doses tested compared to either 
drug alone. Data in Figure 4.13A showed that combining the drugs at IC50 reduced 
viability to 49.23±7.68% compared with either drug alone at 24h, where viability was 
58.32±6.78% and 61.93±4.95% with celastrol and 17-DMAG, respectively. Also, data 
in Figure 4.13B showed a slight reduction in viability to 45.83±18.03% with the 
combined drugs compared with 53.65±6.18% and 55.20±16.65% with celastrol and 
17-DMAG alone, respectively at 48 hours. However, it was not significant. 
Combined dosing of 17-DMAG with celastrol showed drug antagonism indicated by 
high CI values for 24 and 48 hours, reaching 3 at IC50/2 dose at 24h (Figure 4.13). The 
CI value was 2 at IC50 and IC50/4 doses, whilst the higher doses (IC50*2, IC50*4) 
resulted in higher CI values at 2.5 and 2.8 at 24h, respectively. At the 48h time point, 
the CI values were similar at IC50 and IC50/4 doses, (1.5). However, the CI values were 
higher following treatment with IC50*2 and IC50*4 with 1.8 and 1.9 respectively. The 































                                                                                                          (A) T-ALL cells were 
treated with celastrol (116.8-1669.2nM, green), 17-DMAG (215.3-3444.8nM, blue) and in 
combination (red) for 24 hours. (B) Cells were also treated with 17-DMAG (143.6-2298.4nM, 
green), celastrol (107.8-1725.2nM, blue) and in combination (red) for 48 hours. Viability was 
assessed using annexin-V/PI assay. Values represent mean±SD of 3 independent patient 
samples. Data was analysed by two-way ANOVA. The combination index represents the drug 








4.2.4 Validating the effectiveness of pharmacological inducers (HSP90i) of a 
stress response in primary ALL cells 
17-DMAG caused HSP70 induction in HeLa cells. However, it has not been 
investigated if HSP70 is induced following HSP90i (17-DMAG and celastrol) in primary 
ALL cells. To this end, BCP-ALL, T-ALL and NBM cells (n=3) were treated with IC50 
doses for 24h as described in Figure 4.12 and Figure 4.13. Cells were immunostained 
with an anti-HSP70 primary antibody as described in section 4.2.1. Under basal 
conditions, HSP70 was expressed mainly in the cytoplasm in all cell types. Following 
celastrol and 17-DMAG treatments, there was an increase in the nuclear expression 
of HSP70 in NBM (Figure 4.14A), BCP-ALL (Figure 4.14B) and T-ALL (Figure 4.14C) 
cells, indicating that cells are under stress. Quantification of the nuclear HSP70 
fluorescence intensity revealed that HSP70 was significantly overexpressed following 
17-DMAG in BCP-ALL (9.95±1.24, P<0.05) and T-ALL (11.22±1.48) compared with 
NBM (7.06±1.56, Figure 4.14D). Furthermore, HSP70 was overexpressed following 
17-DMAG in BCP-ALL (from 5.87±1.08 to 9.95±1.24), T-ALL (from 6.33±0.60 to 
11.22±1.48) and NBM (from 4.90±1.00 to 7.06±1.56, P<0.05) compared with controls 
(no treatment). There was no increase in the nuclear expression of HSP70 following 
celastrol in BCP-ALL and T-ALL compared with NBM. There was an increase in 
HSP70 expression following DM-Ce in BCP-ALL (9.33±1.52) and T-ALL (10.66±2.51) 































                                                                                               (A) NBM, (B) BCP-ALL and (C) T-ALL cells were treated with celastrol, or 17-
DMAG and DM-Ce using the IC50 doses for 24h. Cells were immunostained with an anti-HSP70 primary antibody and visualised with Alexa 488 
secondary antibody (green). Cells were also stained with Hoechst for nuclear visualisation (blue). Images were captured using a 63x lens confocal 
laser microscope. (D) Bar graph represents HSP70 intensities calculated in 200 cells (2 replicates) using ImageJ. Data was analysed by two-way 
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To monitor the distribution of HSF1 and SAFB1 following 17-DMAG and celastrol in 
primary ALL cells were immunostained with anti-SAFB1 and anti-HSF1 primary 
antibodies as described in section 4.2.1. Under basal conditions, SAFB1 was 
expressed in the nucleus, whereas HSF1 was found in the nucleus and cytoplasm in 
all cell types. Data also showed that SAFB1 expression remained the same following 
celastrol and 17-DMAG treatment with no SAFB1 being recruited into HSF1 sites. After 
celastrol and 17-DMAG treatment, HSF1 expression was altered, with both diffuse 
nuclear and pronounced nuclear border expression being commonly observed in NBM 
(Figure 4.15A), BCP-ALL (Figure 4.15B) and T-ALL (Figure 4.15C) in a similar manner 
to what was seen following heat shock. To quantify SAFB1 and HSF1 expression the 
fluorescence intensity was measured. Under basal conditions, there was no significant 
difference in SAFB1 expression in BCP-ALL (12.12±2.64) and T-ALL (12.66±1.52) 
compared with NBM (15.88±1.88, Figure 4.15D). Data also showed that there was no 
significant difference in SAFB1 expression in BCP-ALL (12.95±1.90, 15.33±2.08, 
13.66±2.11) and T-ALL (15.33±2.08, 12.33±3.51, 13.33±3.21) compared with NBM 
(12.97±2.64, 12.66±1.52, 13.33±2.51) following celastrol, 17-DMAG and DM-Ce 
treatment (Figure 4.15D), respectively. Under basal conditions, there was a significant 
difference in HSF1 expression in BCP-ALL (18.33±2.08) and T-ALL (19.66±2.10, 
P<0.05) cells compared with NBM (13.29±1.58, Figure 4.15E). However, HSF1 
expression remained relatively unchanged following celastrol (10.91±1.90), 17-DMAG 
(12.66±1.62) or DM-Ce (13.33±2.46) in NBM compared with the control (13.29±1.58). 
However, HSF1 expression was reduced in BCP-ALL (13.87±1.78, 15.33±2.28, 
13.73±2.39, 18.33±2.08) and T-ALL (13.53±2.22, 14.30±2.58, 13.47±3.21, 
19.66±2.10) following celastrol, 17-DMAG or DM-Ce compared with the control cells 
but no significant difference was seen. The percentage of cells with the HSF1 nuclear 
border staining was counted. Results showed that HSF1 nuclear border staining 
increased following 17-DMAG in BCP-ALL (58.55±8.46) and T-ALL (59.25±8.42, 
P<0.05) compared with NBM (26.17±7.82, Figure 4.15F). Also, there was an increase 
in HSF1 nuclear border staining following DM-Ce in BCP-ALL (64.50±3.31) and T-ALL 
(64.50±2.64) but there was no significant difference compared with NBM (31.20±8.90). 
In contrast, celastrol caused a reduction in HSF1 nuclear border staining in BCP-ALL 























                                                                                                                 (A) NBM, (B) BCP-ALL and (C) T-ALL cells were treated with 
celastrol, or 17-DMAG and DM-Ce using the IC50 doses for 24h. Cells were immunostained with anti-SAFB1 and anti-HSF1 primary antibodies 
and visualised with Cy2 (green) and Cy3 (red) secondary antibodies respectively. Cells were also stained with Hoechst for nuclear visualisation 
(blue). Images were captured using a 63x lens confocal laser microscope. (D-F) Bar graph represents SAFB1, HSF1 intensities and the 
percentage of cells with HSF1 nuclear border staining respectively quantified in 200 cells (2 replicates) indicated by white arrows using ImageJ. 
Data was analysed by two-way ANOVA. Values represent mean±SD of 4 independent patient samples. * = P<0.05.




Primary ALL cells were also immunostained with anti-SAFB2 and anti-HSF1 primary 
antibodies as described in section 4.2.1. Under basal conditions, SAFB2 was 
expressed in the nucleus, whereas HSF1 was found in the nucleus and cytoplasm in 
all cell types. SAFB2 expression remained unchanged following celastrol and 17-
DMAG with no SAFB2 being recruited into HSF1 sites. After celastrol and 17-DMAG, 
HSF1 expression was altered, with a diffuse nuclear and pronounced nuclear border 
expression being commonly observed in NBM (Figure 4.16A), BCP-ALL (Figure 
4.16B) and T-ALL (Figure 4.16C). To quantify SAFB2 expression the fluorescence 
intensity was measured. Under basal conditions and following celastrol and 17-DMAG 
treatment as single drugs or in combination, there was no significant difference in 
SAFB2 expression in BCP-ALL (16.33±3.21, 13.98±1.91, 15.43±2.61, 13.73±2.58) 
and T-ALL (15.83±2.51, 15.13±2.31, 12.33±3.41, 13.03±3.23) compared with NBM 
(12.65±1.52, 12.63±2.64, 12.33±2.41, 12.24±2.11, Figure 4.16D). Consistent with 
data in Figure 4.15E, there was a slight decrease in HSF1 expression following 
celastrol and 17-DMAG treatment as individual or combined drugs (DM-Ce) compared 
with the control cells but no significant difference was observed. However, there was 
a significant difference in HSF1 expression under basal conditions in BCP-ALL 
(18.33±2.08) and T-ALL (19.66±2.10, P<0.05) cells compared with NBM (13.29±1.58, 
Figure 4.16E). HSF1 expression remained relatively the same following celastrol, 17-
DMAG and DM-Ce treatments in NBM. The percentage of cells with the nuclear border 
staining was counted. Consistent with Figure 4.15 the results showed that HSF1 
nuclear border staining increased following 17-DMAG in BCP-ALL (58.55±8.46) and 
T-ALL (59.25±8.42, P<0.05) compared with NBM (26.17±7.82, Figure 4.16F). Also, 
there was an increase in HSF1 nuclear border staining following DM-Ce in BCP-ALL 
(64.50±3.31) and T-ALL (64.50±2.64) but no significant difference was observed 
compared with NBM (31.20±8.90). In contrast, HSF1 nuclear border staining was 
comparable across all treatment conditions in NBM. However, HSF1 nuclear border 
staining was significantly increased in BCP-ALL (58.55±8.46, 64.50±3.31, 
11.50±26.13) and T-ALL (59.25±8.42, 64.50±2.64, 17.15±3.32) following 17-DMAG 





















                                                                                                                 (A) NBM, (B) BCP-ALL and (C) T-ALL cells were treated with 
celastrol, or 17-DMAG and DM-Ce using the IC50 doses and left for 24h. Cells were immunostained with anti-SAFB2 and anti-HSF1 primary 
antibodies and visualised with Cy2 (green) and Cy3 (red) secondary antibodies respectively. Cells were also stained with Hoechst for nuclear 
visualisation (blue). Images were captured using a 63x lens confocal laser microscope. (D-F) Bar graph represents SAFB2, HSF1 intensities and 
the percentage of cells with HSF1 nuclear border staining respectively quantified in 200 cells (2 replicates) indicated by white arrows using 
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The HSP90 inhibitor anti-cancer drugs (celastrol and 17-DMAG) are considered to be 
inducers of stress response (128),(129),(131) and also induce apoptosis in T-ALL and 
BCP-ALL cells (95). The transcriptional factor HSF1 controls different transcriptional 
programmes, such as oncogenic progression, cell cycle regulation and metabolism 
and HSF1 expression was found to be altered in a wide range of cancers (150),(151). 
Evidence also shows that SAFB1 localises to nSBs. However, it is not known if its 
paralogue, SAFB2, also transloctes to nSBs following a stress. The stress response 
has not been extensively studied following the treatment of cells with HSP90 inhibitors. 
In HeLa cells, which are known to induce a typical stress response, SAFB1, SAFB2 
and HSF1 were recruited into nSBs following heat shock with different kinetics; SAFB2 
and HSF1 being recruited first in HeLa cells. This may indicate SAFB2 is needed to 
stabilise Sat III lncRNAs and/or plays a role in recruiting further proteins to nSBs. Heat 
shock also caused HSP70 induction. 17-DMAG but not celastrol increased HSP70 
expression and induced HSF1 puncta but SAFB1 and SAFB2 were not recruited into 
HSF1 puncta. HeLa cells treated with17-DMAG and celastrol in combination resulted 
in higher toxicity (35.75±7.38% viable) at 24 hours and (28.17±2.03% viable) at 48 
hours compared to treatment with celastrol alone (52.17±7.60% viable) and 
(43.16±19.00% viable), respectively. However, there was no significant difference 
between DM-Ce and 17-DMAG at either timepoint. These data show that 17-DMAG 
acts as an effective inducer of Hsp70 transcription. As both of these drugs are effective 
at reducing viability (albeit at different concentrations) these data suggest they may do 
so via different mechanisms.  
 
During HS, SAFB1 was previously shown to be recruited to distinct bodies, called 
nSBs during a recovery period at 370 C after HS (4), while the role of SAFB2, a 
paralogue of SAFB1, in cellular stress has not been studied. The present study 
suggests that SAFB1 is not immediately recruited into nSBs in HeLa cells. SAFB1 
starts to move into nSBs after 1 hour of recovery following HS in HeLa cells. HSF1 is 
the main regulator of HS and so its expression was evaluated in parallel with SAFB1 
and SAFB2. The changing expression and kinetics of SAFB2 following HS have not 
been previously studied. Interestingly, immediately after heat shock at 420 C for 1h in 




suggesting that SAFB2 moves into nSBs earlier than SAFB1. This may indicate 
SAFB2 is needed to stabilise lncRNAs and/or plays a role in recruiting further proteins 
to nSBs. Weighardt et al. (1999) studied the kinetics of SAFB1 and HSF1 following HS 
in HeLa cells (4). They found that HSF1 and SAFB1 formed nSBs following HS at 420 
C for 30 minutes. At 45 and 60 minutes following HS, SAFB1 co-localisation with HSF1 
was observed and they accumulated into nSBs. After a 3 hour recovery, SAFB1 was 
still concentrated in these granules, whereas HSF1 had diffused back to the nuclear 
compartment. However, in the current study it was found that SAFB2 goes into nSBs 
immediately after HS, whereas SAFB1 did not. This difference could be explained by 
the fact that SAFB1 was transfected into cells (i.e. endogenous SAFB1 was not being 
detected) and that the SAFB1 antibody used by Weighardt et al was cross reacting 
with SAFB2 and possibly they were detecting SAFB2 not SAFB1.  
 
It was not known whether primary ALL cells have the ability to elicit a functional cellular 
stress response following heat shock and/or anti-cancer drug (HSP90i) treatment. In 
primary human ALL cells and NBM, SAFB1 and SAFB2 expression was not altered 
following heat shock. HSF1 expression was however significantly increased in BCP-
ALL and T-ALL compared with NBM. In addition, HSF1 was found enriched at the 
nuclear border in primary NBM, BCP-ALL and T-ALL cells. HSF1 nuclear border 
aggregation was more abundant in BCP-ALL and T-ALL cells compared to NBM 
following HS. The HeLa cell response to stress is considered typical (see discussion 
below) in that it is similar to that elicited by many other cell types (i.e. the transcription 
of heat shock proteins and SatIII transcripts/nSBs formation occurs). These data show 
NBM cells differ in their stress response (did not form nSBs) compared to HeLa cells. 
Further, primary T-ALL and BCP-ALL cancer cells differ when compared to NBMs as 
HSF1 expression is significantly altered with higher percentage of HSF1 aggregation 
at the nuclear border (but no discrete nuclear puncta are seen) following heat shock 
and 17-DMAG treatment. Under normal conditions, HSF1 is normally diffusely enters 
the nucleus upon stress. In this study, HSF1 was aggregating at the nuclear border 
(detected by measuring the average intensities of HSF1 in the nucleus and cytoplasm- 
explained in the Method section) upon stress in ALL cells, which is unusual staining 
pattern and has never shown in other cells (HeLa cells). It is not known what does that 
mean but could be that HSF1 is not fully activated in these cells and further 




cytoplasmic and nuclear proteins, cytoplasmic markers techniques (e.g. 
immunofluorescence staining) could be employed to assess whether HSF1 is also 
detected in the cytoplasm. In addition, neither NBM or primary T-ALL and BCP-ALL 
cells were found to have SAFB2 containing nSBs following HS or 17-DMAG treatment. 
However, BCP-ALL and T-ALL cells were more sensitive to treatment with 17-DMAG 
and celastrol than NBM cells. These data show that NBM cells cannot induce a heat 
shock response. However, T-ALL and BCP-ALL cells show altered HSF1 expression 
and respond to HS and 17-DMAG by increasing hsp70 expression.       
 
HSF1 nuclear border staining was not co-localised with either SAFB1 or SAFB2 after 
HS in primary human cells. Previous reports suggest that the expression of HSF1 is 
up-regulated in various tumours, including prostate, colon and lung cancers (145). The 
altered stress response could be linked to the altered levels of HSF1 reported above 
and the altered expression of SAFB1/SAFB2 ratio observed in BCP-ALL and T-ALL in 
chapter 3. Other reports found that the stress within cancer microenvironment is 
caused by many factors, including hypoxia and low pH. These factors might be altering 
HSF1 levels to accommodate the stress (134,147). In addition, it was reported that 
HSF1 levels were reduced in human T-cells following heat shock, consistent with the 
data presented in this chapter (166). Thus, this might influence its ability to generate 
the normal stress response. Also, it was suggested that lymphocyte activation is 
essential to elicit a proper cytoprotective response. Activated B and T lymphocytes 
were reported to be more protective following stress (167),(168). The lower 
percentage of cells with HSF1 nuclear border staining observed under basal 
conditions and following treatment with HSP90i in NBM cells compared with ALL cells 
might be linked to cellular differentiation. HSF1 was reported to control the cellular 
differentiation which might be altered during tumorigenesis. For example, monocytes 
have less potential to differentiate into macrophages in vivo and in vitro HSF1-/- mouse 
models (169).  
 
Environmental perturbation (hypertonic stresses, heavy metals) and specific cellular 
conditions (HS) activate the stress response to maximise cellular survival (165). An 
immediate block of several cellular processes is triggered in response to stress, 
including DNA replication, transcription, mRNA export and translation (18). The initial 




formation of nSBs is not only induced by HS but also in response to chemical and 
hypertonic stresses (18). Furthermore, HSF1 nSBs have been detected in many cell 
lines, including HeLa, A431 and HOS as well as in primary human cells, including 
epithelial and fibroblasts (4). nSBs were found to be the sites of many pre-mRNA 
processing factors, including SF2/ ASF, 9G8 and SRp30c. The assembly of nSBs is a 
unique process that is found on distinct chromatin regions, consisting of Sat III DNA 
sequences that are only found at pericentromeric heterochromatin on specific 
chromosomes such as 9, 12 and 15 (18) with implications in regulating alternative 
splicing. 
 
For cells to elicit a proper cellular stress response, in addition to nSB formation, HSPs 
are produced following stress to prevent protein mis-folding and aggregation. Treating 
HeLa cells with HSP90i such as 17-N-allylamino-17-demethoxygeldanamycin 
(17AAG) is known to induce a stress response as evaluated by higher HSP70 
expression, which  was found in the nucleus and cytosol following stress 
(170),(130),(171). Celastrol causes cell death in human leukaemia cell lines (Jurkat) 
and human glioblastoma cell lines (U251N) (130). Another class of HSP90 inhibitors 
used in this chapter, 17-DMAG but not celastrol, caused higher induction of HSP70 
expression in HeLa and human BCP-ALL and T-ALL cells compared with NBM cells. 
Interestingly, although a previous report showed that celastrol caused up-regulation of 
inducible HSP70 in HeLa cells and SH-SY5Y (130), our data showed that celastrol did 
not trigger higher induction of HSP70. Although celastrol resulted in the formation of 
HSF1 nuclear border staining, the percentage of cells with this observation was far 
less compared with 17-DMAG. Similar observations were seen in BCP-ALL and T-ALL 
cells in which SAFB2 and SAFB1 were not co-localised with HSF1 following 17-DMAG 
and celastrol. These data suggest that 17-DMAG is inducing a different cellular 
response to celastrol and are likely explained by the fact 17-DMAG is a more effective 
inhibitor of HSP90 and celastrol has additional actions. 17-DMAG directly targets the 
ATP site of HSP90 (122), whereas celastrol indirectly inhibits HSP90 by causing 
disruption to HSP90 and the co-chaperone Cdc37 (130). These data suggest that the 
mechanisms regulating the cellular stress response (assessed by HSF1 and HSP70 





In conclusion, the altered expression of SAFB1 and SAFB2 observed in primary BCP-
ALL and T-ALL influenced the mechanisms regulating the stress response in 
malignant cells. In addition, HSF1 was found to be overexpressed in primary BCP-ALL 
and T-ALL cells following HS and HSP90i treatment, indicating that the stress 
response is altered. Furthermore, HSP90 inhibitors (17-DMAG and celastrol) killed 
primary BCP-ALL and T-ALL cells but not NBM cells at the same dose. This may occur 
due to the altered expression of HSF1 being toxic in BCP-ALL and T-ALL cells and/or 
pathways not related to HSP90 inhibition are activated. The altered stress response 
in ALL, as typified by the lack of SAFB2 containing nSBs, also suggest an altered 
stress response could be involved. For instance, nSB sequester transcription and RNA 
processing factors and are thought to thereby shut down transcription and translation 
during stress. If this does not occur, the chaperone/stress proteins induced during 
stress will bind constitutive proteins and interfere with their correct processing, thereby 









CHAPTER 5 : Characterising SAFB1 and SAFB2 














































SAFB proteins are involved in regulating many cellular functions, including gene 
expression (38), the cellular stress response (19), DNA repair, apoptosis (22), RNA 
processing and splicing (38). However, little is known about the differences/similarities 
between the function of SAFB1 and SAFB2 in regulating these pathways. Therefore, 
identifying the unique and shared SAFB1 and SAFB2 protein partners would help 
elucidate the roles of each of these proteins. 
 
SAFB1 and 2 proteins are highly similar at the amino acid level, sharing 74% overall 
homology (7) with the various functional domains of SAFB proteins sharing higher 
homologies (ranging from 65-100%). The C-terminus region contains the domains 
crucial for protein-protein interactions and the various partner complexes formed are 
responsible for SAFB protein functionality (8). SAFB1 is primarily expressed in the 
nucleus, while SAFB2 is expressed in both the nucleus and cytoplasm (5). This 
suggests that SAFB2 has additional functions distinct from those of SAFB1. However, 
despite evidence suggesting SAFB1 and SAFB2 may have some distinct functions, 
the majority of studies to date have investigated SAFB1 functions with very few 
investigating SAFB2.  
  
RNA binding proteins (such as SAFB1/2) need to interact with a number of partner 
proteins to mediate their actions. In addition, a number of PTMs, for example in 
response to stress and regulatory signals regulate these protein:protein interactions. 
SAFB1 has been reported to interact with hnRNPs, nuclear receptors (4),(40),(9) and 
SR proteins, such as SRSF1 (2). It was also reported that both SAFB1 and SRSF1 
are recruited  into nSBs following heat shock (2). Another study showed that deletions 
within the C-terminal protein interaction domain (638-788 aa region) of SAFB1 
prevented binding to nSBs (20). In addition, deletion of both the E/R and R/G caused 
SAFB1 to translocate to the cytoplasm suggesting multiple C-terminal interactions 
govern SAFB1 function. SAFB proteins have been found to undergo several PTMs 
(SUMOylation, methylation), which are important in regulating protein-protein 
interactions (2),(25),(27),(28), (11). The E/R and R/G domains of SAFB1/2 contain 
RGG/RG motifs (30) that may be methylated differentially to mediate important cellular 




is known about the significance of the arginine methylation of SAFB proteins in 
regulating the cellular response to stress, however preliminary data in our laboratory 
showed that SH-SY5Y cells treated with AdOx (a pan methylation inhibitor) altered the 
nuclear distribution of SAFB1 and SRSF1, suggesting methylation of these proteins 
plays a role in their constitutive functions. The significance of SAFB protein 
SUMOylation status in mediating protein-protein interactions has not been studied. 
However, SAFB1 SUMOylation status was linked to the stress response, with SAFB 
proteins becoming de-SUMOylated upon heat stress (27). Also, it was found that 
SUMOylation was required for transcriptional repression to be mediated by SAFB1 
(29). However, it is not known whether methylation and/or SUMOylation regulate the 
interaction between SRSF1 and SAFB1 or SAFB2 following heat shock.  
 
Hence, although a number of studies have identified specific SAFB1 binding partners 
there have been no comprehensive proteomic analyses to identify the protein binding 
partners of SAFB1 and SAFB2. In addition, the influence of arginine (RGG/RG) 
methylation and SUMOylation on SAFB1/2 protein interactions has not been studied.  
 
The aims of this chapter were therefore to: 
i. Investigate whether SAFB1 and SAFB2 RGG/RG and SUMOylation motifs 
regulate the protein interactions of SAFB1 and SAFB2 
ii. Identify SAFB1/2 protein interactions using Tandem Mass Tag Mass 
Spectrometry (TMT-MS) following pulldown assays in HeLa and T-ALL cells 
iii. Use bioinformatic tools to map the biological processes and functional 
pathways that SAFB1 and SAFB2 regulate  









5.2.1 Exploring whether RGG/RG and SUMOylation motifs regulate 
interactions between SAFB1/SAFB2 and SRSF1 
SAFB1 and SAFB2 are known to be post-translationally modified (PTM) and several 
sites for RGG/RG methylation and stress-dependent SUMOylation have been 
identified. SAFB1 was reported to interact with SRSF1, (also a component of nSBs) 
under stress and non-stress conditions (2). It was hypothesised that SAFB2 may also 
interact with SRSF1 and if this were the case interactions with SRSF1 could be used 
to investigate the role PTMs play in regulating SAFB1/2 function. Thus, SAFB1 
methylation deficient (Δ-methylation) mutants were made at 7 sites (R557, R811, 
R868, R874, R844, R754, R902 aa) using a site directed mutagenesis kit to switch 
arginine (R) residues for lysine (K). SAFB2 Δ-methylation mutants (Renata Raele) and 
SAFB1/2 deficient (Δ-SUMOylation, K231 and K294 aa) mutants (Nicola Buckner) 
were also made in our lab at 8 sites (R773, R897, R903, R883, R932, R566, R835, 
R842 aa). A schematic diagram showing the mutagenesis steps is shown (Figure 
5.1A) and full details of the mutagenesis method is described in chapter 2.   
 
SAFB1 methylation sites are indicated in arrows within the SAFB1 sequence (Figure 
5.1B) located at the C-terminal in the protein-protein interaction domain. To check for 
successful site directed mutagenesis, mutated SAFB1 plasmids were checked for the 
conversion of the arginine codon (CGT/CGC/CGA/CGG/AGA/AGG) to lysine 
(AAA/AAG) by Sanger sequencing. The whole SAFB1 construct was sequenced using 
flanking primers. Results showed that all 7 arginine methylation sites of SAFB1 was 





























































                                                                                                                          (A) Schematic 
diagram showing the steps involved in mutagenesis. (B) SAFB1 domains with a total of 7 
methylation arginine sites indicated in arrows. (C) SAFB1 Δ methylation mutants were created 
using a site directed mutagenesis kit and the conversion of the arginine to lysine was validated 








To investigate the effect of methylation and SUMOylation on the interaction between 
SRSF1 with SAFB1 under basal conditions and following heat shock, co-IPs were 
performed on HeLa cells transfected with EGFP-SAFB1 mutants. Cells were 
transfected with SAFB1 wild type (WT), SAFB1 Δ methylation and Δ SUMOylation 
mutants for 48 hours. Cells were then heat shocked at 420 C for 1 hour followed by 0 
hours recovery (HS+NR) and 1 hour recovery (HS+R). Next, co-IPs were performed 
on HeLa lysate with anti-EGFP antibodies and IgG control. Immunoprecipitates were 
analysed by Western blotting and probed with SAFB1 and SRSF1 antibodies. 
Densitometry was performed on SRSF1 IP relative to SAFB1 IP and values represent 
mean± SD. Under basal conditions (non-heat shock), the SAFB1 Δ-methylation and 
SAFB1 Δ-SUMOylation proteins interaction with SRSF1 was reduced (0.66±0.13) and 
(0.60±0.11) compared with the WT-SAFB1 control (0.85±0.20), however this was not 
significant (Figure 5.2). Following heat shock (HS+NR), there was a significant 
reduction in the interaction between WT-SAFB1 (0.41±0.15, P<0.05) and SRSF1 
following HS+NR compared with the WT-SAFB1:SRSF1 interaction (0.85±0.20) 
measured under basal conditions (Figure 5.2). There was however, no significant 
difference in the interaction of SAFB1 Δ-methylation (0.38±0.04) and SAFB1 Δ-
SUMOylation (0.40±0.18) mutants with SRSF1 when compared to the WT-SAFB1 
control. After the recovery period (HS+R), there was no significant difference between 
the interactions of WT-SAFB1 and SRSF1 when comparing HS+NR (0.41±0.15) to 
HS+R (0.49±0.23). However, the WT-SAFB1:SRSF1 interaction one hour after HS 
(HS+R) remained less than that observed with no heat shock (NHS). No significant 
change in the SAFB1 Δ-methylation:SRSF1 interaction was observed when compared 
to WT-SAFB1:SRSF1 values under any of the conditions. However, the interaction 
between the SAFB1 Δ-SUMOylation mutant and SRSF1 was significantly increased 
(0.85±0.08, P<0.05) when compared to SAFB1-WT:SRSF1 (0.49±0.23) under HS+R 































                                                                                                                    HeLa cells were transfected with EGFP-SAFB1 (WT), EGFP-SAFB1 D-
methylation and EGFP-SAFB1 D-SUMOylation for 48 hours. Cells were subjected to either control (NHS), heat shock with no recovery (HS+NR) 
or heat shock and recovery (HS+R). Co-IPs were performed with EGFP or IgG antibodies. The immunoprecipitates were run on WB and probed 
with SAFB1 (Bethyl) and SRSF1 (Abcam) antibodies. Input and immunodepleted (ID) lysates were run as controls. Densitometry was performed 
on SRSF1 IP relative to SAFB1 IP. Co-IP results are from 3 independent experiments. Values represent mean± SD. * = P<0.05. 




The influence of methylation and SUMOylation on the interaction between SRSF1 with 
SAFB2 was also explored under basal conditions and following heat shock using co-
IPs on HeLa cells transfected with EGFP-SAFB2 mutants. Cells were transfected with 
SAFB2 WT, SAFB2 Δ methylation and Δ SUMOylation mutants for 48 hours. Cells 
were then heat shocked at 420 C for 1 hour followed by 0 hours recovery (HS+NR) 
and 1 hour recovery (HS+R). Next, co-IPs were performed on HeLa cell lysate with 
EGFP antibodies and IgG control. Co-IPs were analysed by Western blotting and 
probed with SAFB2 and SRSF1 antibodies. Densitometry was performed on SRSF1 
IP relative to SAFB2 IP and values represent mean± SD. Under basal conditions, there 
was a significant reduction (P£0.01) in the interaction between the SAFB2 Δ-
methylation mutant (mean+SD=0.26±0.14) and SRSF1 when compared with WT-
SAFB2 basal levels (0.81±0.15), indicating the methylation of SAFB2 increases 
binding to SRSF1. There was no significant reduction in the interaction between the 
SAFB2 Δ-SUMOylation (0.68±0.23) mutant and SRSF1 under basal conditions 
(Figure 5.3). There was however a significant reduction in the interaction between WT-
SAFB2 and SRSF1 (0.33±0.07, P<0.05) following heat shock (HS+NR) compared with 
basal conditions (0.81±0.15, NHS, Figure 5.3). There was also a decrease in the WT-
SAFB2:SRSF1 interaction following HS+NR (as with SAFB1) although there was no 
significant difference when methylation and SUMOylation mutants were compared to 
HS+NR control (WT-SAFB2). However, there was a significant reduction in the 
interaction between the SAFB2 Δ-methylation mutant and SRSF1 following HS+R 
(0.37±0.15, P<0.05) compared with the WT-SAFB2 (0.85±0.13). Likewise, the 
interaction between SAFB2 Δ-SUMOylation with SRSF1 was decreased (0.70±0.16) 































                                                                                                                    HeLa cells were transfected with EGFP-SAFB2 (WT), EGFP-SAFB2 D-
methylation and EGFP-SAFB2 D-SUMOylation for 48 hours. Cells were subjected to either control (NHS), heat shock with no recovery (HS+NR) 
or heat shock and recovery (HS+R). Co-IPs were performed with EGFP or IgG antibodies. The immunoprecipitates were run on WB and probed 
with SAFB2 (Bethyl) and SRSF1 (Abcam) antibodies. Input and immunodepleted (ID) lysates were run as controls. Densitometry was performed 
on SRSF1 IP relative to SAFB2 IP. Co-IP results are from 3 independent experiments. Values represent mean± SD. * = P<0.05, ** = P£0.01.




5.2.2 TMT-MS analysis 
In order to identify SAFB1/2 protein interactions, TMT-MS analysis was used. The 
mass spectrometry was conducted by Dr Kate Heesom at the Proteomic facility 
(University of Bristol). The first step in this process uses antibodies specific to SAFB1 
and SAFB2 to carry out co-IP assays and the co-IP protocol is described. HeLa and 
T-ALL cell lysates were incubated with antibodies and SAFB1 and SAFB2 bound 
proteins immunoprecipitated (and compared to an isotype IgG control). SAFB1, 
SAFB2 and IgG antibodies were conjugated to protein G beads and incubated with 
the cell lysate overnight. Successful immunoprecipitation was confirmed by Western 
blotting for the presence of SAFB1 and SAFB2 and their known interacting proteins. 
The schematic workflow for SAFB1 and SAFB2 and TMT-MS analyses are shown 
(Figure 5.4A). Co-IP samples were desaturated by trypsin, TMT labelled, pooled, 
fractionated, cleaned and analysed by mass spectrometry. Data analyses and 













































































                   (A) Five hundred micrograms of protein cell lysate were used for co-IP. Either 
SAFB1, SAFB2 or IgG co-IPs were performed generating 9 samples from 3 independent 
experiments for each cell type. The immune-complex in co-IPs were checked by Western 









5.2.3 Optimisation of co-IP from HeLa cell lysates 
Immunoprecipitation of SAFB1 and SAFB2 was carried out with and without the 
crosslinking of antibodies to the magnetic beads. A second aim was to validate a new 
custom made SAFB1 antibody. We produced our SAFB1 antibody (custom-made) by 
Invitrogen to save money and with the hope to obtain better specificity. 
 
Initial co-IPs showed an IgG heavy (50kDa) and light (25kDa) chain band on the blots 
and the molecular weight of the latter was similar to the SRSF1 band (27kDa). 
Therefore, crosslinking the SAFB1 and SAFB2 antibodies to the beads was evaluated 
as a method to reduce non-specific IgG interactions and enable the better detection 
of SRSF1.   
 
HeLa cell lysate was immunoprecipitated with SAFB1 (Bethyl and Invitrogen), SAFB2 
(Bethyl) or IgG antibodies with and without crosslinking beads. IP was assessed by 
Western blotting and probing for SAFB1 and SAFB2 (Figure 5.5). Results revealed 
that SAFB1 IP was successful with both the Bethyl and Invitrogen antibodies. The 
SAFB1 band was depleted in the SAFB1 immunodepleted lane suggesting SAFB1 
was mostly captured by the beads. Following crosslinking, the heavy chain IgG band 
was greatly diminished. The light chain IgG band was completely removed. Reducing 
IgG will help in removing non-specific interactions during TMT-MS analyses. Similarly, 
SAFB2 co-IP was successful and the SAFB2 band was detected, which was not found 
in the IgG lane. Also, most of the non-specific IgG band was removed following 
crosslinking (Figure 5.5).  
 
These results revealed that crosslinking antibodies to beads was beneficial in 
removing most of non-specific IgG and also improved the efficiency of the IP itself. 























































                                                                                     HeLa cell lysate (500µg) was 
incubated with SAFB1 (Bethyl and Invitrogen), SAFB2 (Bethyl) and IgG (Invitrogen) antibodies 
either crosslinked to protein G beads or without crosslinking. The immunoprecipitate was run 
on Western blots and probed with SAFB1 (Bethyl) and SAFB2 (Bethyl) antibodies. Input and 









5.2.4 Validation of co-IP from HeLa cell lysates 
In order to confirm the immunoprecipitation was working, Hela cell lysates were 
coimmunoprecipitated with SAFB1 and SAFB2 and probed with SAFB1/2 antibodies 
and an SRSF1 antibody (as SRSF1 is a known binding partner of SAFB1). The results 
showed that SAFB1 was present in the IP and that immunodepletion reduced the 
SAFB1 band suggesting that it was mostly captured by the beads (Figure 5.6). Also, 
there was no SAFB1 band in the IgG IP sample, suggesting the SAFB1 IP was 
specific. SRSF1 was detected in the SAFB1 IP sample but not in the IgG IP sample, 
indicating the interaction of SRSF1 with SAFB1 was specific (Figure 5.6). SRSF1 was 
found in SAFB1 immunodepleted lane, indicating that not all the SRSF1 is bound to 
SAFB1.  
 
Similarly, SAFB2 IP was successful and a SAFB2 band was detected, which was not 
found in the IgG lane. The SAFB2 band was depleted in the SAFB2 immunodepleted 
lane suggesting most of it was bound to the beads. Like SAFB1, SRSF1 was 
coimmunoprecipitated with SAFB2 with some fractions of SRSF1 found in the SAFB2 
immunodepleted lane. However, no SRSF1 was seen in the IgG lane suggesting 





























































          Co-IP was performed with 500µg of pre-cleared lysate with SAFB1 (Invitrogen), SAFB2 
(Bethyl) or IgG (Invitrogen) antibody crosslinked beads. The immunoprecipitate was run on 
Western blots and probed with SAFB1 (Bethyl), SAFB2 (Bethyl) and SRSF1 (Invitrogen) 
antibodies. Input and immunodepleted (ID) lysates were run as controls. Co-IP was performed 














5.2.5 Validation of co-IP in primary T-ALL cell lysates 
The next aim was to assess co-IP of SAFB1 and SAFB2 interacting proteins from 
primary T-ALL cell lysates. To this end, SAFB1, SAFB2 and IgG co-IPs were 
performed using primary T-ALL lysates (n=3) following the protocol optimised using 
HeLa cell lysates. Co-IPs were assessed by western blotting and probed with SAFB1, 
SAFB2 and SRSF1 antibodies. Consistent with the HeLa cell data in Figure 5.6, IP 
was successful and a SAFB1 band was detected in the T-ALL IP samples (Figure 5.7). 
Also, immunodepletion reduced the SAFB1 band, suggesting most SAFB1 was 
captured by the beads. Furthermore, no IgG band was detected in SAFB1 IP lane 
suggesting the IP was specific. An interaction between SRSF1 and SAFB1 was 
detected with SRSF1 present in the IP sample with low levels compared with HeLa 
cell data. However, more SRSF1 was found in the SAFB1 immunodepleted lane. 
However, no SRSF1 was seen in the IgG lane suggesting that the SRSF1 interaction 
with SAFB1 was specific (Figure 5.7). 
 
Similarly, the SAFB2 band was successfully detected in the SAFB2 IP sample but not 
the IgG IP sample. The immunodepletion diminished the SAFB2 band suggesting that 
it was mostly captured by the beads. Unlike in HeLa cells, the interaction between 
SRSF1 and SAFB2 was not detected, suggesting low level of interaction compared 
with HeLa cell data or the interaction is lost. However, the SRSF1 band was found in 
the SAFB2 immunodepleted lane with no SRSF1 detected in the input lane (Figure 
5.7). This might suggest that more protein was loaded in the SAFB2 immunodepleted 





















































                                Co-IP was performed with 500µg of pre-cleared lysate incubated with 
SAFB1 (Invitrogen), SAFB2 (Bethyl) or IgG (Invitrogen) antibody crosslinked beads. The 
immunoprecipitate was run on Western blots and probed with SAFB1 (Bethyl), SAFB2 (Bethyl) 
and SRSF1 (Invitrogen) antibodies. Input and immunodepleted (ID) lysates were run as 










Figure 5.7 Investigating the interaction between SAFB1 or SAFB2 with SRSF1 in 




5.2.6 Identification of novel SAFB1 and SAFB2 protein-protein interactions 
Following the co-IPs performed in Figure 5.3 and Figure 5.4, co-IP samples were 
labelled by Tandem Mass Tag (TMT) and analysed by Nano-LC Mass Spectrometry. 
It is known that SAFB1 and SAFB2 are similar proteins, in which SAFB2 shares 74% 
similarity with SAFB1 (7). However, little is known about the specific protein 
interactions of SAFB1 and SAFB2. In order to investigate these interactions, the 
abundance of proteins in SAFB1 and SAFB2 immunoprecipitates was normalised to 
the corresponding IgG immunoprecipitate and the relative abundance was measured 
and analysed by student’s t-test. SAFB1 and SAFB2 interacting proteins in HeLa and 
T-ALL cells, with a significant difference of (P<0.05) compared to the IgG control were 
selected for further analyses. Lists of SAFB1 and SAFB2 interacting proteins in HeLa 
and T-ALL cells were uploaded to VENNY 2.1 website 
(http://bioinfogp.cnb.csic.es/tools/venny/) and a Venn diagram was created (Figure 
5.8). Results showed that a total of 1061 proteins were identified as interacting with 
SAFB1, while a total of 605 proteins interacted with SAFB2 in HeLa cells. Results also 
showed that in HeLa cells there were more unique partners of SAFB1 (476 proteins, 
44%) than SAFB2 (20 proteins, 1.9%). Furthermore, a significant number of proteins 
interacted with both SAFB1 and SAFB2 (585 proteins, 54.1%). In contrast, in T-ALL 
cells a total of 146 proteins were found to interact with SAFB1, while a total of 348 
proteins interacted with SAFB2. There were also more unique partners of SAFB2 (269 
proteins, 64.8%) than SAFB1 (67 proteins, 16.1%) in T-ALL cells. Also, there was a 
large portion of proteins interacting with both SAFB1 and SAFB2 (79 proteins, 19%) 



































                                                                               A Venn diagram showing the total 
number of SAFB1 and SAFB2 interacting proteins in HeLa and T-ALL cells and highlighting 
SAFB1 unique partners (blue), SAFB2 unique partners (light brown) and the SAFB1/SAFB2 
shared partners. Total number of proteins and corresponding percentage in each group are 
indicated. 




The top interactions for SAFB1 in HeLa cells are shown (Table 5.1). Overall, SAFB1 
binding proteins were associated with a higher statistical significance (lower p values) 
compared with SAFB2. SAFB1 interacted with several RNA binding proteins, including 
ELAVL1, LARP4, RBN27 with roles in regulating gene expression. In addition, SAFB1 
was shown to interact with HNRNPR and HNRNPAB with roles in RNA processing. 
Furthermore, SAFB1 binding proteins were involved in regulating the chromosome 































Table 5.1 Top SAFB1 interactions in HeLa cells 
Protein ID Protein description Gene ID P value 
Q15717 ELAV-like protein 1 ELAVL1 0.00E-06 
Q71RC2 La-related protein 4 LARP4 0.00E-06 
Q6IQ30 Polyadenylate-binding protein PABPC1 2.58E-03 
Q6NSW5 Putative protein  FAM45B 2.58E-03 
Q12834 Cell division cycle protein 20 homolog CDC20 2.58E-03 
Q9P2N5 RNA-binding protein 27 RBN27 2.58E-03 
Q8WXF1 Paraspeckle component 1 PSPC1 2.82E-03 
A0A024R4E2 TAR DNA binding protein TARDBP 2.82E-03 
Q8N684 











Q3MHD2 Protein LSM12 homolog LSM12 3.10E-03 
Q6FI03 G3BP protein G3BP 3.10E-03 
A8K6Q4 cDNA FLJ76888 N/A 3.10E-03 
Q08211 ATP-dependent RNA helicase A DHX9 3.10E-03 
Q8IX12 Cell division cycle and apoptosis regulator protein 1 CCAR1 3.44E-03 
P38919 Eukaryotic initiation factor 4A-III EIF4A3 3.44E-03 
Q9P0K7 Ankycorbin RAI14 3.44E-03 
Q5T1Z8 Pumilio homolog 1 PUM1 4.08E-03 
Q13310 Polyadenylate-binding protein 4 PABPC4 4.17E-03 
Q96N66 Lysophospholipid acyltransferase 7 MBOAT7 4.17E-03 
A0A024RC67 Protein regulator of cytokinesis 1 PRC1 4.17E-03 
A0A024QZ19 TNF receptor-associated factor 4 TRAF4 4.17E-03 
Q9BY77 Polymerase delta-interacting protein 3 POLDIP3 4.17E-03 
O43390 Heterogeneous nuclear ribonucleoprotein R HNRNPR 4.17E-03 
O60826 Coiled-coil domain-containing protein 22 CCDC22 4.17E-03 
O43896 Kinesin-like protein  KIF1C 4.43E-03 
O43143 




Q5SW79 Centrosomal protein of 170 CEP170 4.50E-03 
A0A024QZD5 Small nuclear ribonucleoprotein 70kDa polypeptide SNRP70 4.50E-03 
P51116 




F8W0Q9 Periphilin-1 PPHLN1 5.16E-03 
Q53F64 Heterogeneous nuclear ribonucleoprotein AB HNRNPAB 5.16E-03 
A0A024R395 MRE11 meiotic recombination 11 homolog A MRE11A 5.16E-03 
O14965 Aurora kinase A AURKA 5.16E-03 
Q6P158 Putative ATP-dependent RNA helicase  DHX57 5.16E-03 
A0A0S2Z4Z9 






A8K9T5 E3 ubiquitin-protein ligase UHRF1 5.29E-03 
Q9HBB9 HC56 N/A 5.29E-03 
P61964 WD repeat-containing protein 5 WDR5 6.12E-03 
O75643 U5 small nuclear ribonucleoprotein 200 helicase SNRNP200 6.12E-03 
J3QR07 YTH domain-containing protein 1 YTHDC1 6.45E-03 
Q14444 Caprin-1 CAPRIN1 6.45E-03 
A0A024RAZ7 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 6.45E-03 
Q92878 DNA repair protein RAD50 6.45E-03 
Q9HCD5 Nuclear receptor coactivator 5 NCOA5 6.51E-03 
Q8IYV2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 ddx20 6.51E-03 
Q9UK61 Protein TASOR TASOR 6.60E-03 
Q15182 Small nuclear ribonucleoprotein-associated protein SNRPB 6.60E-03 
Q9Y4W2 Ribosomal biogenesis protein LAS1L LAS1L 6.60E-03 




The top interactions for SAFB2 in HeLa cells are shown (Table 5.2). Like SAFB1, 
SAFB2 binding proteins were associated with some RNA binding proteins, such as 
RBMXL1 and LARP4. Also, SAFB2 was associated with many HNRNPs, including 
HNRNPU, HNRNPH1, HNRNPR, HNRNPK and HNRNPM. Furthermore, SAFB2 was 
involved in regulating protein translation (EIF4A3, MRPL4, SRP68, RPS27). In 
































Table 5.2 Top SAFB2 interactions in HeLa cells 
Protein ID Protein description Gene ID P value 
Q6IQ30 Polyadenylate-binding protein PABPC1 1.10E-02 
Q00839 Heterogeneous nuclear ribonucleoprotein U HNRNPU 1.10E-02 
Q96E39 RNA binding motif protein, X-linked-like-1 RBMXL1 1.10E-02 
Q3MHD2 Protein LSM12 homolog LSM12 1.10E-02 
Q9NV31 U3 small nucleolar ribonucleoprotein protein  IMP3 1.10E-02 
Q13601 





Q12834 Cell division cycle protein 20 homolog CDC20 1.10E-02 
G8JLB6 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 1.10E-02 
Q8TCJ2 
Dolichyl-diphosphooligosaccharide--protein 




A0A024RDQ8 Replication factor C (Activator 1) 3 RFC3 1.10E-02 
P11940 Polyadenylate-binding protein 1 PABPC1 1.10E-02 
Q9HCD5 Nuclear receptor coactivator 5 NCOA5 1.10E-02 
A0A1C7CYX1 ELM2 and SANT domain-containing protein 1 ELMSAN1 1.10E-02 
Q12905 Interleukin enhancer-binding factor 2 ILF2 1.10E-02 
A0A087WTW0 E3 ubiquitin-protein ligase  UHRF1 1.10E-02 
Q6FI03 G3BP protein G3BP 1.10E-02 
P38919 Eukaryotic initiation factor 4A-III EIF4A3 1.10E-02 
O43390 Heterogeneous nuclear ribonucleoprotein R HNRNPR 1.10E-02 
Q5EC54 Heterogeneous nuclear ribonucleoprotein K HNRNPK 1.10E-02 
O00425 Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 1.10E-02 
P52272 Heterogeneous nuclear ribonucleoprotein M HNRNPM 1.10E-02 
J3KTA4 Probable ATP-dependent RNA helicase  DDX5 1.10E-02 
Q96F88 Processing of 1, ribonuclease P/MRP subunit POP1 1.10E-02 
Q9BZH6 WD repeat-containing protein 11 WDR11 1.10E-02 
A8MXP9 Matrin-3 MATR3 1.10E-02 
Q08211 ATP-dependent RNA helicase A DHX9 1.10E-02 
Q13310 Polyadenylate-binding protein 4 PABPC4 1.20E-02 
P67809 Nuclease-sensitive element-binding protein 1 YBX1 1.20E-02 
P38159 RNA-binding motif protein, X chromosome RBMX 1.20E-02 
Q9BYD3 39S ribosomal protein L4, mitochondrial MRPL4 1.20E-02 
A0A024QZ19 TNF receptor-associated factor 4 TRAF4 1.20E-02 
C9JJ19 28S ribosomal protein S34, mitochondrial MRPS34 1.20E-02 
Q9BZI7 Regulator of nonsense transcripts 3B UPF3B 1.20E-02 
A0A024QZD5 Small nuclear ribonucleoprotein 70kDa polypeptide  SNRP70 1.20E-02 
Q15398 Disks large-associated protein 5 DLGAP5 1.20E-02 
Q9UHB9 Signal recognition particle subunit  SRP68 1.20E-02 
O43896 Kinesin-like protein KIF1C KIF1C 1.20E-02 
Q9HBB9 HC56 N/A 1.20E-02 
A0A024R1I7 Tuftelin-interacting protein 11 TFIP11 1.20E-02 
Q71RC2 La-related protein 4 LARP4 1.20E-02 
Q14966 Zinc finger protein 638 ZNF638 1.20E-02 
Q15058 Kinesin-like protein KIF14 KIF14 1.20E-02 
Q8IV48 3'-5' exoribonuclease 1 ERI1 1.30E-02 
O14980 Exportin-1 XPO1 1.30E-02 
H0YJZ4 Striatin-3  STRN3 1.30E-02 
Q9UHK0 




P42677 40S ribosomal protein S27 RPS27 1.30E-02 
Q08379 Golgin subfamily A member 2 GOLGA2 1.30E-02 
D9HTE9 Plasma membrane citrate carrier SLC25A1 1.30E-02 





Also, the most significant interactions for SAFB1 in T-ALL are highlighted (Table 5.3). 
There were several proteins were bound SAFB1 that have roles in protein translation 
(RPL34, RPL37, RPL15, RPL18A, RPS10, RPL27, RPL6, RPL4, RPL8, RPL3, 

































Table 5.3 Top SAFB1 interactions in T-ALL cells 
Protein ID Protein name Gene ID P value 
A0A024RDH8 Ribosomal protein L34 RPL34 2.84E-04 
A0A024R029 Activator of basal transcription 1 ABT1 5.41E-04 
H3BLV9 SRSF protein kinase 1  SRPK1 8.75E-04 
J3KNL6 Protein transport protein sec16 SEC16A 1.10E-03 
Q13045 Protein flightless-1 homolog FLII 1.17E-03 
P61927 60S ribosomal protein L37 RPL37 1.25E-03 
A0A024R2Q4 Ribosomal protein L15 RPL15 1.56E-03 
Q96HS1 Serine/threonine-protein phosphatase PGAM5 1.58E-03 
B2R4C0 60S ribosomal protein L18a RPL18A 2.23E-03 
P46783 40S ribosomal protein S10 RPS10 2.24E-03 
Q9H8M2 Bromodomain-containing protein 9 BRD9 2.91E-03 
Q9H7Z3 Protein NRDE2 homolog NRDE2 3.71E-03 
Q02040 A-kinase anchor protein 17A AKAP17A 3.75E-03 
Q9NXE8 Pre-mRNA-splicing factor CWC25 homolog CWC25 3.91E-03 
L0R588 Alternative protein C11orf48 C11orf48 4.91E-03 
E9PGC8 Microtubule-associated protein 1A MAP1A 5.49E-03 
P00387 NADH-cytochrome b5 reductase 3 CYB5R3 6.07E-03 
J3KNR0 Non-specific serine/threonine protein kinase MARK3 6.53E-03 
A0A024QZW2 Nucleolar protein 7, 27kDa NOL7 6.95E-03 
B3KX14 cDNA FLJ44463 fis MORF4L2 7.09E-03 
Q15149 Plectin PLEC 7.12E-03 
O43684 Mitotic checkpoint protein  BUB3 7.49E-03 
P07437 Tubulin beta chain TUBB 7.56E-03 
V9HW31 ATP synthase subunit beta ATP5F1B 8.37E-03 
Q9BU76 Multiple myeloma tumour-associated protein 2 MMTAG2 8.47E-03 
J3KQN4 60S ribosomal protein L36a RPL36A 8.50E-03 
A0A090N7Y2 ATP-binding cassette, sub-family F (GCN20), member 2 GCN20 9.16E-03 
P61353 60S ribosomal protein L27 RPL27 9.61E-03 
Q16630 




Q96GA3 Protein LTV1 homolog LTV1 9.80E-03 
Q9NP58 




Q9HBB3 60S ribosomal protein L6 RPL6 1.01E-02 
Q9BVP2 Guanine nucleotide-binding protein-like 3 GNL3 1.01E-02 
A0A024R711 E3 ubiquitin-protein ligase UHRF1 1.05E-02 
Q96F86 Enhancer of mRNA-decapping protein 3 EDC3 1.06E-02 
Q59GY2 Ribosomal protein L4  RPL4 1.07E-02 
P62917 60S ribosomal protein L8 RPL8 1.08E-02 
A0A024R704 SFRS protein kinase 2 SRPK2 1.09E-02 
P39023 60S ribosomal protein L3 RPL3 1.10E-02 
P26373 60S ribosomal protein L13 RPL13 1.10E-02 
V9HW22 Epididymis luminal protein 33 HEL-S-72p 1.10E-02 
Q13573 SNW domain-containing protein 1 SNW1 1.11E-02 
Q12873 Chromodomain-helicase-DNA-binding protein 3 CHD3 1.13E-02 
Q8N684 Cleavage and polyadenylation specificity factor 7 CPSF7 1.22E-02 
B4DWA6 cDNA FLJ60094 N/A 1.22E-02 
P0DPB5 Protein POLR1D, isoform 2 POLR1D 1.23E-02 
A0A1U9X972 PRRC2A PRRC2A 1.26E-02 
Q9UGY1 Nucleolar protein 12 NOL12 1.26E-02 
A0A024R6W2 









Also, the most significant interactions for SAFB2 in T-ALL are highlighted (Table 5.4). 
SAFB2 interacted with proteins with roles in gene silencing (SRRT). In addition, 
SAFB2 seemed to be important in regulating splicing (U2AF, SF3B1, DHX15, SF3B6, 
SRPK1, KHDRBS1). Furthermore, some serine proteases interacted with SAFB2 with 





































Table 5.4 Top SAFB2 interactions in T-ALL cells 
Protein ID Protein name Gene ID P value 
Q13045 Protein flightless-1 homolog FLII 1.72E-04 
Q658Y4 Protein FAM91A1 FAM91A1 1.88E-04 
Q9NZB2 Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A 4.88E-04 
Q53HH4 




Q9Y520 Protein PRRC2C PRRC2C 7.32E-04 
P26368 Splicing factor U2AF 65 kDa subunit U2AF 7.46E-04 
Q9BXP5 Serrate RNA effector molecule homolog SRRT 7.61E-04 
A8K588 cDNA FLJ76823 SFRS6 8.70E-04 
Q8ND56 Protein LSM14 homolog A LSM14 1.07E-03 
B4DUQ1 cDNA FLJ54552 N/A 1.11E-03 
P20718 Granzyme H GZMH 1.17E-03 
Q07666 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
 
KHDRBS1 1.53E-03 
A3RJH1 ATP-dependent RNA helicase  DDX1 1.55E-03 
P51116 Fragile X mental retardation syndrome-related protein 2 FXR2 1.59E-03 
A0A2R8YEM9 TPR and ankyrin repeat-containing protein 1 TRANK1 1.65E-03 
P08579 U2 small nuclear ribonucleoprotein B'' SNRPB2 1.81E-03 
A0A0S2Z4Z0 RNA binding motif protein 14 isoform 1 RBM14 1.95E-03 
Q15365 Poly(rC)-binding protein 1 PCBP1 2.35E-03 
B4DI41 cDNA FLJ55972 N/A 2.37E-03 
O75533 Splicing factor 3B subunit 1 SF3B1 2.40E-03 
O15042 U2 snRNP-associated SURP motif-containing protein U2SURP 2.46E-03 
A0A024RAC5 Regulator of chromosome condensation 2 RCC2 2.85E-03 
Q9NUD5 Zinc finger CCHC domain-containing protein 3 ZCCHC3 2.90E-03 
Q59EC0 Adenosine deaminase, RNA-specific isoform ADAR-a  ADAR 3.06E-03 
O43143 Pre-mRNA-splicing factor ATP-dependent RNA helicase  DHX15 3.09E-03 
A0A024RDB4 Heterogeneous nuclear ribonucleoprotein D HNRNPD 3.45E-03 
A8K9U6 cDNA FLJ76121 N/A 3.67E-03 
Q9GZR7 ATP-dependent RNA helicase  DDX24 3.74E-03 
P62081 40S ribosomal protein S7 RPS7 3.76E-03 
Q9BZH6 WD repeat-containing protein 11 WDR11 4.07E-03 
A0A024R3R5 Lamin B receptor LBR 4.08E-03 
Q9P2N5 RNA-binding protein 27 RBM27 4.28E-03 
Q9Y2X3 Nucleolar protein 58 NOP58 4.82E-03 
A8K7N0 cDNA FLJ75556 N/A 5.04E-03 
A8K9C4 Elongation factor 1-alpha EEF1A1 5.09E-03 
P09661 U2 small nuclear ribonucleoprotein A' SNRPA1 5.10E-03 
P41091 Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 5.39E-03 
Q9Y3B4 Splicing factor 3B subunit 6 SF3B6 5.42E-03 
B2RE11 cDNA, FLJ96865 N/A 5.44E-03 
Q13422 DNA-binding protein Ikaros IKZF1 5.61E-03 
Q8IY37 Probable ATP-dependent RNA helicase  DHX37 5.67E-03 
Q9UKM9 RNA-binding protein Raly RALY 5.69E-03 
Q7L2E3 ATP-dependent RNA helicase  DHX30 5.72E-03 
Q15366 Poly(rC)-binding protein 2 PCBP2 5.72E-03 
P08311 Cathepsin G CTSG 6.08E-03 
Q27975 Synaptosomal-associated protein 47 SNAP47 6.09E-03 
O60506 Heterogeneous nuclear ribonucleoprotein Q SYNCRIP 6.39E-03 
H3BLV9 SRSF protein kinase 1 SRPK1 6.64E-03 
P38919 Eukaryotic initiation factor 4A-III EIF4A3 6.72E-03 





5.2.7 Protein-protein interactions and gene ontology (GO) analysis of SAFB1 
and SAFB2 interacting proteins in HeLa cells 
In order to gain more information on the functional relevance of SAFB1 and SAFB2 
interactions, protein-protein interactions network (PPIs), GO analysis and pathway 
analysis were conducted. The Search Tool for the Retrieval of Interacting Genes 
(STRING 11.0 version) database was used to identify PPIs (https://string-db.org). An 
interaction score of not < 0.7 (medium confidence score) was considered to be 
significant and the PPI were visualised. 
 
There are many web based enrichment tools (174),(175) of which some are commonly 
used; Enrichr (https://amp.pharm.mssm.edu/Enrichr/) (176) and the Database 
for Annotation, Visualization and Integrated Discovery (DAVID ) version 6.8 
(https://david.ncifcrf.gov/). DAVID was used as it is commonly used by proteomic and 
RNA-seq users (174),(177). Also, GO of the biological processes (BP) in DAVID can 
be shown at different levels of enrichment. Also, BP-FAT was used to provide specific 
BPs and to filter out very broad GO terms based on a measured specificity of each 
term with reduced GO term redundancies. 
 
Using DAVID, the significant total SAFB1 and SAFB2 interacting protein lists were 
profiled for BP (177), pathway analysis; Kyoto Encyclopaedia of Genes and Genomes 
(KEGG, version 2019) (178) and tissue specific enrichment (179). P value scores were 
computed for all categories and false discovery rates (FDR) with the thresholds of P-

















5.2.7.1 Specific tissue enrichment by GNF database in HeLa cells 
A specific tissue enrichment tool (GNF database), adopted from DAVID, was used to 
show enrichments for up-regulated proteins in human tissue for SAFB1 and SAFB2 
interacting proteins in HeLa cells. GNF database is a gene online portal that provides 
information of gene expression in human tissues. Interestingly, results showed that 
the SAFB1 and SAFB2 interacting proteins were highly up-regulated in different blood-
related tissues. For example, both SAFB1 and SAFB2 interacting proteins were most 
enriched in promyelocytic leukaemia (HL-60) cell line. In addition, SAFB1 and SAFB2 
interacting proteins were also enriched in another leukaemia cell line, T lymphoblastic 
leukaemia (MOLT-4) (Figure 5.9). As SAFB1 and SAFB2 interacting proteins were 
enriched in HL-60 and MOLT-4 leukaemia cell lines, the interacting proteins were 
found to be enriched in specific lymphoid cells, such as CD56+ NK cells and CD4+ and 
CD8+ T cells. Also, SAFB1 and SAFB2 interacting proteins were enriched in CD14+ 
monocytes, CD33+ myeloid cells and CD71+ early erythroid cells (Figure 5.9).  
 
SAFB1 and SAFB2 interacting proteins were enriched in lymph nodes and the Burkitts 
lymphoma (Raji) cell line with less significant enrichment compared with HL-60 and 
MOLT-4 leukaemia cell lines. Finally, SAFB1 and SAFB2 interacting proteins were 
found to be widely up-regulated in other tissues, including heart, adipocyte, placenta, 













































                    SAFB1 and SAFB2 lists were loaded into DAVID and the tissue specific 
enrichment tool was selected. The protein enrichments were based on thresholds of P-value 
















5.2.7.2 Protein-protein interactions for SAFB1 interacting proteins in HeLa cells 
In order to show the SAFB1 protein interaction network and the processes associated 
with the distinct clusters (in HeLa cells), STRING analysis was used. STRING analysis 
was computed with a high degree of connectivity for the network edges and the highest 
confidence for the interaction score. Results showed that total SAFB1 interacting 
proteins (1061) could be grouped into 6 broad functional categories, highlighted in 
black rectangles (Figure 5.10). The STRING analysis showed a cluster of: (i)  
ribosomal proteins, important in protein translation; (ii) mitochondrial ribosomal 
proteins ; (iii) DEAD-box proteins and hnRNPs, which are known to essential in RNA 
processing; (iv), proteins involved in the transcription processes (initiation, elongation, 
termination); (v)  histones enzymes and chromatin modifiers, suggesting a role in the 
nucleosome organisation; (vi) centromere regulators and microtubules, which are 




















































                                                                                                                              SAFB1 
interacting proteins were loaded into STRING and the network edges were based on 
confidence. The interaction score was set for the highest confidence (≥0.7). Circles represent 


















5.2.7.3 Protein-protein interactions for SAFB2 interacting proteins in HeLa cells 
The total SAFB2 binding proteins (605) were also loaded into STRING to give insight 
on the broad processes that SAFB2 interacting proteins regulate in HeLa cells. Similar 
to the SAFB1 data, results showed that the main processes regulated by SAFB2 
interacting proteins were RNA processing, protein translation, protein translation in 
mitochondria, nucleosome organisation, transcription and the cell cycle (Figure 5.10). 
Regulating similar processes is not surprising, as SAFB2 interacting proteins were 
mostly overlapped with SAFB1 binding proteins and only 20 proteins were unique to 































































                                                                                                                   SAFB2 
interacting proteins were loaded into STRING and the network edges were based on 
confidence. The interaction score was set for the highest confidence (≥0.7). Circles represent 











5.2.7.4 Pathway analysis (KEGG) in HeLa cells 
The next aim was to explore the main pathways that SAFB1 (1061) and SAFB2 (605) 
interacting proteins regulate in HeLa cells. The KEGG database was used as it is 
thought to be the gold standard for pathway analysis (Qi et al., 2016). Results showed 
that SAFB1/2 regulated the same pathways with lower FDRs for SAFB1 binding 
proteins compared with SAFB2. Results also showed that the most enriched pathway 
for both SAFB1 and SAFB2 interacting proteins was the ribosome for SAFB1 (8.5%) 
and SAFB2 (7.7%) with FDR of 2.60E-59 and 2.60E-26, respectively (Table 5.5). 
These data reflect the observations on STRING where there was a cluster of proteins 
involved in protein translation and they were mainly ribosomal proteins. The second 
most enriched pathway was the spliceosome for SAFB1 (6.6%) and SAFB2 (7.6%) 
with FDR of 8.70E-37 and 1.50E-25, respectively. Another pathway that was found to 
be enriched by SAFB1 and SAFB2 interacting proteins was RNA transport for SAFB1 
(5.2%) and SAFB2 (5.2%) with FDR of 3.50E-17 and 1.70E-10, respectively (Table 
5.5). Lastly, SAFB1 interacting proteins (3.5%) were found to be more enriched than 
SAFB2 (3.9%) in regulating the RNA transport and mRNA surveillance pathways with 




Table 5.5 Pathway analysis (KEGG) for SAFB1 and SAFB2 interacting proteins in HeLa 
cells. 
  SAFB1  SAFB2 
Term % FDR % FDR 
Ribosome 8.5 2.60E-59 7.7 2.60E-26 
Spliceosome 6.6 8.70E-37 7.6 1.50E-25 
RNA transport 5.2 3.50E-17 5.5 1.70E-10 
mRNA surveillance pathway 3.5 5.20E-14 3.9 8.00E-09 











5.2.7.5 The top overlapping GO biological processes for SAFB1/2 in HeLa cells 
The next aim was to identify specific SAFB1 and SAFB2 functions. Thus, SAFB1 
(1061) and SAFB2 (605) lists were loaded into DAVID and searched against BP-FAT 
to provide specific functions. There were 535 and 402 biological processes (BP-FAT) 
that were significantly enriched for SAFB1 and SAFB2 interacting proteins in HeLa 
cells, respectively. The key most enriched categories for SAFB1 and SAFB2 
interacting proteins were selected (Table 5.6). Overall, the top BP for SAFB1/2 is 
similar but is variable in SAFB1 compared with SAFB2. Also, the BP for SAFB1 was 
associated with lower FDRs compared with SAFB2. Specifically, SAFB1 (33.4%) and 
SAFB2 (37.8%) interacting proteins were highly enriched for RNA processing with 
FDR of 4.10E-180 and 4.70E-125, respectively. Also, there were several processes 
related to RNA, including mRNA, rRNA, ncRNA processing, RNA splicing, RNA 
localisation and RNA transport found to be enriched.  
 
In addition, SAFB1 (22%) and SAFB2 (23.1%) interacting proteins were found to be 
associated with ribonucleoprotein complex biogenesis with FDR of 1.30E-135 and 
6.00E-79, respectively (Table 5.6). Broadly, SAFB1 (62.8%) and SAFB2 (66.1%) 
interacting proteins were highly enriched for gene expression with FDR of 4.00E-106 
and 1.10E-71, respectively. Furthermore, there are other processes found to be 
enriched, such as translation with FDR of 1.90E-85 and 1.20E-48 for SAFB1 (19.8%) 
and SAFB2 (20.3%) interacting proteins, respectively. Also, SAFB1 and SAFB2 
















Table 5.6 The top 10 GO biological processes for total SAFB1 and SAFB2 interacting 
proteins in HeLa cells 
  SAFB1  SAFB2 
Term % FDR % FDR 
RNA processing 33.4 4.10E-180 37.8 4.70E-125 
ribonucleoprotein complex biogenesis 22 1.30E-135 23.1 6.00E-79 
gene expression 62.8 4.00E-106 66.1 1.10E-71 
ncRNA processing 16.7 1.40E-90 17.3 4.30E-52 
translation 19.8 1.90E-85 20.3 1.20E-48 
RNA splicing 15 4.60E-75 18.1 1.50E-57 
RNA localisation 6.6 5.0E-26 6.8 3.4E-14 
chromosome organisation 15.7 1.90E-20 14.6 7.20E-08 
RNA transport 5.3 1.1E-19 5.7 2.0E-11 
DNA-templated transcription 3.6 1.20E-14 4.6 6.80E-12 







5.2.7.6 The involvement of SAFB1/2 in regulating the cell cycle 
SAFB1/2 interacting proteins were significantly involved in regulating the cell cycle. 
STRING was used to show the functional connections between the SAFB1/2 
interactome (Figure 5 12). For instance, the BRCA1 protein is known to interact with 
regulators of the cell cycle (CDKN2A) and cell division (CDC20 and CDC27). Another 













































                                               SAFB1/2 interacting proteins implicated in regulating the cell 
cycle were loaded into STRING and the network edges were based on confidence. The 







5.2.7.7 The involvement of SAFB1/2 in regulating the gene silencing by miRNA 
DAVID analyses showed that SAFB1/2 binding proteins were important regulators of 
gene silencing. The binding proteins were loaded into STRING to investigate how 
those proteins associated together (Figure 5.13). ELAVL1, which was shown to be the 
top interactor with SAFB1 (Table 1.1), found to interact with important regulators of 









Figure 5.12 STRING analysis of SAFB1/2 interacting proteins implicated in regulating 































                                                 SAFB1/2 interacting proteins implicated in regulating gene 
silencing were loaded into STRING and the network edges were based on confidence. The 






5.2.7.8 The involvement of SAFB1/2 in regulating methylation 
SAFB1/2 interacting proteins were shown to regulate protein methylation using 
DAVID. It was found that SAFB proteins are methylated differentially with RGG/RG 
motifs (Norman et al., 2016; Scott et al., 2017; Nozawa et al., 2017). STRING analysis 
showed that SAFB1/2 binding proteins interacted with histones (HIST1H1C, 
HIST1H1E, HIST1H1B) and DNA methyltransferases (DNMT1), thereby regulating 
methylation (Figure 5.14). Small nuclear ribonucleoprotein Sm D3 (SNRPD3) were 
shown as a cluster with CHTOP and SNW1 and the former proteins was shown to 
interact with PRMT5 (Hiroki et al., 2014).  
 
 
Figure 5.13 STRING analysis of SAFB1/2 interacting proteins implicated in regulating 



































                                             SAFB2 interacting proteins implicated in regulating methylation 
were loaded into STRING and the network edges were based on confidence. The interaction 




5.2.7.9 Unique GO BP terms identified in HeLa cells following analysis of all 
proteins pulled down by SAFB1 (1061) and SAFB2 (605) 
Data in Table 5.6 shows that SAFB1 and SAFB2 interacting proteins shared a lot of 
functions (BP) in HeLa cells. The aim here was to identify unique SAFB1 and SAFB2 
biological processes. Thus, total SAFB1 (1061) and SAFB2 (605) interacting proteins 
were loaded into DAVID and unique biological processes for SAFB1/2 were identified. 
From a total of 535 and 402 biological processes that were significantly enriched for 
Figure 5.14 STRING analysis of SAFB2 interacting proteins implicated in regulating 




SAFB1 and SAFB2, respectively, some BP terms were only unique to SAFB1 or 
SAFB2.  
 
Results showed that SAFB1 has more unique BP processes than SAFB2. SAFB1 was 
enriched and involved in regulating protein localisation (19.1%) and transport (15%, 
Table 5.7). Data also showed that SAFB1 is important in the formation of the 
translation preinitiation complex (0.9%) and in regulating chromatin organisation 
(2.1%). Furthermore, SAFB1 regulates other processes, including small nuclear RNA 
(snoRNA) localisation (0.4%), anatomical structure homeostasis (3.5%) and cellular 




Table 5.7 Unique SAFB1 BP terms in HeLa cells following analysis of all proteins pulled 
down by SAFB1 (1061) 
Term % FDR 
protein localisation 19.1 3.10E-05 
protein transport 15 8.48E-05 
formation of translation preinitiation complex 0.9 4.27E-04 
protein-DNA complex assembly 2.7 0.011 
chromatin organisation 2.1 0.021 
snoRNA localisation 0.4 0.023 
anatomical structure homeostasis 3.5 0.024 
cellular response to oxidative stress 2.5 0.029 





SAFB1 is expressed in the nucleus, while SAFB2 is found in the nucleus and 
cytoplasm, suggesting that SAFB2 function is likely to differ from SAFB1. Thus, it was 
interesting to identify unique functions for SAFB2 in HeLa cells. Results showed that 
SAFB2 is important in regulating the cytoskeleton (9.2%) and centrosome organisation 
(1.6%, Table 5.8). Furthermore, SAFB2 functions as an important regulator for mitotic 
spindle elongation (0.5%, Table 5.8). All GO terms were significantly enriched 







Table 5.8 Unique SAFB2 BP terms in HeLa cells following analysis of all proteins pulled 
down by SAFB2 (605) 
Term % FDR 
cytoskeleton organisation 9.2 0.106 
centrosome organisation 1.6 0.223 
mitotic spindle elongation 0.5 0.289 





5.2.7.10 Biological process analyses of SAFB1/2 binding proteins in HeLa 
cells that only found in SAFB1 (476) or SAFB2 (20) pull downs 
Data in Figures (5.10- 5.15) and Tables (5.5, 5.6, 5.7, 5.8) were all based on SAFB1 
(1061) interacting proteins and most SAFB1 binding proteins were also bound to 
SAFB2 (54.1%). Thus, those (476) proteins bound by SAFB1 and not bound by SAFB2 
were analysed using DAVID (Figure 5.9). Results showed that SAFB1 binding proteins 
were predominantly enriched in regulating ribonucleoprotein complex biogenesis 
(20.3%), RNA processing (26.3%), RNA splicing (20.3%) and translation (18.6%). 
Consistent with Table (5.7), protein localisation (15.7%), protein transport (18.8%), 
chromatin organisation (8.7%) and protein-DNA complex assembly (3.4%) were found 




Table 5.9 BP terms in HeLa cells following analysis of proteins (476) only found in 
SAFB1 pull down 
Term % FDR 
ribonucleoprotein complex biogenesis 20.3 5.00E-46 
RNA processing 26.3 6.60E-45 
RNA splicing  20.3 1.70E-34 
translation 18.6 5.50E-30 
protein localisation  15.7 8.30E-13 
protein transport 18.8 3.50E-04 
chromatin organisation 8.7 8.80E-03 
protein-DNA complex assembly 3.4 3.20E-03 






A total of 585 SAFB2 out of 605 interacting proteins were found to bind SAFB1. 
However, only 20 proteins were uniquely bound to SAFB2 in HeLa cells (Figure 5.9). 
Therefore, the BP for those proteins were investigated (Table 5.10). Consistent with 
Table 5.8, SAFB2 binding proteins were enriched and involved in the regulation of 
microtubule-based process (26.3%), mitotic cell cycle (15.8%) and cytoskeleton 
organisation (26.3%), suggesting a role in regulation cell division and associated with 
significant FDRs. Furthermore, the binding proteins were involved in regulating the 




Table 5.10 BP terms in HeLa cells following analysis of proteins (20) only found in 
SAFB2 pull down 
Term % FDR 
microtubule-based process 26.3 3.00E-03 
mitotic cell cycle 15.8 1.50E-02 
cytoskeleton organisation 26.3 2.60E-02 
natural killer cell mediated cytotoxicity 10.5 5.30E-02 
FDR= false discovery rate, %= percentage of proteins involved from the whole list. 
 
 
5.2.8 Protein-protein interactions and GO analysis of SAFB1 and SAFB2 
interacting proteins in T-ALL cells 
 
5.2.8.1 Specific tissue enrichment for SAFB1 and SAFB2 
interacting proteins found in T-ALL cells 
The SAFB1 and SAFB2 interacting proteins in T-ALL cells were highly up-regulated in 
different blood-related cell lines. Similar to HeLa cell data, results showed that both 
SAFB1 and SAFB2 interacting proteins were up-regulated in promyelocytic leukaemia 
(HL-60) cell line, which was found to be the most highest enriched. T lymphoblastic 
leukaemia (MOLT-4) cell line was also enriched for both SAFB1 and SAFB2 
interacting proteins. 
 
Although the interacting proteins were also up-regulated in specific lymphoid cells 




CD56+ NK were also enriched. In addition, CD71+ early erythroid cells were also 
enriched (Figure 5.15). 
 
SAFB1 and SAFB2 interacting proteins were enriched in a wide range of different 
tissues, including thyroid, heart, whole brain and uterus corpus. Trachea tissue was 
only found to be enriched for SAFB1 interacting proteins. In contrast, Burkitts 
lymphoma cells lines, Raji and Daudi, CD34+, CD19+ cells and placenta were 


































                                                    SAFB1 and SAFB2 lists were loaded into DAVID and the 
GO-BP was selected for BP-1 and BP-2. The protein enrichments were based on the 
thresholds of P-value < 0.05 and enrichment gene count > 2. Shared tissues for SAFB1 and 
SAFB2 are indicated in orange boxes. Unique SAFB1 tissues are indicated in blue, while 
unique SAFB2 tissues are indicated in green. 
Figure 5.15 Specific tissue enrichment for SAFB1 and SAFB2 interacting 




5.2.8.2 Protein-protein interactions for SAFB1 interacting proteins in T-ALL 
cells 
Data in Figure 5.6 showed that SAFB1 interacting proteins in HeLa cells were mainly 
involved in regulating RNA processing, protein translation, protein translation in 
mitochondria, transcription, nucleosome organisation and the cell division. However, 
it is not known which processes are regulated in primary T-ALL cells. Thus, SAFB1 
interacting proteins (146) for T-ALL were uploaded into STRING and the interaction 
networks are shown (Figure 5.16). Results show that there was a cluster of ribosomal 
proteins, which are known to be involved in protein translation (Figure 5.16). Also, 
another group of DEAD-box proteins and hnRNPs were strongly clustered and these 
are known to play a role in RNA processing (Figure 5.16). Furthermore, another cluster 
of histone enzymes was highlighted, suggesting they were involved in nucleosome 


























































                                                                                                                               SAFB1 
interacting proteins were loaded into STRING and the network edges were based on 
confidence. The interaction score was set for the highest confidence (≥0.7). Circles represent 








5.2.8.3 Protein-protein interactions for SAFB2 interacting proteins in T-ALL 
cells 
Next, it was interesting to examine the interaction network for SAFB2 (348) interacting 
proteins using STRING in primary T-ALL cells. Overall, there were more SAFB2 
interacting proteins than SAFB1. Similar to SAFB1 network in T-ALL cells, results 
showed 2 clusters of strongly connected proteins. The first cluster represents a group 
of DEAD-box proteins and hnRNPs, which are known to be involved in regulating RNA 
processing (Figure 5.17). The other cluster contains many ribosomal proteins, which 
are known to regulate protein translation (Figure 5.17). Furthermore, microtubules and 
cyclin kinases were clustered, indicating they were involved in regulating the cell 
division. Also, several histone enzymes and chromatin modifiers were found in a 
cluster, suggesting they were important in the chromatin organisation (Figure 5.17). 

























































                                                                                                                                    SAFB2 
interacting proteins were loaded into STRING and the network edges were based on 
confidence. The interaction score was set for the highest confidence (≥0.7). Circles represent 











5.2.8.4 GO pathway analysis (KEGG) in T-ALL cells 
The pathway analysis by KEGG was used to investigate the SAFB1 (146) and SAFB2 
(348) interacting proteins in primary T-ALL cells. SAFB1 and SAFB2 interacting 
proteins were found to be important in regulating similar pathways. However, they 
were associated with distinct FDR values and lower FDRs for SAFB2 binding proteins.  
The spliceosome pathway was found to be the most significant enriched pathway for 
SAFB1 interacting proteins (16.9%, FDR= 3.80E-17), while the FDR rate was higher 
for SAFB2 (13.4%, 1.70E-30). In contrast, the ribosome pathway was the highest 
enriched pathway for SAFB2 (13.7%) interacting proteins and the least for SAFB1 
(7.3%) with FDR of 1.80E-31 and 2.30E-02, respectively (Table 5.11). Furthermore, 
the mRNA surveillance pathway was enriched for SAFB1 (8.9%) and less so for 
SAFB2 (6.2%) interacting proteins with FDR of 5.10E-06 and 5.80E-09, respectively. 
Lastly, RNA transport was found to be enriched for both SAFB1 (8.1%) and SAFB2 





Table 5.11 Pathway analysis for SAFB1 and SAFB2 interacting proteins in T-ALL cells 
  SAFB1  SAFB2 
Term % FDR % FDR 
Spliceosome 16.9 3.80E-17 13.4 1.70E-30 
mRNA surveillance pathway 8.9 5.10E-06 6.2 5.80E-09 
RNA transport 8.1 1.70E-02 5.8 7.90E-04 
Ribosome 7.3 2.30E-02 13.7 1.80E-31 






5.2.8.5 Overlapping GO biological processes for SAFB1/2 in T-ALL cells 
Next, the aim was to identify more specific biological process terms for SAFB1 and 
SAFB2 interacting proteins in T-ALL cells. Total SAFB1 (146) and SAFB2 (348) 
binding proteins were uploaded into DAVID and BP-FAT was selected to identify more 
specific biological terms. Results found a total of 245 and 315 biological processes 




key most enriched categories for SAFB1 and SAFB2 interacting proteins were 
selected (Table 5.12). Overall, results showed that SAFB1/2 binding proteins had 
similar BP terms. Although most of BP terms are similar to data in HeLa cells (Table 
5.6), BPs for SAFB2 binding proteins in T-ALL cells were associated with lower FDRs 
compared with SAFB1. Results also showed that both SAFB1 and SAFB2 interacting 
proteins were most highly enriched in the regulation of gene expression for SAFB1 
(82.3%) and SAFB2 (74.9%) with FDR of 5.80E-32 and 2.30E-59, respectively. RNA 
processing was the second highest enriched process for SAFB1 (56.5%) and SAFB2 
(54.6%) interacting proteins with FDR of 7.20E-54 and 1.20E-127, respectively (Table 
5.11). There were other RNA-related processes enriched for SAFB1 and SAFB2 
interacting proteins. For example, they were highly enriched for RNA splicing, RNA 
localisation ncRNA processing and RNA transport (Table 5.11). Furthermore, 
ribonucleoprotein complex biogenesis processes were enriched for SAFB1 (20.2%) 
and SAFB2 (25.4%) interacting proteins with FDR of 3.90E-11 and 1.50E-47, 
respectively. In addition, there were other processes found to be enriched for SAFB1 
(20.2%) and SAFB2 (24.4%) interacting proteins, including translation with FDR of 





Table 5.12 The 10 top GO biological process for total SAFB1 and SAFB2 interacting 
proteins in T-ALL cells 
  SAFB1  SAFB2 
Term % FDR % FDR 
RNA processing 56.5 7.20E-54 54.6 1.20E-127 
RNA splicing 41.1 4.00E-47 33.3 5.80E-85 
gene expression 82.3 5.80E-32 74.9 2.30E-59 
ribonucleoprotein complex biogenesis 20.2 3.90E-11 25.4 2.70E-48 
translation 20.2 2.00E-08 24.4 1.00E-36 
ncRNA processing 14.5 2.40E-07 21.6 4.00E-32 
RNA localisation 10.5 1.20E-06 11.7 1.80E-21 
DNA-templated transcription, termination 6.5 1.50E-04 6.9 1.20E-13 
chromosome organisation 18.5 3.50E-04 13.1 1.50E-03 
RNA transport 4.7 7.5E-3 10.1 9.9E-20 







5.2.8.6 The involvement of SAFB1/2 in regulating the cell cycle 
SAFB1/2 interacting proteins were shown to be important regulators of the cell cycle 
in T-ALL using DAVID. Thus, it was interesting to see how they are related to each 
other. STRING analysis showed that some cell cycle check-point regulators were 
involved (CDK7, CDK13, CDKN2A). Also, BUB3, the important regulator of the 
centromere was shown. Interestingly, the oncogene LEF1 was found to be a member 

































                                                 SAFB1/2 interacting proteins implicated in regulating the cell 
cycle were loaded into STRING and the network edges were based on confidence. The 




Figure 5.18 STRING analysis of SAFB1/2 interacting proteins implicated in regulating 




5.2.8.7 The involvement of SAFB2 only in regulating gene silencing by miRNA 
SAFB1/2 were shown to regulate gene silencing in HeLa cells (Figure 5.14). However, 
DAVID analyses showed that SAFB2 interacting proteins only were involved in 
regulating gene silencing in T-ALL. Next, it was interesting to investigate the 
interaction network using STRING. The analyses showed that the proteins involved in 
regulating gene silencing were highly connected (Figure 5.19). ELAVL1, SRRT and 

























                                                   SAFB2 interacting proteins implicated in regulating the gene 
silencing were loaded into STRING and the network edges were based on confidence. The 





5.2.8.8 The involvement of SAFB2 only in regulating methylation 
SAFB2 interacting proteins but not SAFB1 appeared to be important in regulating 
protein methylation. STRING was used to identify those proteins and see how they 
interact with each other. Like the HeLa cell data, results showed that histones were 
involved (HIST1H1C, HIST1H1D), SNW1, SNRPD3 and CHTOP (Figure 5.20). 
Figure 5.19 STRING analysis of SAFB2 interacting proteins implicated in regulating 

































                                               SAFB2 interacting proteins implicated in regulating the 
methylation were loaded into STRING and the network edges were based on confidence. The 





5.2.8.9 Unique GO biological processes for total SAFB1/2 interacting proteins 
in T-ALL cells 
It was interesting to identify novel functions of SAFB1 (146) in T-ALL cells and 
investigate whether they are similar to those identified in HeLa cells. Specific SAFB1 
functions were investigated using BP-FAT using DAVID. Interestingly, results found 
that SAFB1 in T-ALL cells have some functions that were unique to SAFB2 in HeLa 
cells, such as the regulation of transcription from RNA polymerase II promoter (19.6%) 
and cytoskeleton organisation (3.1%, Table 5.12). However, SAFB1 also has specific 
functions in T-ALL cells, which were not found in HeLa cells, including positive 
Figure 5.20 STRING analysis of SAFB2 interacting proteins implicated in regulating 




regulation of type I interferon production (4.7%) and intermediate filament-based 
process (3.1%, Table 5.12). 
 
Table 5.13 Unique SAFB1 BP terms in T-ALL cells following analysis of all proteins 
pulled down by SAFB1 (146) 
Term % FDR 
positive regulation of type I interferon production 4.7 0.002 
regulation of transcription from RNA polymerase II 
promoter 19.6 0.018 
cytoskeleton organisation 3.1 0.033 
intermediate filament-based process 3.1 0.035 




Also, unique functions for SAFB2 (348) interacting proteins were explored. Similarly, 
SAFB2 possesses some functions that were exclusive to SAFB1 in HeLa cells, such 
as protein localisation (23.0%), protein transport (18.9%), protein-DNA complex 
assembly (4.4%) and snoRNA localisation (1.0%, Table 5.13). In contrast, SAFB2 has 
distinct functions in T-ALL cells, including mRNA cleavage (2.0%), UTR-mediated 
mRNA stabilisation (1.7%), rRNA modification (2.0%), gene silencing by miRNA 




Table 5.14 Unique SAFB2 BP terms in T-ALL cells following analysis of all proteins 
pulled down by SAFB2 (348) 
Term % FDR 
protein localisation 23.0 2.35E-04 
protein transport 18.9 2.37E-04 
mRNA cleavage 2.0 0.001 
UTR-mediated mRNA stabilisation 1.7 0.002 
rRNA modification 2.0 0.003 
protein-DNA complex assembly 4.4 0.007 
gene silencing by miRNA 2.0 0.033 
regulation of DNA damage checkpoint 1.0 0.037 
snoRNA localisation 1.0 0.037 








5.2.8.10 Biological process analyses of binding proteins in T-ALL cells that 
are only found in SAFB1 (67) or SAFB2 (269) pull downs 
Sixty seven proteins were uniquely bound to SAFB1 in T-ALL cells (Figure 5.9). Thus, 
it was interesting to investigate if the BP for the SAFB1 binding proteins (67) were 
comparable to the BPs identified for the whole SAFB1 interactome (146). The unique 
SAFB1 interacting proteins (67) were loaded into DAVID and biological processes 
were identified (Table 5.14). Results showed that SAFB1 binding proteins were 
enriched and involved in regulating ribonucleoprotein complex biogenesis (43.9%), 
RNA processing (35.1%) and translation (31.6%). However, these BP terms were also 
associated with the total SAFB2 (348) interactome (Table 5.14). However, SAFB1 




Table 5.15 BP terms in T-ALL cells following analysis of proteins (67) only found in 
SAFB1 pull down 
Term % FDR 
ribonucleoprotein complex biogenesis 43.9 1.00E-20 
RNA processing 35.1 5.50E-18 
translation 31.6 4.90E-09 
cytoskeleton organisation 8.8 4.20E-02 




Many proteins (269) were uniquely bound to SAFB2 (and not SAFB1) in T-ALL cell 
from the total SAFB2 (348) interacting proteins (Figure 5.9). Therefore, the BP for 
those proteins were investigated (Table 5.15). Similar to SAFB1 binding proteins, 
SAFB2 was involved in regulating RNA processing (55.5%), ribonucleoprotein 
complex biogenesis (24.2%), and translation (22%). In contrast, SAFB2 binding 
proteins were enriched in regulating protein localisation (20.3%), protein transport 
(15.7%), mRNA cleavage (1.7%) and rRNA modification (1.7%), gene silencing by 










Table 5.16 BP terms in T-ALL cells following analysis of proteins (269) only found in 
SAFB2 pull down 
Term % FDR 
RNA processing 55.5 1.80E-104 
ribonucleoprotein complex biogenesis 24.2 4.10E-34 
translation 22 1.10E-22 
protein localisation 20.3 4.30E-03 
mRNA cleavage 1.7 4.70E-03 
gene silencing by miRNA 3.4 5.10E-03 
rRNA modification 1.7 9.90E-03 
protein transport 15.7 1.10E-02 
regulation of DNA damage checkpoint 1.3 1.60E-02 




































SAFB1 was previously reported to interact with the splicing factor SRSF1 
(2),(4),(40),(9) and both are co-localised in nSBs, suggesting that they might play 
important roles in splicing (2). However, whether stress related PTM, such as 
methylation and SUMOylation, can alter SAFB1/2 interactions is not known. The 
interaction between WT-SAFB1/WT-SAFB2 and SRSF1 was reduced significantly 
following heat shock and this may occur due to stress induced PTM of the proteins 
facilitating new interactions (e.g. with SATII transcripts in nSBs) and/or promoting a 
looser association between the proteins so as to allow a cessation of their non-stress 
related, constitutive actions. During stress, most constitutive transcription, splicing and 
translation is stopped to prevent damage to nascent RNA transcripts and proteins 
(4),(18). Hence, the decrease in SAFB1/2:SRSF1 interactions likely reflects a general 
stress induced mechanism whereby proteins responsible for coordinating RNA 
processing are ‘inactivated’. Interestingly, the SAFB2:SRSF1 interactions had 
recovered to basal levels 1hr after HS while SAFB1:SRSF1 interaction remained 
significantly decreased. This may well reflect the need for SAFB2:SRSF1 mediated 
functions to be ‘turned back on’ following a stress sooner than those mediated by 
SAFB1:SRSF1. In addition, it suggests that the reversal of stress mediated PTMs 
occurs in an order that favours SAFB2 being reactivated prior to SAFB1. 
 
Studies using SAFB1/2 constructs with mutated RGG/RG methylation and 
SUMOylation sites revealed that SAFB1 SUMOylation mutants had a significantly 
increased interaction with SRSF1 compared with WT-SAFB1 following heat shock and 
recovery. SUMOylation regulate many processes, including DNA damage repair, cell 
cycle, protein-protein interaction, stress response and apoptosis (182),(183). SAFB1 
SUMOylation status was linked to the stress response, with SAFB1/2 becoming de-
SUMOylated upon heat stress (27). Also, it was found that SUMOylation was required 
for transcriptional repression to be mediated by SAFB1 (29). Furthermore, it was found 
that transcription of ribosomal proteins was enhanced by SUMOylated SAFB1 (28). 
SRSF1 was reported to regulate the SUMOylation pathway and promotes SUMO 
conjugation to RNA processing factors (184),(185). It was also reported that the 
dysregulation of SUMOylation pathway is associated with development of cancer 




occurs following a stress has a marked effect on its functional interactions.  
In addition, the results suggested that the SAFB1 Δ-methylation mutant had a reduced 
interaction with SRSF1 under basal levels (p=0.55). In contrast, the interaction 
between the SAFB2 RGG/RG methylation mutants and SRSF1 was significantly 
reduced when compared to WT-SAFB2 under basal and HS+R, conditions. Overall, 
the data suggest that SAFB1 SUMOylation status appears to be important for SRSF1 
interactions following heat shock and recovery, while the methylation status of SAFB2 
is important for regulating interactions with SRSF1 under basal conditions. It is 
however acknowledged that further experiments to increase the n number and analyse 
the importance of individual mutation sites are needed before we can be totally 
confident of these conclusions.  
 
Interestingly, the interaction between SAFB1/2 and SRSF1 appeared to be reduced 
in T-ALL cells compared to HeLa cells. As repeated attempts to conduct IP 
experiments in NBM cells failed we do not have a bone marrow SAFB1/2: SRSF1 
control, we can therefore only conclude that this result may reflect the diminished need 
for SAFB1/2: SRSF1 interactions in T-ALL cells or that this interaction is lost in primary 
T-ALL cells. The homology (65-100%) between SAFB1 and SAFB2 suggests that both 
proteins are likely to share many functions. However, the differences in SAFB1 and 
SAFB2 expression in human tissues suggest that both proteins will also have distinct 
functions. The observation that the interaction between two important proteins with 
roles in gene expression, splicing and the regulation of the cell cycle is altered by 
methylation and SUMOylation status has important implications.  In many cancers, the 
methylation and SUMOylation status is altered (180),(181), our data suggests that the 
decreased expression of SAFB1 plus potential stress/cancer induced changes in PTM 
status would alter their function and interactions with SRSF1, a powerful oncogene 
(180).  SRSF1 is overexpressed in many cancers and correlated with poor prognosis 
(180). SRSF1 overexpression is associated with oncogenic transformation of human 
mammary epithelial cells and immortalized rodent fibroblasts (180). 
 
Arginine methylation has been implicated in regulating gene expression, RNA 
processing and protein translocation (30). The RGG/RG motif mediates nucleic acid 




transcription, pre-mRNA splicing, DNA damage signalling, mRNA translation and the 
regulation of apoptosis. Several RGG/RG containing motif proteins, such as 
Bromodomain-containing protein 4 (BRD4), Bromodomain adjacent to zinc finger 
domain protein 1A (BAZ1A), DROSHA, Inhibitor of growth protein 5 (ING5) and 
hnRNPK are reported to be mis-regulated in cancer (186).  
The RGG domain and SAF–box of SAF-A have been shown to play a role in anchoring 
Xist RNA to DNA (187) and suggests that both SAFB2 and SAFB1 may play similar 
roles in RNA recognition (188),(30). Scaffold attachment factor A (SAF-A), like SAFB 
proteins contains a SAF-box, RRM domain and C-terminal GAR motifs and has 
functions similar to SAFB-1 (11). The GAR motifs of SAF-A were reported to mediate 
the binding of the lnc-RNA Xist and transcriptional silencing (188). A subsequent study 
found that the SAF box of SAF-A also tethered Xist to DNA (189). In addition, SAF-A 
also interacts with the SWI/SNF complex and RNA Pol II to mediate transcription 
(190). Recently, hnRNPG, an interactor of SAFB1, was found to bind RNA and 
proteins using RGG motifs interacts directly with the CTD of RNA polymerase II via 
the RGG motifs (191). 
PRMT5, an enzyme that catalyses RG/RGG arginine methylation, was reported to be 
important in haemopoiesis where PRMT5 knockout in mouse bone marrow 
haemopoietic stem and progenitor cells impaired T and B lymphocyte development 
(192). PRMT5 was overexpressed in a wide range of cancers, including leukaemia 
and inhibiting PRMT5 was associated with anti-cancer activity in lymphomas (193) 
and AML in vitro (194),(195). PRMT5 was expressed at high levels in primary BCP-
ALL at diagnosis but decreased at complete remission, indicating that PRMT5 might 
have an oncogenic role in BCP-ALL progression (181). PRMT5 overexpression in 
BCP-ALL was partially by the dysregulation of B-cell lineage differentiation, suggesting 
that PRMT5 can be a potential biomarker in BCP-ALL (181). However, the role of 
PRMT5 has never been investigated in T-ALL. Profiling of the whole genome DNA 
methylation was performed in primary BCP-ALL and found SAFB proteins were 
hypermethylated (196). Together these data suggest that SAFB proteins, in common 
with several other proteins regulated by arginine methylation, may play important roles 
in regulating the cell cycle. PRMT5 was also shown to regulate DNA double-strand 




(197),(192). PRMT5 was reported to be essential for cell proliferation and correlated 
with G1 phase regulators, including  CDK4 and CDK6 (198). PRMT5 knockdown was 
reported to result in the cell cycle arrest and eventually apoptosis (198). Given that 
SAFB1 are arginine methylated by PRMT5 and interacted with many cell cycle 
regulators suggest that targeting PRMT5 might be an interesting strategy to disrupt 
the cell cycle. GSK3326595 (a PRMT5 inhibitor) has been shown to be a promising 
drug candidate in phase I (solid tumours and non- Hodgkin lymphoma) and phase I/II 
trials (myelodysplastic syndromes and acute myeloid leukaemia) and associated with 
lower IC50 in vitro (204). The cell cycle regulator, CDKN2A was found to interact with 
SAFB1/2 in T-ALL and reported to co-depleted with 5-methylthioadenosine 
phosphorylase (MTAP), leading to methylthioadenosine (MTA) accumulation and 
further sensitisation of cells to PRMT5 inhibition (192).  
Advances in proteomic technologies and the availability of new antibodies, enabled 
analyses to identify novel SAFB1 and SAFB2 interactions in HeLa and primary T-ALL 
cells. The analyses also helped to identify potential SAFB1/2 functions. Interestingly, 
the number of SAFB1 and SAFB2 interactions were reversed in T-ALL cells compared 
with HeLa cells with more SAFB1 interactions identified in HeLa compared with T-ALL. 
Likewise, more SAFB2 interactions were found in T-ALL compared with HeLa cells, 
indicating that SAFB2 may substitute for the decreased expression of SAFB1 in T-ALL 
cells. SAFB1 and SAFB2 interacting proteins shared many functions, such as RNA 
processing, translation and transcription but they also have distinct functions, such as 
protein localisation and transport. Interestingly, some of the unique SAFB1 functions 
in HeLa cells were found to be unique for SAFB2 in T-ALL, such as protein localisation 
and transport. Similarly, some unique SAFB2 functions in HeLa cells were functions 
for SAFB1 in T-ALL, such as cytoskeleton organisation. These data suggest that 
although SAFB1 and 2 functions are largely overlapping, both proteins have distinct 
functions, some of which are reversed for SAFB1 in HeLa compared with T-ALL cells 
and vice versa.  
 
It was interesting to investigate potential novel protein interactions for SAFB1 and 
SAFB2 in HeLa and T-ALL cells, so genome-wide proteomic analyses using TMT 
technology were performed. For the first time, proteomic analyses for SAFB1/2 were 




SAFB1/2 functions. It was shown that the majority of proteins were interacting with 
SAFB1 in HeLa cells and with SAFB2 in T-ALL cells. This could be related to the data 
presented in chapter 3 when SAFB1/2 ratio was altered in T-ALL cells compared with 
NBM cells and SAFB2 protein expression was elevated in T-ALL, suggesting that 
SAFB2 is likely to play more fundamental roles in T-ALL. The abundance of SAFB2 
interactions in T-ALL cells compared with SAFB1 might be supported by the tissue 
expression data where SAFB1 and SAFB2 interacting proteins were found to be highly 
up-regulated in various blood cells, such as lymphoid and myeloid cells in T-ALL cells 
and surprisingly in HeLa cells. The abundance of SAFB1/2 interacting proteins in 
lymphoid and myeloid cells suggest that SAFB1/2 play more significant roles in blood 
cell regulation and function than previously thought. Also, it was reported that SAFB1 
and 2 are regulated by a bidirectional promotor and knockdown of SAFB1 results in 
the up-regulation of SAFB2 (39).  
 
SAFB1 has been implicated in a variety of processes, including transcriptional 
regulation, chromatin organisation, cellular stress response, DNA damage response, 
apoptosis, RNA splicing and metabolism (11). However, whether SAFB2 has similar 
or distinct functions to SAFB1 is not known. Bioinformatics analyses found that both 
SAFB1 and SAFB2 were involved in regulating similar processes, such as RNA 
processing and splicing. Sharing similar functions could be due to the fact that both 
proteins have 65-100% similarity for their domains or SAFB1/2 antibodies used for the 
co-IP cross-react with each other. Furthermore, the bioinformatics analyses showed 
that SAFB1 and 2 interacted with many hnRNPs and DEAD-boxes, indicating they are 
important in regulating the RNA processing. Also, the involvement of SAFB1/2 in 
regulating RNA is not surprising as they interact with RNA via the RRM domain. 
SAFB1 was previously reported to interact with several hnRNP proteins, including 
hnRNPC (4), hnRNPD (40), hnRNPG (9) and hnRNPPI (4). SAFB1 was identified to 
be a component of the spliceosomes (42), macromolecular complexes of snRNA and 
small nuclear ribonucleoproteins assisting in removal of introns (43), thus suggesting 
that both proteins are involved in the regulation of RNA splicing. The role of SAFB1 in 
RNA processing was supported by transcriptomic analyses using iCLIP, which found 






The bioinformatics analyses showed that both SAFB1 and SAFB2 are likely involved 
in the regulation of the cell cycle, chromosome and cytoskeleton organisation. This 
was consistent with previous data that found high levels of SAFB1 arrested human 
urinary bladder cancer (T24) cells in the G2-M phase suggesting a role in the control 
of cell division (23). It was shown that binding proteins found in SAFB2 pull down (20 
proteins) in HeLa cells were mainly microtubule proteins, suggesting that SAFB2 might 
have predominant roles in regulating the cytoskeleton and thereby cell division. 
However, SAFB1 binding proteins were found to be important in regulating the 
cytoskeleton in T-ALL cells. Further to the genetic alterations that are observed in T-
ALL, which was discussed in chapter 1, the cell cycle is frequently altered in T-ALL 
(70),(69). CDKs are set of proteins with functions in regulating the cell cycle include 
cell renewal, differentiation, transcription and epigenetic regulation (199). CDKN2A 
deletions are one of the most frequent abnormalities and found in over 70% of T-ALL 
patients. The p16INK4A and p14ARF tumour suppressor genes are found in the short 
arm of chromosome 9 where CDKN2A is located. However, patients with CDKN2A 
deletions are associated with good prognosis (70),(69). CDK7 is a component of the 
transcription factor IIH complex (TFIIH) and regulates transcription elongation 
process. Inhibitions of CDK7 using THZ1 was shown to generally dampens mRNA 
transcription of key drivers of T-ALL, such as RUNX-1 (62). 
In the present study, it was found that LEF1 was bound with SAFB1/2 and therefore 
might be involved in regulating the cell cycle in T-ALL. The Wnt signalling pathway 
regulates many processes, including differentiation and proliferation of progenitor 
cells. b-Catenin is the main mediator of this pathway and accumulates in the cytoplasm 
and moves to the nucleus where it interacts with the T-cell factor (Tcf)/lymphoid 
enhancer factor (LEF) family (200), leading to activation of target genes, including c-
Myc and cyclin D1 (important regulators of G1 to S cell cycle transition) (201). LEF1 is 
a member of the Tcf/LEF family of DNA-binding transcription factors (202). b-Catenin 
and LEF1 expression was up-regulated in T-ALL patients (200). LEF1 was found to 
be mutated in 15% of cases in T-ALL (70),(69). LEF1 inactivation was reported in T-
ALL patients and associated with activating NOTCH1 mutations (202). LEF1 was 
shown to function as an oncogene or tumour suppressor gene. LEF1 is associated 
with T and B lymphocyte development. High levels of LEF1 is associated with good 




signalling by interacting with LEF1 transcription factor and thereby regulating cell 
differentiation and proliferation in T-ALL cells.  
In the current study, it was found that SAFB1 and SAFB2 were might be involved in 
regulation of chromatin organisation and transcription. Evidence showed that SAFB1 
has been found to interact with several important modifiers of chromatin structure e.g. 
CHD1 (46), NCOR (29), HDAC3 (29), BRG1 (15), Matrin 3 (47) and suggests that 
SAFB1 might be important for chromatin organisation. Another interesting finding was 
the potential involvement of SAFB1/2 proteins in the regulation of transcription. SAFB1 
was identified as a protein that bound and repressed hsp27 promoter activity (3) and 
hence SAFB1 was believed to be a negative regulator of transcription. Another study 
demonstrated that knockdown of SAFB1 and SAFB2 resulted in the induction of 457 
genes and repression of 259 genes (12). SAFB1 represses the androgen receptor and 
SAFB1 knockdown resulted in higher transcription of PSA in cultured prostate cells 
(16). It was evident that SAFB1 resulted in transcriptional repression of XOR (15) and 
SAFB1 knockdown inhibited the expression of skeletal muscle genes, indicating a 
positive regulatory role of SAFB1 (17). In addition, SAFB1 interacts with proteins 
involved in transcription, such as RNA polymerase III (2) and p53 (45). The 
involvement of SAFB1 in regulating such processes emphasises the previous findings 
and indicates that SAFB2 is playing similar roles.  
The bioinformatics data suggested that SAFB1 and 2 were involved in regulating 
protein translation in T-ALL cells and HeLa cells. Also, it was found that SAFB1/2 
interacted with many ribosomal proteins in HeLa and T-ALL cells. SAFB1 and SAFB2 
were shown to interact with RNA polymerase II at the C-terminal  (2),(9). The 
SUMOylated SAFB1 and SAFB2 were shown to be associated with recruiting RNA 
polymerase II to the promotor of ribosomal genes (15). Also, it was shown that 
knockdown of both proteins was associated with reduction in RNA expression of the 
ribosomal genes (15). These data suggest that SAFB1 and SAFB2 are important 
proteins involved in the regulation of protein translation and synthesis. Protein 
synthesis and ribosome biogenesis are essential processes for cancer cell growth and 
several defects in the translation machinery have been reported. Some ribosomal 
proteins include ribosomal protein L5 (RPL5), RPL10 and RBL22 have been reported 




with inactivating mutations and deletions, whereas RPL10 is associated with missense 
mutations (69). It was reported that many ribosomal proteins were arginine methylated 
by PRMT5 and involved in mRNA translation (204).  
Although SAFB1 and SAFB2 share many potential functions, it was interesting to 
investigate whether both proteins have distinct functions in HeLa and T-ALL cells. It 
was found that protein localisation and transport processes were potentially exclusive 
functions for SAFB1 in HeLa cells, however, these functions were found to be specific 
for SAFB2 in T-ALL. These data suggest that some SAFB1/2 functions were reversed 
in HeLa cells compared T-ALL cells and vice versa. The previous observations that 
SAFB1/2 is reversed in T-ALL compared with NBM cells support these findings. 
However, it should be highlighted that the reverse SAFB1 or SAFB2 functions were 
generated when HeLa cells were compared with T-ALL cells, rather than comparing 
T-ALL with NBM cells. The involvement of SAFB1 or SAFB2 in regulating protein 
localisation and transport was not surprising as SAFB1/2 have a protein-protein 
interaction domain to mediate and regulate protein interactions (204).  
 
In conclusion, SAFB1/2 RGG/RG methylation and SUMOylation are likely significant 
for its interaction with SRSF1. The proteomic analyses for SAFB1 and SAFB2 
interactions were undertaken for the first time in HeLa and T-ALL cells. Also, SAFB1/2 
interactions and functions seem to be altered in HeLa cells compared with T-ALL, 
indicating unique functions of both proteins in HeLa and T-ALL cells. SAFB1/2 were 
involved in regulating RNA processing, transcription, translation and the cell division 
in both cell types. These data form the foundation for SAFB1/2 interactions and 
functions and highlighted the importance of SAFB1/2 in potentially regulating critical 
processes. However, further experiments are needed to comprehensively elucidate 



















































The SAFB proteins help regulate a number of important cellular processes (e.g. gene 
expression (38), the cellular stress response (19), DNA repair (22), apoptosis (162), 
RNA processing and splicing (38) whose dysregulation is linked to cancer formation. 
The down-regulation of SAFB1 is linked to the aetiology of some cancers, however 
little was known about the biological relevance/significance of SAFB proteins in 
primary BCP-ALL and T-ALL cancers.  
 
Experiments detailed in this thesis, attempt to explore the significance and/or functions 
of SAFB proteins in ALL using different strategies. Firstly, investigating the expression 
levels of SAFB proteins in ALL subtypes in comparison with NBM cells. Following that, 
examining whether modulating SAFB1/2 expression in ALL cells has a compensatory 
pro-apoptotic effect with minimal cytotoxicity on various normal cells was investigated 
(Chapter 3). Secondly, characterising the expression/localisation of SAFB1/2, HSF1 
and HSP70 proteins following Hsp90 inhibitors and heat shock in ALL cells was 
conducted. HSP90 inhibitors (e.g. 17-DMAG and celastrol) were reported to induce 
the expression of heat shock proteins and hence it has been inferred they induce a 
stress response (128),(129),(131),(95). However, a heat shock/stress response is 
characterised by the expression of heat shock proteins and the formation of nuclear 
stress bodies. Thus, the aim was to characterise a heat induced stress response in 
primary ALL cells and HeLa cells and determine whether Hsp90 inhibitors (Chapter 4) 
instigated a similar response. The results of these experiments may also help identify 
additional mechanisms by which HSP90 inhibitors mediate selective cytotoxicity in 
cancer cells. Lastly, I hypothesised that by identifying the proteins that SAFB1/2 
interacted with in T-ALL (and HeLa) cells a better understanding of the biological 
processes/functions and pathways regulated by SAFB1/2 in health and disease would 
be obtained (Chapter 5).   
 
6.1 SAFB1/2 expression in ALL  
In Chapter 3, SAFB levels were measured in BCP-ALL and T-ALL cells and compared 
with NBM cells and the results showed there was decreased SAFB1 mRNA and 
protein expression in T-ALL cells. These results are in broad agreement with previous 




breast cancers (33). The expression of SAFB2 has not been investigated in many 
human cancers. However, SAFB2 protein expression was found to be significantly 
elevated in both ALL subtypes. Also, the SAFB1/SAFB2 ratio was reduced 
significantly in both BCP- and T-ALL cells compared with NBM. SAFB proteins have 
been shown to play important roles in regulating gene expression and the cell cycle, 
suggesting that aberrant SAFB1/2 expression may be associated with the 
development of cancer. Going forward, as SAFB1 and SAFB2 expression is controlled 
by a bidirectional promoter (39), it was of interest to investigate the ratio of SAFB1/2 
in ALL cells. Results showed that modulating the SAFB1/SAFB2 ratio was associated 
with pro-apoptotic effects. Data showed that SAFB1 overexpression was associated 
with apoptosis in both BCP-ALL and T-ALL cells, with no significant alterations in 
viability on different normal cells, including NBM, MEFs or primary neuronal cells. 
SAFB1 was reported to play a role in the apoptotic process (162) and SLTM 
overexpression (which shares 30% homology with SAFB1), has been shown to induce 
apoptosis in cancer lines (6), suggesting that cancer cells are uniquely sensitive to 
SAFB1 overexpression. The possible mechanisms for the potential pro-apoptotic of 
SAFB1 overexpression were detailed in chapter 3, including methylation and binding 
to chromatin modifiers. The effect of SAFB2 overexpression on ALL cells was also 
examined. It was shown that SAFB2 overexpression induced apoptosis in both 
primary T-ALL and BCP-ALL cells to less extent compared with SAFB1. However, 
SAFB2 overexpression did not induce apoptosis in NBM cells. The potential pro-
apoptotic effect of SAFB2 is not well established compared with SAFB1 role and 
further experiments are warranted to define these observations. However, there are a 
number of possible reasons for the potential pro-apoptotic actions of SAFB2 
overexpression: (i) SAFB2 could be competing with SAFB1, as SAFB2 was shown to 
co-localise with SAFB1 (9) (ii) SAFB1 and SAFB2 are under the control of a 
bidirectional promoter and it could be that a feedback mechanism for SAFB1/2 
regulation can be involved. If more time was available, the effect of knocking down 
SAFB2 on tumour cell viability could also have been investigated. Data in Chapter 5 
revealed that SAFB1/2 binding proteins were implicated in regulating methylation, 
chromatin organisation and the cell cycle and hence altered SAFB1/2 expression 





6.2 Effect of HSP90 inhibitors (17-DMAG and celastrol) on the stress response 
in ALL 
The HSP90 inhibitors, celastrol and 17-DMAG, are considered to be inducers of a 
stress response (128),(129),(131) and they induce apoptosis in T-ALL and BCP-ALL 
cells (95). Whether primary ALL cells respond to Hsp90 inhibitors by inducing a stress 
response is not known. In addition, the contribution of stress response pathways (e.g. 
heat shock protein expression and nSB formation) to cancer cell survival has not been 
investigated in ALL. Evidence shows that SAFB1 localises to nSBs with HSF1. 
However, it is not known if its paralogue, SAFB2, also translocates to nSBs following 
a stress in HeLa cells (4),(142). In chapter 4, the expression/localisation of SAFB1/2, 
HSF1 and HSP70 proteins were evaluated following treatment with HSP90 inhibitors 
(17-DMAG and celastrol) and heat shock in HeLa and ALL cells. HeLa cells exposed 
to a HS showed SAFB2 and HSF1 were recruited into nSBs earlier than SAFB1, and 
that HSP70 was induced. This may indicate SAFB2 is possibly needed to stabilise Sat 
III lncRNAs and/or plays a role in recruiting further proteins to nSBs. SAFB1 may need 
to be inactivated during stress or that it is forming new processing centres (21). The 
stress response following HSP90 inhibitors was different in comparison to heat shock. 
For example, 17-DMAG but not celastrol increased HSP70 expression and induced 
HSF1 puncta but SAFB1 and SAFB2 were not recruited into HSF1 puncta, suggesting 
that 17-DMAG is an effective inducer of Hsp70 transcription but does not induce the 
formation of SAFB1/2 containing SBs at 48 hours. Whether NBM and ALL cells 
exposed to HSP90 inhibitors or heat shock can induce the formation of nSBs and the 
transcription of HSP70 has not been investigated. Data showed that SAFB1 and 
SAFB2 expression was not altered following heat shock compared with basal 
conditions, however HSF1 expression was significantly increased in BCP-ALL and T-
ALL compared with NBM. In addition, HSF1 nuclear border expression was 
significantly increased in T-ALL and BCP-ALL cells compared with NBM following a 
heat shock and 17-DMAG treatment (but no discrete nuclear puncta are seen), 
suggesting that HSF1 does not mediate nSB formation in NBM and ALL cells. Under 
normal conditions, HSF1 is normally diffusely enters the nucleus upon stress. In this 
study, HSF1 was aggregating at the nuclear border upon stress in ALL cells, which is 




known what does that mean but could be that HSF1 is not fully activated in these cells 
and further experiments are needed to define these observations.  
 
6.3 SAFB1/2 interaction with SRSF1 
SAFB1 was previously reported to interact with the splicing factor SRSF1 
(2),(4),(40),(9) and both co-localised in nSBs, possibly suggesting that they need to 
be inactivated during stress or that they are forming new processing centres (21). 
However, whether stress related PTM, such as methylation, can alter SAFB1/2 
interactions is not known. The interaction between WT-SAFB1 or WT-SAFB2 with 
SRSF1 was reduced significantly following heat shock and this may occur due to 
stress induced PTMs of the proteins facilitating new interactions (e.g. with SATII 
transcripts in nSBs) and/or promoting a looser association between the proteins to 
allow a cessation of their non-stress related, constitutive actions. During stress, most 
constitutive transcription, splicing and translation is stopped to prevent damage to 
nascent RNA transcripts and proteins. Hence, the decrease in SAFB1/2:SRSF1 
interactions likely reflects a general stress induced mechanism whereby proteins 
responsible for coordinating RNA processing are ‘inactivated’. Interestingly, the 
SAFB2:SRSF1 interactions had recovered to basal levels 1hr after HS while 
SAFB1:SRSF1 interaction remained significantly decreased. This may well reflect the 
need for SAFB2:SRSF1 mediated functions to be ‘turned back on’ following a stress 
sooner than those mediated by SAFB1:SRSF1. In addition, it suggests that the 
reversal of stress mediated PTMs occurs in an order that favours SAFB2 being 
reactivated prior to SAFB1. Interestingly, the interaction between SAFB1/2 and 
SRSF1 appeared to be reduced in T-ALL cells compared to HeLa cells. As repeated 
attempts to conduct IP experiments in NBM cells failed we do not have a bone marrow 
SAFB1/2: SRSF1 control, we can therefore only conclude that this result may reflect 
the diminished need for SAFB1/2: SRSF1 interactions in T-ALL cells or that this 





6.4 Influence of RGG/RG methylation of SAFB1/2 proteins  
SAFB proteins have been found to undergo several PTMs (methylation, 
SUMOylation), which are important in regulating protein-protein interactions (2),(25), 
(27),(28),(11). The RGG/RG motifs may be methylated differentially to mediate 
important cellular functions such as RNA binding and protein-protein interactions (30), 
(11),(172),(173). Little is known about the significance of the methylation of SAFB 
proteins in regulating the cellular response to stress. Studies in Chapter 5 using 
SAFB1/2 mutants with the RGG/RG methylation sites mutated found that the 
interaction between the SAFB2 RGG/RG methylation mutants and SRSF1 was 
significantly reduced when compared to WT-SAFB2 under basal and HS+R, 
conditions. However, SAFB1 Δ-methylation mutant had a reduced interaction with 
SRF1 under basal levels, this was not significant. These data suggest that the 
methylation status of SAFB2 is important for regulating interactions with SRSF1 under 
basal conditions. It is however acknowledged that further experiments to increase the 
n number and analyse the importance of individual mutation sites are needed before 
we can be totally confident of these conclusions. The demonstration that the 
interaction between two important proteins with roles in gene expression, splicing and 
the regulation of the cell cycle is altered by methylation status has important 
implications. In many cancers, the methylation status of gene and proteins is altered 
(181). These data suggest that the decreased expression of SAFB1/2 plus potential 
stress/cancer induced changes in PTM status would alter their function and 
interactions with SRSF1. PRMT5, an enzyme that catalyses RGG/RG arginine 
methylation, was overexpressed in a wide range of cancers, including leukaemia, and 
inhibiting PRMT5 was associated with anti-cancer activity in lymphomas (193) and 
AML in vitro (194),(195). PRMT5 was reported to be essential for cell proliferation and 
correlated with G1 phase regulators (198). PRMT5 was proposed as an important 
regulator of the cell cycle and was reported to result in the cell cycle arrest (198). 
Evidence showed that SAFB proteins were methylated in primary BCP-ALL (196). 
Thus, it would be interesting to explore whether SAFB proteins are also methylated in 
T-ALL. If this is the case, a PRMT5 inhibitor, such as GSK3326595 inhibitor, could be 
used to treat T-ALL cells and viability assessed using annexin-PI assay. GSK3326595 




Hodgkin lymphoma) and phase I/II trials (myelodysplastic syndromes and acute 
myeloid leukaemia) and associated with lower IC50 of GSK3326595 in vitro (204).  
 
6.5 Influence of SUMOylation of SAFB1/2 proteins  
SUMOylation regulates many processes, including DNA damage repair, cell cycle, 
protein-protein interactions, stress response and apoptosis (182),(183). SAFB1 
SUMOylation status was linked to the stress response, with SAFB1/2 becoming de-
SUMOylated upon heat stress (27). Also, it was found that SUMOylation was required 
for transcriptional repression to be mediated by SAFB1 (29). Furthermore, it was found 
that transcription of ribosomal proteins was enhanced by SUMOylated SAFB1 (28). 
SRSF1 was reported to regulate the SUMOylation pathway and promotes SUMO 
conjugation to RNA processing factors (184),(185). It was also reported that the 
dysregulation of SUMOylation pathway is associated with development of cancer 
(183). Studies using SAFB1/2 constructs with mutated SUMOylation sites revealed 
that SAFB1 SUMOylation mutants had a significantly increased interaction with 
SRSF1 compared with WT-SAFB1 following heat shock and recovery. Together these 
results strongly suggest that the de-SUMOylation of SAFB1 that occurs following a 
stress has a marked effect on its functional interactions and that SAFB1 SUMOylation 
status appears to be important for SRSF1 interactions following heat shock and 
recovery.  
 
6.6 Characterising SAFB1 and SAFB2 protein: protein interaction 
The main aim of chapter 5 was to identify potential protein-protein interactions in HeLa 
and T-ALL cells. Interestingly, more SAFB2 interactions were found in T-ALL 
compared with HeLa cells, indicating that SAFB2 may substitute for the decreased 
expression of SAFB1 in T-ALL cells that was observed in Chapter 3. The abundance 
of SAFB1/2 interacting proteins in lymphoid and myeloid cells plus the increase in 
SAFB2 expression in T-ALL (Chapter 3) might suggest that SAFB1/2 play more crucial 
roles in blood cell regulation and function than previously thought. Data in Chapter 5 
suggested that SAFB1/2 binding proteins were implicated in regulating many known 




all of which were reported to be regulated by arginine methylation (204). For example, 
it was reported that many ribosomal proteins were arginine methylated by PRMT5 and 
involved in mRNA translation (204). The proteomic data also found to be involved in 
potentially regulating unique SAFB1/2 processes, including gene silencing. However, 
SAFB1/2 binding proteins profile in T-ALL should be compared with normal cells.  
 
6.7 Future directions 
In Chapter 3, it was shown that the ratio of SAFB1/2 was altered in ALL cells. As 
SAFB1 and SAFB2 expression is controlled by a bidirectional promoter (39), it could 
be that genetic mutations might be identified in this region which would be responsible 
for the alter expression of SAFB1/2. To do this, the SAFB1/2 promotor can be 
sequenced in both ALL subtypes and compared with NBM. Also, a lentiviral vector 
made in the laboratory expressing the SAFB1/2 promotor could be used as a strategy 
to investigate the transcriptional regulation of the SAFB1/2 promotor in ALL in 
comparison to NBM. SAFB1 is tagged to EGFP and SAFB2 was tagged to mScarlet 
to allow for visualisation/quantification. Thus, ALL and NBM cells can be transduced 
with the lentiviral vector and EGFP and mScarlet levels would be measured by flow 
cytometer. Furthermore, as SAFB2 protein levels were shown to be elevated in ALL 
subtypes compared with NBM, it would be interesting to investigate if ALL cells are 
dependent on SAFB2 for their survival. One strategy would be to knockdown SAFB2 
and evaluate viability to see if reducing SAFB2 expression would be associated with 
apoptosis using annexin-PI assay. 
 
In Chapter 4, 17-DMAG but not celastrol increased HSP70 expression and induced 
HSF1 puncta but SAFB1 and SAFB2 were not recruited into HSF1 puncta. Why 
SAFB1/2 were nor recruited to HSF1 puncta is not known. Further experiments using 
different time-points should be performed to investigate if the co-localisation between 
SAFB1/2 and HSF1 following 17-DMAG would be attained as the optimal time-point 
would have been missed or this would be via a different mechanism. Under normal 
conditions, HSF1 is normally diffusely enters the nucleus upon stress. In this study, 
HSF1 was aggregating at the nuclear border (detected by measuring the average 




upon stress in ALL cells, which is unusual staining pattern and has never shown in 
other cells (HeLa cells). It is not known what does that mean but could be that HSF1 
is not fully activated in these cells and further experiments are needed to define these 
observations. To differentiate localisation of cytoplasmic and nuclear proteins, 
cytoplasmic markers techniques (e.g. immunofluorescence staining) could be 
employed to assess whether HSF1 is also detected in the cytoplasm. 
 
In Chapter 4, the assumption that nSBs were present or absent following stress was 
based on the recruitment of SAFB1/2 with HSF1 into nSBs. Upon stress, in addition 
to HSP production, HSF1 also transcribes G-rich lncSatIII RNAs  (135) mediating nSB 
formation (136). To confirm whether SAFB1/2 were found in nSBs with HSF1, 
fluorescence in situ hybridization (FISH) can be used to investigate whether SAFB1/2 
would be detected in SATIII in ALL compared with NBM cells. FISH probes targeting 
SATIII that were described (136) can be used and this should be followed by staining 
SAFB1/2 and HSF1 using immunofluorescence techniques. This would allow to see if 
SAFB1/2 and HSF1 are co-localised with SATIII loci following a stress, as SATIII 
transcription was shown to be associated with formation of nSBs (136). Furthermore, 
the transcription of SATIII can be measured using qPCR, which was shown to be 
highly induced following heat shock (136). The absence of nSBs following heat shock 
in NBM and ALL cells might be due to the fact that bone marrow cells did not induce 
normal stress response (nSBs formation and hsp70 transcription) or they can be more 
resistant to heat stress. NBM and ALL cells have been heat shocked at 420C; however, 
evidence suggests that different temperatures (420C, 430C, 450C) resulted in various 
levels of SATIII transcription (136).  
 
In Chapter 5, the potential significance of the RGG/RG status of SAFB1/2 on the 
interaction with SRSF1 needs to be refined. The mutants used in this study contain 7 
and 8 sites for SAFB1 and SAFB2, respectively. Future studies should focus to 
investigate the specific methylation sites that were responsible for the significant effect 
of SAFB1/2 interaction with SRSF1 using single mutations of RGG/RG sites. Data in 
Chapter 5 revealed that SAFB1/2 binding proteins were implicated in regulating the 
cell cycle and methylation. Future studies could establish the biological link between 
the cell cycle and the RGG/RG methylation of SAFB1/2 and investigate whether 




Therefore, T-ALL can be treated with GSK3326595 inhibitor and viability can be 
assessed using annexin-PI assay. 
 
The proteomic data in Chapter 5 lacked normal control cells to compare the SAFB1/2 
proteome with. A few attempts using SAFB1 and SAFB2 pulldowns were made in 
NBM cells but were unsuccessful. NBM cells are a heterogeneous population of cells 
so a purified subset bone marrow cells would be ideal to isolate using fluorescence-
activated cell sorting (FACS) method. CD7+, a marker that is expressed on normal 
lymphoid cells and highly expressed in many T-ALL patients, can be isolated using 
FACS in NBM cells and eventually yield pure population of cells. The CD7+ NBM cells 
would be used as controls for SAFB1/2 pulldowns and thereby TMT-MS analysis. 
Therefore, SAFB1/2 interactions in T-ALL can be compared with CD7+ NBM cells. 
 
6.8 Conclusions 
This thesis provided insights of SAFB1/2 expression in ALL compared with NBM cells 
and showed that modulating SAFB1 levels induce apoptosis selectively in ALL cells. 
The altered expression of SAFB1 and SAFB2 influenced the mechanisms regulating 
the stress response in malignant cells. In addition, HSF1 was found to be constitutively 
significantly increased in primary BCP-ALL and T-ALL cells compared with NBM 
following HS and HSP90i treatment, indicating that the stress response is altered. In 
addition, HSF1 was found enriched at the nuclear border in primary NBM, BCP-ALL 
and T-ALL cells. HSF1 nuclear border aggregation was more abundant in BCP-ALL 
and T-ALL cells compared to NBM. The altered stress response in ALL, as typified by 
the lack of SAFB2 containing nSBs, also suggest an altered stress response could be 
involved. SAFB1/2 RGG/RG methylation and SUMOylation are likely significant for its 
interaction with SRSF1. The proteomic analyses for SAFB1 and SAFB2 interactions 
were undertaken for the first time in HeLa and T-ALL cells and it highlighted the pivotal 
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